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A B S T R A C T
Background
Down’s syndrome occurs when a person has three, rather than two copies of chromosome 21; or the specific area of chromosome 21
implicated in causing Down’s syndrome. It is the commonest congenital cause of mental disability and also leads to numerous metabolic
and structural problems. It can be life-threatening, or lead to considerable ill health, although some individuals have only mild problems
and can lead relatively normal lives. Having a baby with Down’s syndrome is likely to have a significant impact on family life.
Non-invasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates
of the risk of a pregnancy being affected and provides information to guide decisions about definitive testing.
Before agreeing to screening tests, parents need to be fully informed about the risks, benefits and possible consequences of such a test.
This includes subsequent choices for further tests they may face, and the implications of both false positive and false negative screening
tests (i.e. invasive diagnostic testing, and the possibility that a miscarried fetus may be chromosomally normal). The decisions that
may be faced by expectant parents inevitably engender a high level of anxiety at all stages of the screening process, and the outcomes
of screening can be associated with considerable physical and psychological morbidity. No screening test can predict the severity of
problems a person with Down’s syndrome will have.
Objectives
To estimate and compare the accuracy of first trimester ultrasound markers alone, and in combination with first trimester serum tests
for the detection of Down’s syndrome.
Search methods
We carried out extensive literature searches including MEDLINE (1980 to 25 August 2011), Embase (1980 to 25 August 2011),
BIOSIS via EDINA (1985 to 25 August 2011), CINAHL via OVID (1982 to 25 August 2011), and The Database of Abstracts
of Reviews of Effects (the Cochrane Library 2011, Issue 7). We checked reference lists and published review articles for additional
potentially relevant studies.
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Selection criteria
Studies evaluating tests of first trimester ultrasound screening, alone or in combination with first trimester serum tests (up to 14
weeks’ gestation) for Down’s syndrome, compared with a reference standard, either chromosomal verification or macroscopic postnatal
inspection.
Data collection and analysis
Data were extracted as test positive/test negative results for Down’s and non-Down’s pregnancies allowing estimation of detection
rates (sensitivity) and false positive rates (1-specificity). We performed quality assessment according to QUADAS criteria. We used
hierarchical summary ROCmeta-analytical methods to analyse test performance and compare test accuracy. Analysis of studies allowing
direct comparison between tests was undertaken. We investigated the impact of maternal age on test performance in subgroup analyses.
Main results
We included 126 studies (152 publications) involving 1,604,040 fetuses (including 8454Down’s syndrome cases). Studies were generally
good quality, although differential verification was common with invasive testing of only high-risk pregnancies. Sixty test combinations
were evaluated formed from combinations of 11 different ultrasound markers (nuchal translucency (NT), nasal bone, ductus venosus
Doppler, maxillary bone length, fetal heart rate, aberrant right subclavian artery, frontomaxillary facial angle, presence of mitral gap,
tricuspid regurgitation, tricuspid blood flow and iliac angle 90 degrees); 12 serum tests (inhibin A, alpha-fetoprotein (AFP), free
beta human chorionic gonadotrophin (ßhCG), total hCG, pregnancy-associated plasma protein A (PAPP-A), unconjugated oestriol
(uE3), disintegrin and metalloprotease 12 (ADAM 12), placental growth factor (PlGF), placental growth hormone (PGH), invasive
trophoblast antigen (ITA) (synonymous with hyperglycosylated hCG), growth hormone binding protein (GHBP) and placental protein
13 (PP13)); and maternal age. The most frequently evaluated serum markers in combination with ultrasound markers were PAPP-A
and free ßhCG.
Comparisons of the 10 most frequently evaluated test strategies showed that a combined NT, PAPP-A, free ßhCG and maternal age test
strategy significantly outperformed ultrasound markers alone (with or without maternal age) except nasal bone, detecting about nine
out of every 10 Down’s syndrome pregnancies at a 5% false positive rate (FPR). In both direct and indirect comparisons, the combined
NT, PAPP-A, free ßhCG and maternal age test strategy showed superior diagnostic accuracy to an NT and maternal age test strategy (P
< 0.0001). Based on the indirect comparison of all available studies for the two tests, the sensitivity (95% confidence interval) estimated
at a 5% FPR for the combined NT, PAPP-A, free ßhCG and maternal age test strategy (69 studies; 1,173,853 fetuses including 6010
with Down’s syndrome) was 87% (86 to 89) and for the NT and maternal age test strategy (50 studies; 530,874 fetuses including 2701
Down’s syndrome pregnancies) was 71% (66 to 75). Combinations of NT with other ultrasound markers, PAPP-A and free ßhCG
were evaluated in one or two studies and showed sensitivities of more than 90% and specificities of more than 95%.
High-risk populations (defined before screening was done, mainly due to advanced maternal age of 35 years or more, or previous
pregnancies affected with Down’s syndrome) showed lower detection rates compared to routine screening populations at a 5% FPR.
Women who miscarried in the over 35 group were more likely to have been offered an invasive test to verify a negative screening results,
whereas those under 35 were usually not offered invasive testing for a negative screening result. Pregnancy loss in women under 35
therefore leads to under-ascertainment of screening results, potentially missing a proportion of affected pregnancies and affecting test
sensitivity. Conversely, for the NT, PAPP-A, free ßhCG and maternal age test strategy, detection rates and false positive rates increased
with maternal age in the five studies that provided data separately for the subset of women aged 35 years or more.
Authors’ conclusions
Test strategies that combine ultrasound markers with serum markers, especially PAPP-A and free ßhCG, and maternal age were
significantly better than those involving only ultrasound markers (with or without maternal age) except nasal bone. They detect about
nine out of 10 Down’s affected pregnancies for a fixed 5% FPR. Although the absence of nasal bone appeared to have a high diagnostic
accuracy, only five out of 10 affected Down’s pregnancies were detected at a 1% FPR.
P L A I N L A N G U A G E S U M M A R Y
Screening tests for Down’s syndrome in first 24 weeks of pregnancy
Background
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Down’s syndrome (also known as Down’s or Trisomy 21) is an incurable genetic disorder that causes significant physical and mental
health problems, and disabilities. However, there is wide variation in how Down’s affects people. Some individuals are severely affected
whilst others have mild problems and are able to lead relatively normal lives. There is no way of predicting how badly a baby might be
affected.
Expectant parents are given the choice to be tested for Down’s during pregnancy to assist them in making decisions. If a mother is
carrying a baby with Down’s, then there is the decision about whether to terminate or continue with the pregnancy. The information
offers parents the opportunity to plan for life with a Down’s child.
The most accurate tests for Down’s involve testing fluid from around the baby (amniocentesis) or tissue from the placenta (chorionic
villus sampling (CVS)) for the abnormal chromosomes associated with Down’s. Both these tests involve inserting needles through
the mother’s abdomen and are known to increase the risk of miscarriage. Thus the tests are not suitable for offering to all pregnant
women. Rather, tests that measure markers in the mother’s blood, urine or on ultrasound scans of the baby are used for screening.
These screening tests are not perfect, they can miss cases of Down’s and also give a ‘high risk’ test results to a number of women whose
babies are not affected by Down’s. Thus pregnancies identified as ‘high risk’ using these screening tests require further testing using
amniocentesis (from 15 weeks’ gestation) or CVS (from 10 + 0 to 13 + 6 weeks’ gestation) to confirm a diagnosis of Down’s.
What we did
The aim of this review was to find out which of the first trimester ultrasound screening tests, with or without first trimester serum tests
done during the first 14 weeks of pregnancy are the most accurate at predicting the risk of a pregnancy being affected by Down’s. We
looked at 11 different ultrasound markers and 12 different serum markers that can be used alone, in ratios or in combination, taken
before 14 weeks’ gestation, thus creating 60 screening tests for Down’s. We found 126 studies, involving 1,604,040 fetuses (including
8454 fetuses affected by Down’s syndrome).
What we found
For the first 14 weeks of pregnancy, the evidence supports the use of first trimester ultrasound tests in combination with two serum
(blood) markers - especially pregnancy-associated plasma protein A (PAPP-A) and free beta human chorionic gonadotrophin (ßhCG) -
and maternal age, for Down’s syndrome screening. In general, these tests are better than ultrasound markers on their own. They detect
nine out of 10 pregnancies affected by Down’s syndrome. Five per cent of women undertaking the test will have a high risk test result,
however the majority of these pregnancies will not be affected by Down’s syndrome.
Other important information to consider
The ultrasound tests themselves have no adverse effects for the woman, blood tests can cause discomfort, bruising and rarely infection.
However some women who have a ‘high risk’ screening test result, and are given amniocentesis or CVS have a risk of miscarrying a
baby unaffected by Down’s. Parents will need to weigh up this risk when deciding whether or not to have an amniocentesis or CVS
following a ‘high risk’ screening test result.
B A C K G R O U N D
This is one of a series of reviews on antenatal screening for
Down’s syndrome following a generic protocol (Alldred 2010) -
see Published notes for more details.
Target condition being diagnosed
Down’s syndrome
Down’s syndrome affects approximately one in 800 live-born ba-
bies (Cuckle 1987). It results from a person having three, rather
than two, copies of chromosome 21 - or the specific area of chro-
mosome 21 implicated in causing Down’s syndrome - as a result
of trisomy or translocation. If not all cells are affected, the pattern
is described as ’mosaic’. Down’s syndrome can cause a wide range
of physical and mental problems. It is the commonest cause of
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mental disability, and is also associated with a number of congeni-
tal malformations, notably affecting the heart. There is also an in-
creased risk of cancers such as leukaemia, and numerous metabolic
problems including diabetes and thyroid disease. Some of these
problemsmay be life-threatening, or lead to considerable ill health,
while some individuals with Down’s syndrome have only mild
problems and can lead a relatively normal life.
There is no cure for Down’s syndrome, and antenatal diagnosis
allows for preparation for the birth and subsequent care of a baby
with Down’s syndrome, or for the offer of a termination of preg-
nancy. Having a baby with Down’s syndrome is likely to have a
significant impact on family and social life, relationships and par-
ents’ work. Special provisions may need to be made for education
and care of the child, as well as accommodating the possibility of
periods of hospitalisation.
Definitive invasive tests (amniocentesis and chorionic villus sam-
pling (CVS)) exist that allow the diagnosis of Down’s syndrome
before birth but carry a risk of miscarriage. No test can predict the
severity of problems a person with Down’s syndrome will have.
Non-invasive screening tests based on biochemical analysis of ma-
ternal serum or urine, or fetal ultrasound measurements, allow
an estimate of the risk of a pregnancy being affected and provide
parents with information to enable them to make choices about
definitive testing. Such screening tests are used during the first and
second trimester of pregnancy.
Screening tests for Down’s syndrome
Initially, screening was determined solely by using maternal age to
classify a pregnancy as high or low risk for trisomy 21, as it was
known that older women had a higher chance of carrying a baby
with Down’s syndrome (Penrose 1933).
Further advances in screening were made in the early 1980s, when
Merkatz and colleagues investigated the possibility that lowmater-
nal serum alpha-fetoprotein (AFP), obtained frommaternal blood
in the second trimester of pregnancy could be associatedwith chro-
mosomal abnormalities in the fetus. Their retrospective case-con-
trol study showed a statistically significant relationship between
fetal trisomy, such as Down’s syndrome, and lowered maternal
serum AFP (Merkatz 1984). This was further explored by Cuckle
and colleagues in a larger retrospective trial using data collected
as part of a neural tube defect (NTD) screening project (Cuckle
1984). This work was followed by calculation of risk estimates
using maternal serum AFP values and maternal age, which ulti-
mately led to the introduction of the two screening parameters in
combination (Alfirevic 2004).
In 1987, in a small case-control study of women carrying fe-
tuses with known chromosomal abnormalities, Bogart and col-
leagues investigated maternal serum levels of human chorionic go-
nadotrophin (hCG) as a possible screening tool for chromosomal
abnormalities in the second trimester (Bogart 1987). This fol-
lowed the observations that low hCG levels were associated with
miscarriages, which are commonly associated with fetal chromo-
somal abnormalities. They concluded that high hCG levels were
associated with Down’s syndrome and because hCG levels plateau
at 18 to 24 weeks, that this would be themost appropriate time for
screening. Later work suggested that the ß subunit of hCG was a
more effective marker than total hCG (Macri 1990; Macri 1993).
Second trimester unconjugated oestriol (uE3), produced by the
fetal adrenals and the placenta, was also evaluated as a potential
screening marker. In another retrospective case-control study, uE3
was shown to be lower in Down’s syndrome pregnancies compared
with unaffected pregnancies.Whenused in combinationwithAFP
andmaternal age, it appeared to identifymore pregnancies affected
by Down’s syndrome than AFP and age alone (Canick 1988).
Further work suggested that all three serum markers (AFP, hCG
and uE3) showed even higher detection rates when combined with
maternal age (Wald 1988a; Wald 1988b) and appeared to be a
cost-effective screening strategy (Wald 1992a).
Two other serum markers, produced by the placenta, have
been linked with Down’s syndrome, namely pregnancy-associ-
ated plasma protein A or PAPP-A, and Inhibin A. PAPP-A has
been shown to be reduced in the first trimester of Down’s syn-
drome pregnancies, with its most marked reduction in the early
first trimester (Bersinger 1995). Inhibin A is high in the second
trimester in pregnancies affected by Down’s syndrome (Cuckle
1995; Wallace 1995). There are some issues concerning the bio-
logical stability and hence reliability of this marker, and the effect
this will have on individual risk.
In addition to serum and ultrasound markers for Down’s syn-
drome, work has been carried out looking at urinary markers.
These markers include invasive trophoblast antigen, ß-core frag-
ment, free ßhCGand total hCG (Cole 1999). There is controversy
about their value (Wald 2003a.
Screening and parental choice
Antenatal screening is used for several reasons (Alfirevic 2004), but
the most important is to enable parental choice regarding preg-
nancy management and outcome. Before a woman and her part-
ner opt to have a screening test, they need to be fully informed
about the risks, benefits and possible consequences of such a test.
This includes the choices they may have to face should the re-
sult show that the woman has a high risk of carrying a baby with
Down’s syndrome and implications of both false positive and false
negative screening tests. They need to be informed of the risk of a
miscarriage due to invasive diagnostic testing, and the possibility
that a miscarried fetus may be chromosomally normal. If, follow-
ing invasive diagnostic testing, the fetus is shown to have Down’s
syndrome, further decisions need to be made about continuation
or termination of the pregnancy, the possibility of adoption and
finally, preparation for parenthood. Equally, if a woman has a test
that shows she is at a low risk of carrying a fetus with Down’s
syndrome, it does not necessarily mean that the baby will be born
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with a normal chromosomal make up. This possibility can only be
excluded by an invasive diagnostic test (Alfirevic 2003). The deci-
sions that may be faced by expectant parents inevitably engender
a high level of anxiety at all stages of the screening process, and the
outcomes of screening can be associated with considerable physi-
cal and psychological morbidity. No screening test can predict the
severity of problems a person with Down’s syndrome will have.
Index test(s)
This review examined ultrasound and serum screening tests used
in the first trimester of pregnancy (up to 14 weeks’ gestation).
The tests included the following individual ultrasound markers:
nuchal translucency (NT), nasal bone, ductus venosus Doppler,
maxillary bone length, fetal heart rate, aberrant right subclavian
artery, frontomaxillary facial angle, presence of mitral gap, tricus-
pid regurgitation, tricuspid blood flow and iliac angle 90 degrees;
and the following individual serum markers: inhibin A, AFP, free
ßhCG, total hCG, pregnancy-associated plasma protein A (PAPP-
A), uE3, a disintegrin and metalloprotease 12 (ADAM 12), pla-
cental growth factor (PlGF), placental growth hormone (PGH)
invasive trophoblast antigen (ITA) (synonymous with hypergly-
cosylated hCG), growth hormone binding protein (GHBP) and
placental protein 13 (PP13).
These markers can be used individually, in combination with age,
and can also be used in combination with each other. The risks are
calculated by comparing a woman’s test result for eachmarker with
values for an unaffected population, and multiplying this with her
age-related risk. Where several markers are combined, risks are
computed using risk equations (often implemented in commercial
software) that take into account the correlational relationships
between the different markers andmarker distributions in affected
and unaffected populations.
Alternative test(s)
Down’s syndrome can be detected during pregnancy with invasive
diagnostic tests such as amniocentesis or CVS, with or without
prior screening. These tests are considered to be reference tests
rather than index or screening tests. The ability to determine fetal
chromosomal make up (also known as a karyotype) from amniotic
fluid samples was demonstrated in 1966 by Steele and Breg (Steele
1966), and the first antenatal diagnosis of Down’s syndrome was
made in 1968 (Valenti 1968). Amniocentesis is an invasive pro-
cedure which involves taking a small sample of the amniotic fluid
(liquor) surrounding the baby, using a needle which goes through
the abdominal wall into the uterus, and is usually performed after
15 weeks’ gestation. Chorionic villus sampling involves taking a
sample of the placental tissue using a needle which goes through
the abdominal wall and uterus or a cannula through the cervix.
It is usually performed between 10 and 13 weeks’ gestation. Am-
niocentesis and CVS are both methods of obtaining fetal chromo-
somematerial, which are then used to diagnose Down’s syndrome.
Both tests use ultrasound scans to guide placement of the needle.
Amniocentesis carries a risk of miscarriage in the order of 1%;
transabdominal CVS may carry a similar risk (Alfirevic 2003). A
more recent systematic review suggests that the procedure-related
risk of pregnancy loss is lower than this (Akolekar 2015).
Recent developments in the use of cell-free fetal DNA detection
in maternal serum are paving the way for non-invasive diagnosis
of Down’s syndrome and other trisomies, however these tests were
not used as reference standards in any of the studies examined for
this review, and were not included in the search strategy, which
preceded their widespread introduction. A systematic review con-
ducted by another group is currently in preparation, examining
this newer screening technology (Badeau 2015).
There are many different screening tests which are available and
offered which are the subject of additional Cochrane reviews
and there are other reviews looking at this area. Tests being as-
sessed in the other Cochrane reviews include first trimester serum
tests (Alldred 2015); urine tests (Alldred 2015a); second trimester
serum markers (Alldred 2012); and tests that combine markers
from the first trimester with markers from the second trimester (in
press). Second trimester ultrasound markers have been assessed in
a previous systematic review (Smith-Bindman 2001).
Rationale
This is one of a suite of Cochrane reviews, the aim of which is to
identify all screening tests for Down’s syndrome used in clinical
practice, or evaluated in the research setting, in order to try to iden-
tify the most accurate test(s) available, and to provide clinicians,
policy-makers and women with robust and balanced evidence on
which to base decisions about interpreting test results and imple-
menting screening policies to triage the use of invasive diagnostic
testing. The full set of reviews is described in the generic protocol
(Alldred 2010).
The topic has been split into several different reviews to allow for
greater ease of reading and greater accessibility of data, and also to
allow the reader to focus on separate groups of tests, for example,
first trimester serum tests alone, first trimester ultrasound alone,
first trimester serumandultrasound, second trimester serumalone,
first and second trimester serum, combinations of serum and ul-
trasound markers and urine markers alone. An overview review
will compare the best tests, focusing on commonly used strategies,
from each of these groups to provide comparative results between
the best tests in the different categories. This review is written with
the global perspective in mind, rather than to conform with any
specific local or national policy, as not all tests will be available in
all areas where screening for Down’s syndrome is carried out.
A systematic review of second trimester ultrasound markers in
the detection of Down’s syndrome fetuses was published in 2001
which concluded that nuchal fold thickening may be useful in
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detecting Down’s syndrome, but that it was not sensitive enough
to use as a screening test. The review concluded that the other
second trimester ultrasound markers did not usefully distinguish
between Down’s syndrome and pregnancies without Down’s syn-
drome (Smith-Bindman 2001). There has yet to be a systematic
review and meta-analysis of the observed data on serum, urine
and first trimester ultrasound markers, in order to draw rigorous
and robust conclusions about the diagnostic accuracy of available
Down’s syndrome screening tests.
O B J E C T I V E S
The aim of this review was to estimate and compare the accuracy
of first trimester ultrasound with and without serum markers for
the detection of Down’s syndrome in the antenatal period, both
as individual markers and as combinations of markers. Accuracy
is described by the proportion of fetuses with Down’s syndrome
detected by screening before birth (sensitivity or detection rate)
and the proportion with a low-risk screening test result (negative)
from amongst babies bornwithoutDown’s syndrome.We grouped
our analyses to focus on investigating the value of adding increasing
numbers of markers (comparing single, dual, triple, quadruple,
quintuple and sextuple tests).
Investigation of sources of heterogeneity
We had planned to investigate whether a uniform screening test
is suitable for all women, or whether different screening methods
are more applicable to different groups, defined by advanced ma-
ternal age, ethnic groups and aspects of the pregnancy and med-
ical history such as multiple (multifetal) pregnancy, diabetes and
family history of Down’s syndrome. We also planned to examine
whether there was evidence of overestimation of test accuracy in
studies evaluating risk equations in the derivation sample rather
than in a separate validation sample.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies in which all women from a given popula-
tion had one or more index test(s) compared to a reference stan-
dard. Both consecutive series and diagnostic case-control study
designs were included. Randomised trials where individuals were
randomised to different screening strategies and all verified us-
ing a reference standard were also eligible for inclusion. Studies
in which test strategies were compared head-to-head either in the
same women, or between randomised groups were identified for
inclusion in separate comparisons of test strategies. Studies were
excluded if they included less than five Down’s syndrome cases, or
more than 20% of participants were not followed up.
Participants
Pregnant women at less than 14 weeks’ gestation confirmed by
ultrasound, who had not undergone previous testing for Down’s
syndrome in their pregnancy were eligible. Studies were included
if the pregnant women were unselected, or if they represented
groups with increased risk of Down’s syndrome, or difficulty with
conventional screening tests including maternal age greater than
35 years old, multifetal pregnancy, diabetes mellitus and a family
history of Down’s syndrome.
Index tests
Improved diagnostic performance can be obtained by using sev-
eral tests in combination, such as maternal age and serum marker
combinations, or combinations of maternal age, serum mark-
ers and sonographic measurements. We examined individual first
trimester ultrasound markers or combinations of these markers
with one or more first trimester serum tests, with and without
adjustment for maternal age.
The following ultrasoundmarkers were examined:NT, nasal bone,
ductus venosus Doppler, maxillary bone length, fetal heart rate,
aberrant right subclavian artery, frontomaxillary facial angle, pres-
ence of mitral gap, tricuspid regurgitation, tricuspid blood flow
and iliac angle 90 degrees.
The serum markers examined in different combinations with ul-
trasound markers were inhibin A, AFP, free ßhCG, total hCG,
PAPP-A, uE3, ADAM12, PlGF, PGH, ITA (h-hCG), GHBP and
PP13.
We examined comparisons of ultrasound markers in isolation and
in various combinationswith or without serummarkers. The com-
binations included one or two ultrasound markers with single (one
marker), double (two markers), triple (three markers), quadruple
(four markers), quintuple and sextuple (six markers) serum mark-
ers, with or without adjustment for maternal age.
Where tests were used in combinations, we examined the perfor-
mance of test combinations according to predicted probabilities
computed using risk equations and dichotomised into high risk
and low risk at some standard high-risk value. Risk equations are
often coded into software to produce ’risk score’ computations,
which provide an individual’s predicted probability of Down’s syn-
drome.
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Target conditions
Down’s syndrome in the fetus due to trisomy, translocation or
mosaicism.
Reference standards
Weconsidered several reference standards, involving chromosomal
verification and postnatal macroscopic inspection.
Amniocentesis and chorionic villus sampling (CVS) are inva-
sive chromosomal verification tests undertaken during pregnancy.
They are highly accurate, but the process carries a 1% miscarriage
rate, and therefore they are only used in pregnancies considered to
be at high risk of Down’s syndrome, or on the mother’s request.
All other types of testing (postnatal examination, postnatal kary-
otyping, birth registers and Down’s syndrome registers) are based
on information available at the end of pregnancy. The greatest
concern is not their accuracy, but the loss of the pregnancy to mis-
carriage between the urine test and the reference standard. Miscar-
riage with cytogenetic testing of the fetus is included in the refer-
ence standard where available. We anticipated that older studies,
and studies undertaken in older women are more likely to have
used invasive chromosomal verification tests in all women.
Studies undertaken in younger women and more recent studies
were likely to use differential verification as they often only used
prenatal karyotypic testing on fetuses considered screen positive/
high risk according to the screening test; the reference standard for
most unaffected infants being observing a phenotypically normal
baby. Although the accuracy of this combined reference standard
is considered high, it is methodologically a weaker approach as
pregnancies that miscarry between the index test and birth are
likely to be lost from the analysis, and miscarriage is more likely
to occur in Down’s than normal pregnancies. We investigated the
impact of the likely missing false negative results in sensitivity
analyses.
Search methods for identification of studies
Electronic searches
We applied a sensitive search strategy to search the following
databases using the search strategies listed in Appendix 1. We used
one generic search to identify studies for all reviews in this series.
We searched the following databases
1. MEDLINE via OVID (1980 to 25 August 2011)
2. Embase via Dialog Datastar (1980 to 25 August 2011)
3. BIOSIS via EDINA (1985 to 25 August 2011)
4. CINAHL via OVID (1982 to 25 August 2011)
5. The Database of Abstracts of Reviews of Effects (the
Cochrane Library 2011, Issue 7)
6. MEDION (25 August 2011)
7. The Database of Systematic Reviews and Meta-Analyses in
Laboratory Medicine (www.ifcc.org/) (25 August 2011)
8. The National Research Register (archived 2007)
9. Health Services Research Projects in Progress database (
HSRPROJ) (25 August 2011)
The search strategy combined three sets of search terms (see
Appendix 1). The first set was made up of named tests, general
terms used for screening/diagnostic tests and statistical terms.Note
that the statistical terms were used to increase sensitivity and were
not used as a methodological filter to increase specificity. The sec-
ond set was made up of terms that encompass Down’s syndrome,
and the third set made up of terms to limit the testing to pregnant
women. All termswithin each set were combinedwith the Boolean
operator OR and then the three sets were combined using AND.
The terms used were a combination of subject headings and free-
text terms. The search strategy was adapted to suit each database
searched.
We attempted to identify cumulative papers that reported data
from the same data set, and contacted authors to obtain clarifi-
cation of the overlap between data presented in these papers, in
order to prevent data from the same women being analysed more
than once.
Searching other resources
In addition, we examined references cited in studies identified as
being potentially relevant, and those cited by previous reviews.
We contacted authors of studies where further information was
required. We did not apply a diagnostic test filter, and we did not
apply language restrictions to the search.
We carried out forward citation searching of relevant items, using
the search strategy in ISI citation indices, Google Scholar and
Pubmed ‘related articles’.
Data collection and analysis
Selection of studies
Two review authors screened the titles and abstracts (where avail-
able) of all studies identified by the search strategy. Full-text ver-
sions of studies identified as being potentially relevant were ob-
tained and independently assessed by two review authors for in-
clusion, using a study eligibility screening pro forma according to
the pre-specified inclusion criteria. Any disagreement between the
two review authors was settled by consensus, or where necessary,
by a third party.
Data extraction and management
A data extraction form was developed and piloted using a subset
of 20 identified studies (from all identified studies in this suite of
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reviews). Two review authors independently extracted data, and
where disagreement or uncertainty existed, a third review author
validated the information extracted.
Data on eachmarker were extracted as binary test positive/test neg-
ative results for Down’s and non-Down’s pregnancies, with a high-
risk result - as defined by each individual study - being regarded as
test positive (suggestive or diagnostic of Down’s syndrome), and
a low-risk result being regarded as test negative (suggestive of ab-
sence of Down’s Syndrome).Where results were reported at several
thresholds, we extracted data at each threshold.
We noted those in special groups that posed either increased risk of
Down’s syndrome or difficulty with conventional screening tests
including maternal age greater than 35 years old, multifetal preg-
nancy, diabetes mellitus and family history of Down’s syndrome.
Assessment of methodological quality
Weused amodified version of theQUADAS tool (Whiting 2003),
a quality assessment tool for use in systematic reviews of diagnostic
accuracy studies, to assess the methodological quality of included
studies. We anticipated that a key methodological issue would be
the potential for bias arising from the differential use of invasive
testing and follow-up for the reference standard according to in-
dex test results, bias arising due to higher loss to miscarriage in
false negatives than true negatives. We chose to code this issue
as originating from differential verification in the QUADAS tool:
we are aware that it could also be coded under delay in obtaining
the reference standard, and reporting of withdrawals. We omitted
the QUADAS item assessing quality according to length of time
between index and reference tests, as Down’s syndrome is either
present or absent rather than a condition that evolves and resolves,
and disregarding the differential reference standard issue, thus any
length of delay is acceptable. Two review authors assessed each in-
cluded study separately. Any disagreement between the two review
authors was settled by consensus, or where necessary, by a third
party. Each item in the QUADAS tool was marked as ‘yes’, ‘no’ or
‘unclear’, and scores were summarised graphically. We did not use
a summary quality score.
QUADAS criteria included the following 10 questions.
1. Was the spectrum of women representative of the women
who will receive the test in practice? (Criteria met if the sample
was selected from a wide range of childbearing ages, or selected
from a specified ‘high-risk’ group such as over 35s, family history
of Down’s syndrome, multifetal pregnancy or diabetes mellitus,
provided all affected and unaffected fetuses included that could
be tested at the time point when the screening test would be
applied; criteria not met if the sample taken from a select or
unrepresentative group of women (i.e. private practice), was an
atypical screening population or recruited at a later time point
when selection could be affected by selective fetal loss.)
2. Is the reference standard likely to correctly classify the target
condition? (Amniocentesis, chorionic villus sampling, postnatal
karyotyping, miscarriage with cytogenetic testing of the fetus, a
phenotypically normal baby or birth registers are all regarded as
meeting this criteria.)
3. Did the whole sample or a random selection of the sample
receive verification using a reference standard of diagnosis?
4. Did women receive the same reference standard regardless
of the index test result?
5. Was the reference standard independent of the index test
result (i.e. the index test did not form part of the reference
standard)?
6. Were the index test results interpreted without knowledge
of the results of the reference standard?
7. Were the reference standard results interpreted without
knowledge of the results of the index test?
8. Were the same clinical data (i.e. maternal age and weight,
ethnic origin, gestational age) available when test results were
interpreted as would be available when the test is used in practice?
9. Were uninterpretable/intermediate test results reported?
10. Were withdrawals from the study explained?
Statistical analysis and data synthesis
We initially examined each test or test strategy at each of the com-
mon risk thresholds used to define test positivity by plotting esti-
mates of sensitivity and specificity from each study on forest plots
and in receiver operating characteristic (ROC) space. Test strate-
gies were selected for further investigation if they were evaluated
in four or more studies or, if there were three or fewer studies,
but the individual study results indicated performance likely to be
superior to a sensitivity of 70% and specificity of 90%.
Estimation of average sensitivity and specificity
The analysis for each test strategy was undertaken first restricting
to studies which reported a common threshold to estimate average
sensitivity and specificity for each test at each threshold. Although
data on all thresholds were extracted, we present only key common
thresholds (historically reported in literature based on age-related
risk) close to risks of 1:384, 1:250 and the 5% false positive rate
(FPR), unless other thresholds were more commonly reported.
Where combinations of tests were used in a risk score, we extracted
the result for the test combination using the risk score and not the
individual components that made up the test.
Meta-analyses were undertaken using hierarchical summary ROC
(HSROC) models, which included estimation of random-effects
in accuracy and threshold parameters when there were four or
more studies. When there was an insufficient number of studies
to reliably estimate all the parameters in the HSROC model, uni-
variate random-effects logistic regression models were used to ob-
tain pooled estimates of sensitivity and specificity. It is common
in this field for studies to report sensitivity for a fixed specificity
(usually a 5% FPR). This removes the requirement to account
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for the correlation between sensitivity and specificity across stud-
ies by using a bivariate model since all specificities are the same
value. Thus, at a fixed specificity value, the summary estimate of
sensitivity was obtained using a univariate random-effects logistic
regression model. This model was further simplified to a fixed-
effect model when there were only two or three studies and het-
erogeneity was not observed on the SROC plot. All analyses were
undertaken using the NLMIXED procedure in SAS (version 9.2;
SAS Institute, Cary, NC) and the xtmelogit command in Stata
version 11.2 (Stata-Corp, College Station, TX, USA).
Comparisons between tests
Comparisons between tests were first made utilising all available
studies, selecting one threshold for each test from each study to
estimate a SROCcurvewithout restricting to a common threshold.
The threshold for each test was chosen from each study according
to the following order of preference: a) the risk threshold closest
to one in 250; b) a multiples of the median (MoM) or presence/
absence threshold; c) the performance closest to a 5% FPR or 95th
percentile. The 5% FPR was chosen as a cut-off point as this is
the cut-off most commonly reported in the literature. The analysis
that used all available studies was performed by including themost
evaluated or best performing test strategies in a single HSROC
model. The model included two indicator terms for each test to
allow for differences in accuracy and threshold. As there were very
few studies for each test, a symmetric summary ROC curve was
assumed. In addition, because the analysis failed to converge, we
assumed fixed-effect for the threshold and accuracy parameters.
An estimate of the sensitivity of each test for a 5%FPRwas derived
from the SROC curve, and associated confidence intervals were
obtained using the delta method.
Direct comparisons between tests were based on results of very few
studies, and were analysed using a simplified HSROCmodel with
fixed-effect and symmetrical underlying SROC curves because the
number of studies was insufficient to estimate between study het-
erogeneity in accuracy and threshold or asymmetry in the shape
of the SROC curves. A separate model was used to make each
pair-wise comparison. Comparisons between tests were assessed
by using likelihood ratio tests to test if the differences in accuracy
were statistically significant or not. The differences were expressed
as ratios of diagnostic odds ratios and were reported with 95%
confidence intervals. As studies rarely report data cross-classified
by both tests for Down’s and normal pregnancies, the analytical
method did not take full account of the pairing of test results, but
the restriction to direct head-to-head comparisons should have re-
moved the potential confounding of test comparisons with other
features of the studies. The strength of evidence for differences
in performance of test strategies relied on evidence from both the
direct and indirect comparisons.
Investigations of heterogeneity
If there were 10 or more studies available for a test, we had
planned to investigate heterogeneity by adding covariate terms to
the HSROC model (meta-regression) to assess the effect of each
factor stated in the Investigation of sources of heterogeneity sec-
tion on accuracy and threshold.
Sensitivity analyses
Mothers with pregnancies identified as high risk for Down’s syn-
drome by ultrasound and serum testing were often offered imme-
diate definitive testing by amniocentesis, whereas those considered
low risk were assessed for Down’s syndrome by inspection at birth.
Such delayed and differential verification will introduce bias most
likely through there being greater loss to miscarriage in theDown’s
syndrome pregnancies that were not detected by the ultrasound
and serum testing (the false negative diagnoses). Testing and de-
tection of miscarriages is impractical in many situations, and no
clear data are available on themagnitude of these miscarriage rates.
To account for potential bias introduced by such a mechanism,
where possible, we performed sensitivity analyses by increasing the
number of false negatives in studies where delayed verification in
test negatives occurred (Mol 1999). We increased the number of
false negatives in such studies by a multiplicative factor that we
applied incrementally from 10% to 50%. The final value of 50%
assumes the true number of false negatives is 1.5 times the observed
number of false negatives, implying the observed number of false
negatives.is 67% (i.e. 1/1.5) of the true number and the fetal loss
rate is 33%. Since no increments were added to the number of true
negatives, this represents a scenariowhere a thirdmore pregnancies
affected by Down’s syndrome is likely to miscarry compared to
those unaffected byDown’s syndrome. This is thought to be higher
than the likely value.
We intended to conduct these sensitivity analyses on analyses in-
vestigating the effect of maternal age on test sensitivity. However,
due to limited data, we performed the sensitivity analyses when
comparing high-risk populations with routine screening popula-
tions. This comparison was considered a proxy for the effect of
maternal age because the main indication for referral for invasive
testing was often increased risk due to advanced maternal age.
R E S U L T S
Results of the search
After the results from each bibliographic database were combined
and duplicates were removed, the search for the whole suite of
reviews identified a total of 15,394 papers. After screening out
obviously inappropriate papers based on their title and abstract,
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1145 papers remained and we obtained full-text copies for formal
assessment of eligibility. From these, a total of 269 papers were
deemed eligible and were included in the suite of reviews. A to-
tal of 126 studies (reported in 152 publications) were included
in this review of first trimester ultrasound alone or in combina-
tion with first trimester serum screening. Since women with mul-
tifetal pregnancies were included in six of the 126 studies, where
a study included multifetal pregnancies, we report fetuses rather
than women or pregnancies. The review involved 1,604,040 fe-
tuses including 8454 Down’s syndrome cases.
A total of 60 different test strategies were evaluated in the 126
studies. These tests were formed from combinations of different
ultrasound markers, serum tests and maternal age. The 11 indi-
vidual ultrasound markers were nuchal translucency (NT), nasal
bone, ductus venosus Doppler (ductus venosus a-wave reversed,
ductus venosus pulsivity index), maxillary bone length, fetal heart
rate, aberrant right subclavian artery, frontomaxillary facial angle,
presence of mitral gap, tricuspid regurgitation, tricuspid blood
flow and iliac angle 90 degrees. The 12 individual serum mark-
ers were inhibin A, alpha-fetoprotein (AFP), free beta human
chorionic gonadotrophin (ßhCG), total hCG, pregnancy-associ-
ated plasma protein A (PAPP-A), unconjugated oestriol (uE3),
disintegrin and metalloprotease 12 (ADAM 12), placental growth
factor (PlGF), placental growth hormone (PGH), invasive tro-
phoblast antigen (ITA) (h-hCG), growth hormone binding pro-
tein (GHBP), and placental protein 13 (PP13). The strategies
evaluated, with or without maternal age, included 13 single ul-
trasound markers; five combinations of two or more ultrasound
markers; six ultrasound and single serum marker combinations;
22 ultrasound and double serummarker combinations; nine ultra-
sound and triple serummarker combinations; one ultrasound and
quadruple serummarker combination; three ultrasound and quin-
tuple serum marker combinations; and one ultrasound and sextu-
ple serum marker combination. Seventy-eight of the 126 studies
only evaluated the performance of a single first trimester ultra-
sound or ultrasound and serum test or test strategy; 27 studies
evaluated two tests, 10 evaluated three tests, four evaluated four
tests, four evaluated five tests, one evaluated eight tests (Koster
2011), one evaluated 11 tests (Kagan 2010), and one evaluated 19
tests (Wald 2003).
The following test combinations were evaluated by four or more
studies.
Ultrasound and triple serum markers
• NT, PAPP-A, free ßhCG, ADAM 12 and maternal age
(four studies; 2571 women, including 256 Down’s syndrome
pregnancies)
Ultrasound and double serum markers
• NT, PAPP-A, free ßhCG and maternal age (69 studies;
1,173,853 fetuses, including 6010 Down’s syndrome cases)
Ultrasound and single serum markers
• NT, free ßhCG and maternal age (five studies; 10,795
women, including 421 Down’s syndrome pregnancies)
• NT, PAPP-A and maternal age (five studies; 9,814 women
including 372 Down’s syndrome pregnancies)
Ultrasound markers alone
• NT, nasal bone and maternal age (five studies, 29,699
women, including 221 Down’s syndrome pregnancies)
• NT and maternal age (50 studies; 530,874 fetuses
including 2701 Down’s syndrome cases)
• Nasal bone and maternal age (four studies; 25,303 women,
including 165 Down’s syndrome pregnancies)
• Ductus and maternal age (five studies; 5,331 women
including 165 Down’s syndrome pregnancies)
• Nasal bone (11 studies; 48,279 fetuses including 290
Down’s syndrome cases)
• NT (13 studies; 90,978 fetuses, including 593 Down’s
syndrome cases)
Of the remaining test combinations, four were evaluated in three
studies, six were evaluated in two studies and the remaining 40 in
single studies only.
Methodological quality of included studies
The studies were judged to be of high methodological quality
in most categories (Figure 1) and details are provided in the
Characteristics of included studies. The spectrum of participants
was judged to be representative in all study cohorts. The refer-
ence standard used was judged unclear in three studies (Hafner
1998; Krantz 2000; Orlandi 1997) and unacceptable in one study
(Noble 1995). Due to the nature of testing for Down’s syndrome
screening and the potential side effects of invasive testing, differen-
tial verification is almost universal in the general screening popu-
lation, as most women whose screening test result is defined as low
risk (negative) will have their screening test verified at birth, rather
than by invasive diagnosis in the antenatal period. Partial verifica-
tion was avoided in 81 study cohorts (64%) and differential veri-
fication was avoided in 15 study cohorts (12%). Both differential
and partial verification was avoided in 14 study cohorts (Biagiotti
1998; Borenstein 2008; Christiansen 2005; Cicero 2004a; De
Graaf 1999; Hewitt 1996;Maiz 2007; Matias 1998;Matias 2001;
Mavrides 2002;Molina 2010 high risk;Otaño2002; Pajkrt 1998a;
Prefumo 2005). Of the 14 study cohorts, the populations in 13
were high-risk referral for invasive testing (prior to screening be-
ing undertaken), while one (Christiansen 2005) obtained mater-
nal serum samples through screening programmes for syphilis and
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Down’s syndrome. Reference standard results were unblinded in
124 study cohorts and unclear in three study cohorts. In contrast,
index test results were blinded in 113 study cohorts and unclear
in 14. It would be difficult to blind clinicians performing invasive
diagnostic tests (reference standards) to the index test result, unless
all women received the same reference standard, which would not
be appropriate in most scenarios. Any biases secondary to a lack
of clinician blinding are likely to be minimal.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Most studies seemed to indicate 100% follow-up, however there
will inevitably be losses to follow-up due to women moving out
of area, for example. Studies sometimes accounted for these and
it is unlikely that there were enough losses to follow-up to have
introduced significant bias. There was likely under-ascertainment
of miscarriage, and very few papers accounted for miscarriage or
performed tissue karyotyping in pregnancies resulting in miscar-
riage. Some studies attempted to adjust for predicted miscarriage
rate and the incidence of Down’s syndrome in this specific pop-
ulation, but most did not. We have not attempted to adjust for
expected miscarriage rate in this review. There is a higher natural
miscarriage rate in the first trimester, however this will be uniform
across studies and therefore unlikely to introduce significant bias.
Some studies which provided estimates of risk using multivariable
equations used the same data set to evaluate performance of the
risk equation as was used to derive the equation. This is often
thought to lead to over-estimation of test performance.
Findings
The results for the 10 most evaluated test strategies are presented
in Summary of findings 1. Additional information and results at
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specific thresholds are provided below.
1) NT, PAPP-A, free ßhCG and maternal age (Figure 2)
Figure 2. Study estimates of sensitivity and specificity with a summary ROC curve for the NT, PAPP-A, free
ßhCG and maternal age test combination at different cut-points. Each symbol represents a pair of sensitivity
and specificity at one cut-point from each study.
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This was the most evaluated test strategy and accounted for most
(73%) of the fetuses in this systematic review. The test was eval-
uated by 69 studies and involved 1,173,853 fetuses (including
6010Down’s syndrome cases). Six studies (Cowans 2009; Ekelund
2008; Kagan 2010; Merz 2011; Nicolaides 2005; Wright 2010)
contributed more than half the total number of fetuses affected
by Down’s syndrome (3057); the largest study (Wright 2010) in-
cluded 223,361 women in whom 886 pregnancies were affected
by Down’s syndrome. Across the 69 studies, data were presented at
10 cut-points (1% false positive rate (FPR), 3% FPR, 4.5% FPR,
5% FPR, 1:150 risk, 1:200 risk, 1:220 risk, 1:250 risk, 1:270 risk
and 1:300 risk). At a cut-point of 5% FPR (24 studies, 391,874
fetuses including 2521 fetuses affected by Down’s syndrome), the
estimated sensitivity was 87% (95% CI 84 to 89); at a cut-point
of 1:250 risk (25 studies; 174,712 fetuses including 1032 fetuses
affected by Down’s syndrome), the estimated sensitivity was 85%
(95% CI 81 to 87) and the specificity was 95% (95% CI 95 to
96).
2) NT, PAPP-A, free ßhCG, ADAM 12 and maternal age
This combination of NT, triple serum markers and maternal age
was evaluated by four studies (Christiansen 2010; Koster 2011;
Spencer 2008; Torring 2010) and included 2571 women (256
pregnancies were affected byDown’s syndrome). Studies presented
data for cut-points of 5% FPR (Christiansen 2010; Koster 2011;
Spencer 2008; Torring 2010) and 1;250 risk (Christiansen 2010;
Torring 2010). At a cut-point of 5% FPR (four studies, 2571
women), the estimated sensitivity was 85% (95% confidence in-
terval (CI) 75 to 91); at a cut-point of 1:250 risk (two studies;
1222 women in whom 74 pregnancies were affected by Down’s
syndrome), the estimated sensitivity was 86% (95% CI 77 to 93)
and the specificity was 97% (95% CI 96 to 98).
3) NT, PAPP-A and maternal age
This test strategy was evaluated by five studies (Biagiotti 1998;
Habayeb 2010; Krantz 2000; Spencer 1999; Wald 2003) and in-
volved 9814 women (including 372 Down’s syndrome pregnan-
cies). Data were presented at cut-points of 5% FPR (Biagiotti
1998; Spencer 1999;Wald 2003), 1:100 risk (Habayeb 2010) and
1:185 risk (Krantz 2000). Habayeb 2010 estimated a sensitivity
of 67% (95% CI 35 to 90) and specificity of 98% (95% CI 97 to
98) at a cut-point of 1:100 risk based on 1507 women in whom
12 pregnancies were affected by Down’s syndrome. At a cut-point
of 1:185 risk, Krantz 2000 estimated a sensitivity of 82% (95%
CI 65 to 93) and specificity of 95% (95% CI 94 to 96) based on
5809 women in whom 33 pregnancies were affected by Down’s
syndrome. For the three studies (2498 women in whom 327 preg-
nancies were affected by Down’s syndrome) that reported a 5%
FPR, the estimated sensitivity was 80% (95% CI 75 to 84).
4) NT, nasal bone and maternal age
This combination of two ultrasoundmarkers andmaternal age was
evaluated by five studies (Has 2008; Kagan 2010; Prefumo 2005;
Prefumo 2006; Sepulveda 2007) and involved 29,699 women (in-
cluding 221 Down’s syndrome pregnancies). Data were presented
at cut-points of 1:100 risk (Kagan 2010) and1:300 risk (Has 2008;
Prefumo 2005; Prefumo 2006; Sepulveda 2007). Kagan 2010 es-
timated a sensitivity of 83% (95% CI 75 to 89) and specificity of
97% (95% CI 97 to 97) based on 19,736 women in whom 122
pregnancies were affected by Down’s syndrome. At a cut-point of
1:300 risk (four studies; 9963 women in whom 99 pregnancies
were affected by Down’s syndrome), the estimated sensitivity was
61% (95% CI 22 to 89) and the specificity was 97% (95% CI 90
to 99).
5) NT, free ßhCG and maternal age
Results for this combination of NT, a single serummarker andma-
ternal age were obtained from five studies (Biagiotti 1998; Krantz
2000; Noble 1995; Spencer 1999; Wald 2003) involving 10,975
women in whom 421 were affected by Down’s syndrome pregnan-
cies. Datawere presented at cut-points of 5%FPR (Biagiotti 1998;
Noble 1995; Spencer 1999; Wald 2003) and 1:240 risk (Krantz
2000). At a cut-point of 5% FPR (four studies; 4986 women in
whom 388 pregnancies were affected by Down’s syndrome), the
estimated sensitivity was 77% (95% CI 68 to 84). At a cut-point
of 1:240 risk, Krantz 2000 estimated a sensitivity of 79% (95%
CI 61 to 91) and specificity of 95% (95% CI 94 to 96) based on
5799 women in whom 33 pregnancies were affected by Down’s
syndrome.
6) NT and maternal age (Figure 3)
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Figure 3. Study estimates of sensitivity and specificity with a summary ROC curve for NT and maternal age
across different cut-points. Each symbol represents a pair of sensitivity and specificity at one cut-point from
each study.
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This ultrasound marker was evaluated in 50 studies that in-
cluded 530,874 fetuses including 2701 fetuses affected by Down’s
syndrome. Seven studies (Bestwick 2010; Gasiorek-Wiens 2001;
Kagan 2010; O’Leary 2006; Snijders 1998; Wald 2003; Wright
2008) each included over 20,000 fetuses and contributed over
half the data (296,481 fetuses including 1444 Down’s syndrome
cases); Snijders 1998 was the largest study (95,802 fetuses). The
50 studies reported diagnostic accuracy at five different cut-points
(1% FPR, 3% FPR, 5% FPR, 1:250 risk and 1:300 risk). At a
cut-point of 5% FPR (22 studies; 288,853 fetuses including 1784
Down’s syndrome cases), the estimated sensitivity was 71% (95%
CI 67 to 75); at a cut-point of 1:250 risk, the estimated sensitivity
was 72% (95% CI 62 to 80) and specificity was 94% (95% CI
90 to 96) based on 10 studies of 79,412 fetuses including 247
affected by Down’s syndrome.
7) NT (Figure 4)
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Figure 4. Study estimates of sensitivity and specificity with a summary ROC curve for NT. Each symbol
represents a pair of sensitivity and specificity at one cut-point from each study.
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Thirteen studies (Acacio 2001; Babbur 2005; Bestwick 2010;
Hafner 1998; Hewitt 1996; Kim 2006; Marsis 2004; Michailidis
2001; Nicolaides 1992; Pajkrt 1998a; Schuchter 2002; Spencer
1999; Wald 2003) evaluated NT in 90,978 fetuses including
593 affected by Down’s syndrome. Of the 13 studies, two stud-
ies (Bestwick 2010; Wald 2003) had a sample size of more than
20,000 and contributed 69% (62,729 fetuses) of the data. Data
were presented at cut-points of 2.5 mm (Acacio 2001; Hafner
1998; Kim 2006; Schuchter 2002), 3 mm (Babbur 2005; Hewitt
1996; Kim 2006; Marsis 2004; Nicolaides 1992; Pajkrt 1998a),
5% FPR (Bestwick 2010; Spencer 1999; Wald 2003) and 99th
centile (Michailidis 2001). At a 5% FPR, the estimated sensitivity
from the three studies was 62% (95% CI 54 to 69), based on
63,885 fetuses including 401 affected byDown’s syndrome. At the
2.5 mm cut-point, the estimated sensitivity from the four studies
was 61% (95% CI 42 to 77) and the specificity was 96% (95%
CI 90 to 98) based on 64 affected cases and a total of 11,835 fe-
tuses. For the 3 mm cut-point, the estimated sensitivity from the
six studies was 58% (95% CI 48 to 68) and the specificity was
97% (95% CI 96 to 98) based on 136 cases and a total of 10,381
fetuses.
8) Nasal bone and maternal age
Nasal bone adjusted for maternal age was evaluated in four stud-
ies (Monni 2005; Prefumo 2005; Prefumo 2006; Viora 2003) in-
volving 25,303 women and included 165 Down’s syndrome preg-
nancies.Monni 2005 accounted for 66% (16,641 women) of the
data. The estimated summary sensitivity was 49% (95% CI 37 to
60) and the summary specificity was 98% (95% CI 95 to 99).
9) Ductus and maternal age
Five studies (Borrell 2005; Matias 2001; Mavrides 2002; Molina
2010 high risk; Prefumo 2005) evaluated this single ultrasound
marker in 5,331 women including 165 Down’s syndrome preg-
nancies. Borrell 2005 contributed 70% (3731 women) of the data.
Data were presented at 5% FPR (Borrell 2005;Mavrides 2002), 1:
250 risk (Borrell 2005), or fetuses were categorised as negative or
positive for Down’s syndrome based on normal or abnormal duc-
tus venous flow (Matias 2001; Mavrides 2002; Prefumo 2005).
At a 5% FPR, the estimated sensitivity from the two studies was
67% (95% CI 54 to 78) based on 3965 women in whom 55 were
affected by Down’s syndrome pregnancies.
10) Nasal bone
Results for this single marker were obtained from 11 studies
(Cicero 2006;Has 2008; Leung 2009;Malone 2004;Molina 2010
high risk;Moon 2007; Orlandi 2003; Orlandi 2005; Otaño 2002;
Ramos-Corpas 2006; Sepulveda 2007) involving 48,279 fetuses
including 290 affected by Down’s syndrome. Cicero 2006 was the
largest study (20,418 women including 140 affected cases), ac-
counting for 42% of the data. The estimated summary sensitivity
was 49% (95%CI 34 to 64) and the summary specificity was 99%
(95% CI 99 to 100).
11) Other test strategies
The results for the remaining test strategies are presented in
Summary of findings 2. Of the 50 test strategies evaluated in fewer
than four studies, 33 test strategies showed estimated sensitivities
of at least 70% and estimated specificities of 90%; none of the
eight single tests without maternal age achieved this level of test
performance. The following seven test strategies evaluated in one
or two studies showed sensitivities of more than 90% and speci-
ficities of more than 95%.
• NT, free ßhCG and PAPP-A evaluated in a single study
(Hormansdorfer 2011) estimated a sensitivity of 90% (95% CI
76 to 97%) and specificity of 95% (95% CI 95 to 96) at a first
trimester incidence rate of 63.3%.
• NT, PAPP-A, free ßhCG, GHBP and maternal age
evaluated in a single study (Christiansen 2009) estimated a
sensitivity of 91% (95% CI 81 to 96) at a cut-point of 5% FPR.
• NT, tricuspid blood flow, free ßhCG, PAPP-A and
maternal age evaluated in a single study (Kagan 2010) estimated
a sensitivity of 91% (95% CI 84 to 95) and specificity of 97%
(95% CI 97 to 98) at a cut-point of 1:100 risk.
• NT, fetal heart rate, free ßhCG, PAPP-A and maternal
age evaluated in two studies (Kagan 2010; Maiz 2009) estimated
a sensitivity of 92% (95% CI 89 to 94) at a cut-point of 5% FPR.
• NT, fetal heart rate, nasal bone, free ßhCG, PAPP-A and
maternal age evaluated in a single study (Kagan 2010) estimated
a sensitivity of 95% (95% CI 90 to 98) and specificity of 96%
(95% CI 95 to 96) at a cut-point of 1:200 risk.
• NT, fetal heart rate, tricuspid blood flow, free ßhCG,
PAPP-A and maternal age evaluated in a single study (Kagan
2010) estimated a sensitivity of 96% (95% CI 91 to 99) at a cut-
point of 5% FPR.
• NT, fetal heart rate, ductus, free ßhCG, PAPP-A and
maternal age evaluated in a single study (Maiz 2009) estimated a
sensitivity of 97% (95% CI 92 to 99) at a cut-point of 5% FPR.
Comparative analysis of the 10 selected test
strategies
For each test we obtained the detection rate (sensitivity) for a
fixed false positive rate (FPR) (1-specificity), a metric which is
commonly used in Down’s syndrome screening to describe test
performance. We chose to estimate detection rates at a 5% FPR
in common with much of the literature. However, because the
5% FPR was not within the range of the data for the nasal bone
marker (the specificities were between 97% and 100%), we did
not compute the detection rate at a 5% FPR for this test; the
summary sensitivity was 49% (95%CI 34 to 64) and the summary
specificity was 99% (95% CI 99 to 100). Figure 5 shows point
estimates of the detection rate (and their 95% CIs) at a 5% FPR
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based on all available data for the remaining nine test strategies; the
test strategies are ordered according to decreasing detection rates.
The plot shows that for the combined NT, PAPP-A, free ßhCG
and maternal age test strategy, the estimated detection rate was
87% (95% CI 86 to 89) based on data from 69 studies with 6010
affected cases out of a total of 1,173,853 participants. The four
single ultrasound markers (NT and maternal age; NT; nasal bone
and maternal age; and ductus and maternal age) showed the worst
performance, whereas, the three test strategies containing PAPP-A
showed the highest performance with detection rates above 80%.
However, it should be noted that the confidence intervals around
the estimates generally overlap though the confidence interval for
the combined NT, PAPP-A, free ßhCG and maternal age test
strategy is very narrow and not overlapped by five of the other test
strategies.
Figure 5. Detection rates (% sensitivity) at a 5% false positive rate for nine of the most evaluated first
trimester ultrasound markers alone or in combination with first trimester serum tests. A = NT, PAPP-A, free
ßhCG and maternal age; B = NT, PAPP-A, free ßhCG, ADAM 12 and maternal age; C = NT, PAPP-A and
maternal age; D = NT, nasal bone and maternal age; E= NT, free ßhCG and maternal age; F= NT and maternal
age; G = NT; H = Nasal bone and maternal age; and I = Ductus and maternal age.Each square represents the
summary sensitivity for a test strategy at a 5% false positive rate. The size of each square is proportional to the
number of Down’s cases. The estimates are shown with 95% confidence intervals. The test strategies are
ordered on the plot according to decreasing detection rate. For each test strategy, the number of included
studies, Down’s syndrome cases and pregnancies are shown on the horizontal axis.
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The strength of evidence for differences in the diagnostic perfor-
mance of the 10 test strategies relied on evidence from both direct
and indirect comparisons. Table 1 shows pair-wise direct com-
parisons (head-to-head), where studies were available. Such com-
parisons are regarded as providing the strongest evidence as dif-
ferences between tests are unconfounded by study characteristics.
The table shows the number of studies (K), the ratios of diagnostic
odds ratios (DORs) with 95% CIs and P values for each test com-
parison. The diagnostic accuracy of NT (with or without mater-
nal age) alone tended to be inferior unlike when combined with
serum tests (PAPP-A and free ßhCG). However, all comparisons
in this table, except for the combined NT, PAPP-A, free ßhCG
and maternal age versus NT and maternal age test comparison (25
studies), were based on five or fewer studies and so are unlikely to
be powered to detect differences in accuracy.
Table 2 shows the same comparisons made using all available data.
Results are generally in agreement with the direct comparisons,
and in addition, showed some statistically significance differences
(P < 0.05) suggesting that nasal bone outperformed other ultra-
sound markers and had similar accuracy with strategies compris-
ing NT and serum markers. Nasal bone was the best performing
ultrasound marker (DOR (95% CI): 132 (71 to 245)), and the
combined NT, PAPP-A, free ßhCG and maternal age test strategy
was the best performing ultrasound and serum test combination
(DOR (95%CI): 133 (114 to 155)). Both tests had amuch higher
diagnostic accuracy than the other tests, and the difference in ac-
curacy was statistically significant in several comparisons especially
when compared with single ultrasound markers with or without
maternal age. The difference in accuracy between the nasal bone
marker and test strategies that included at least one serum test was
statistically significant (P = 0.04) for only the comparison with the
combined NT, free ßhCG and maternal age test strategy. There
were no statistically significant differences in accuracy between
combinations that included nasal bone and NT with or without
maternal age, and test strategies that included both NT and one or
more serum markers. However, these comparisons are potentially
confounded by differences between the studies.
Investigation of heterogeneity and sensitivity analyses
We explored the effect of advanced maternal age (< 35 years ver-
sus ≥ 35 years) on test performance. However, we were unable to
use meta-regression to formally investigate the effect of advanced
maternal age due to limited data. Of the 126 included studies,
13 did not report maternal age. The available data for all studies
are summarised in Table 3 which also shows the four test com-
binations (NT, PAPP-A, free ßhCG and maternal age; NT and
maternal age; nasal bone alone; and NT alone) that included 10
or more studies. Two studies included only pregnant women with
maternal age of 35 years or more; one study (Centini 2005) eval-
uated the NT, PAPP-A, free ßhCG and maternal age test combi-
nation and the other study (Marsis 2004) evaluated NT. Across
the four tests there were 12 studies of women considered high-risk
referrals; one of the studies (Centini 2005), included only preg-
nant women ≥ 35 years old. The main indication for referral for
invasive testing was often increased risk due to advanced mater-
nal age and so we compared high-risk populations with routine
screening populations. The analysis was not performed for nasal
bone because only two of the 11 studies were conducted in high-
risk populations. The results of the investigation for the remaining
three tests together with the sensitivity analyses inflating the false
negatives from 10% to 50% in studies where delayed verification
in test negatives occurred are shown in Table 4.
Delayed verification was not common in high-risk referral studies
as women tended to be offered invasive testing on the basis of
the increased risk, and the corrections to the false negatives made
very little or no difference to the estimates of sensitivity. However,
in screening populations the correction reduced sensitivity, and
consequently reduced the apparent relationship between type of
population and test performance, observed through the ratio of
DORs approaching one. Up to an increase of 40% in the false neg-
atives, the difference in sensitivity between high risk and screening
populations for the NT and maternal age test strategy remained
statistically significant; the magnitude of the difference dropping
from 25% to 17%. However, it should be noted that there were
few high-risk referral studies for each of the three tests and the
results should be interpreted with caution.
In six studies (Hadlow 2005;Hafner 1998; Krantz 2000;Marchini
2010; Schielen 2006; Wapner 2003), we were able to extract data
for the subset of women ≥ 35 years old (≥ 36 years for Schielen
2006). The five NT, PAPP-A, free ßhCG and maternal age test
combination studies all showed higher sensitivity and higher FPR
for the ≥ 35 years subgroup compared to the < 35 years subgroup
as shown on the forest plot (Figure 6) and summary ROC plot
(Figure 7). We did not formally compare the two age groups in a
meta-analysis because the younger age group had very few cases,
thresholds were mixed and there were few studies.
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Figure 6. Forest plot of the NT, PAPP-A, free ßhCG and maternal age test strategy by maternal age group
(< 35 years versus ≥ 35 years).
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Figure 7. Summary ROC plot of the NT, PAPP-A, free ßhCG and maternal age test strategy by maternal
age group (< 35 years versus ≥ 35 years).
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Women with multifetal pregnancies were included in six studies
(Chasen 2003; Hewitt 1996; Leung 2009; Marchini 2010; Moon
2007; O’Callaghan 2000). Hewitt 1996 evaluated NT alone.
Chasen 2003 andO’Callaghan 2000 evaluated the combination of
NTandmaternal age. Both Leung 2009 andMoon 2007 evaluated
nasal bone. Leung 2009 and Marchini 2010 both evaluated the
combination of NT, PAPP-A, free βhCG and maternal age. We
excluded both studies in a sensitivity analysis to determine the
effect on our estimates of test accuracy, due to the potential effect
of multifetal pregnancy on serummarker levels. Our findings were
unchanged.
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Summary of findings
Review question What is the accuracy of ultrasound based markers alone and in combinat ion with maternal age and/ or f irst trimester serum markers for screening
for Down’s syndrome?
Population Pregnant women at less than 14 weeks’ gestat ion conf irmed by ultrasound, who had not undergone previous test ing for Down’s syndrome. Some
studies were undertaken in women ident if ied to be at high risk based on maternal age
Settings All sett ings.
Numbers
of studies, pregnan-
cies and Down’s syn-
drome cases
126 studies (reported in 152 publicat ions) involving 1,604,040 fetuses of which 8454 were Down’s syndrome cases
Index tests Risk scores computed using maternal age and f irst trimester ultrasound and serum markers for ultrasound markers - NT, nasal bone, ductus
venosus Doppler, maxillary bone length, fetal heart rate, aberrant right subclavian artery, f rontomaxillary facial angle, presence of mitral gap, tricuspid
regurgitat ion, tricuspid blood f low and iliac angle 90 degrees - and serum markers - inhibin A, AFP, f ree ßhCG, total hCG, PAPP-A, uE3, ADAM 12, PlGF,
PGH, ITA (h-hCG), GHBP and PP13
Reference standards Chromosomal verif icat ion (amniocentesis and CVS undertaken during pregnancy, and postnatal karyotyping) and postnatal macroscopic inspect ion
Study limitations 116 studies only used select ive chromosomal verif icat ion during pregnancy, and were at risk of under-ascertainment of Down’s syndrome cases due
to pregnancy loss between administering the serum test and the reference standard
Test strategy Studies Women (Down’s cases) Sensitivity (95% CI) Specificity
(95% CI)*
Consequences in a hypothetical cohort of 10,000
pregnant women assuming Down’s syndrome af-
fects approximately one in 800 live-born babies
M issed cases False positives
Nasal bone 11 48,279 (290) 49 (34, 64) 99 (99, 100) 7 100
NT 13 90,978 (593) 70 (61, 78) 95 4 500
NT and maternal age 50 530,874 (2701) 71 (66, 75) 95 4 500
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Nasal bone and mater-
nal age
4 25,303 (165) 68 (28, 92) 95 4 500
Ductus and maternal
age
5 5331 (165) 68 (49, 83) 95 4 500
NT, nasal bone and ma-
ternal age
5 29,699 (221) 78 (55, 91) 95 3 500
NT, f ree ßhCG and ma-
ternal age
5 10,795 (421) 77 (72, 82) 95 3 500
NT, PAPP-A and mater-
nal age
5 9814 (372) 81 (75, 86) 95 3 500
NT, PAPP-A, f ree ßhCG
and maternal age
69 1,173,853 (6010) 87 (86, 89) 95 2 500
NT, PAPP-A, f ree ßhCG,
ADAM 12 and maternal
age
4 2571 (256) 82 (75, 87) 95 3 500
*We est imated sensit ivity (with a 95% conf idence interval) at a 5% false posit ive rate f rom the summary ROC curve obtained
for each test except nasal bone. For nasal bone, the pooled specif icity is reported because the cut-point was absence or
presence of nasal bone, and all studies reported false posit ive rates below 5% so est imation of sensit ivity at a f ixed 5%
FPR was not appropriate.
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Test strategy Studies Women (Down’s cases) Sensitivity* (95% CI) Specificity* (95% CI) Threshold
Without maternal age
Ultrasound markers alone
Aberrant right subclavian
artery
1 425 (51) 8 (2, 19) 99 (98, 100) Feature
Frontomaxillary facial angle 1 242 (22) 18 (5, 40) 98 (95, 99) > 95 th percent ile
Presence of mitral gap 1 217 (20) 20 (6, 44) 87 (81, 91) Feature
Maxillary bone length 1 927 (88) 24 (15, 34) 95 (93, 96) 5th cent ile
Tricuspid regurgitat ion 1 312 (20) 50 (27, 73) 98 (96, 99) Feature
Iliac angle 90 degrees 1 2032 (52) 60 (45, 73) 98 (97, 98) Feature
Ductus venosus a-wave re-
versed
1 378 (72) 68 (56, 79) 70 (64, 75) Feature
Ductus venosus pulsivity in-
dex
1 378 (72) 81 (70, 89) 58 (52, 63) > 95 th percent ile
NT and nasal bone 1 486 (38) 89 (75, 97) 93 (91, 95) Absent nasal bone and NT ≥ 95th cent ile
Ultrasound and double
serum markers
NT, f ree ßhCG and PAPP-A 1 6508 (40) 90 (76, 97) 95 (95, 96) First trimester incidence rate 63.3%
With maternal age
Ultrasound markers alone
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NT-adjusted risk > 1:300
and abnormal ductus veno-
sus f low and absent nasal
bones
1 544 (47) 21 (11, 36) 100 (99, 100) 1:300 risk
NT and ductus 3 23,697 (177) 76 to 93 73 to 99 5% FPR, 1:250 risk, feature
NT and tricuspid blood f low 1 19,736 (122) 85 (78, 91) 97 (97, 98) 1:100 risk
Ultrasound and single
serum markers
NT and inhibin A 2 1150 (97) 61 to 75 95 to 96 5% FPR, 1:250 risk
NT and AFP 1 1110 (85) 61 (50, 72) 95 (94, 96) 5% FPR
NT and total hCG 1 1110 (85) 61 (50, 72) 95 (94, 96) 5% FPR
NT and ITA 1 278 (54) 80 (66, 89) 95 (91, 98) 5% FPR
Ultrasound and double
serum markers
NT, AFP and f ree ßhCG 2 2766 (90) 66 to 100 93 to 95 5% FPR, 1:250 risk
NT, PAPP-A and inhibin A 2 1150 (97) 80 to 83 95 to 96 5% FPR, 1:250 risk
NT, total hCG and inhibin A 1 1110 (85) 62 (51, 73) 95 (94, 96) 5% FPR
NT, f ree ßhCG and inhibin A 1 1110 (85) 66 (55, 76) 95 (94, 96) 5% FPR
NT, f ree ßhCGand ADAM 12 1 351 (31) 68 (49, 83) 95 (92, 97) 5% FPR
NT, PAPP-A and uE3 1 576 (24) 79 (58, 93) 95 (93, 97) 5% FPR
NT, total hCG and PAPP-A 1 1110 (85) 80 (70, 88) 95 (94, 96) 5% FPR
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NT, AFP and PAPP-A 1 1110 (85) 80 (70, 88) 95 (94, 96) 5% FPR
NT, PAPP-A and ITA 2 11,053 (77) 83 (73, 90) 95 5% FPR
NT, PAPP-A and ADAM 12 2 1042 (77) 83 (73, 90) 95 5% FPR
Free ßhCG and PAPP-A,
if risk between 1:42 and
1:1000 (intermediate risk),
NTof fered, f inal composite
risk !:250
1 10,189 (44) 89 (75, 96) 94 (94, 95) 1:250 risk
NT, ductus, f ree ßhCG and
PAPP-A
3 30,061 (212) 83 to 96 97 to 99 1:100 risk, 1:250 risk
NT, nasal bone, f ree ßhCG
and PAPP-A
3 41,842 (271) 89 to 94 95 to 98 5% FPR, 1:100 risk, 1:300 risk
NT, PAPP-A, f ree ßhCG and
ductus venosus pulsivity in-
dex
1 7,250 (66) 89 (79, 96) 95 (94, 95) 5% FPR
NT, tricuspid blood f low,
f ree ßhCG and PAPP-A
1 19,736 (122) 91 (84, 95) 97 (97, 98) 1:100 risk
NT, fetal heart rate, f ree
ßhCG and PAPP-A
2 76,385 (517) 92 (89, 94) 95 5% FPR
NT, fetal heart rate, nasal
bone, f ree ßhCG and PAPP-
A
1 19,736 (122) 95 (90, 98) 96 (95, 96) 1:200 risk
NT, fetal heart rate, tricus-
pid blood f low, f ree ßhCG
and PAPP-A
1 19,736 (122) 96 (91, 99) 95 (95, 95) 5% FPR
NT, fetal heart rate, ductus,
f ree ßhCG and PAPP-A
1 19,614 (122) 97 (92, 99) 95 (95, 95) 5% FPR
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Ultrasound and triple
serum markers
NT, AFP, f ree ßhCG and
PAPP-A
3 6789 (135) 73 to 84 95 5% FPR, 1:250 risk
NT, PAPP-A, f ree ßhCG and
PP13
1 998 (151) 77 (69, 83) 95 (93, 96) 5% FPR
NT, PAPP-A, f ree ßhCG and
total hCG
1 998 (151) 77 (69, 83) 95 (93, 96) 5% FPR
NT, total hCG, inhibin A and
PAPP-A
1 1110 (85) 81 (71, 89) 95 (94, 96) 5% FPR
NT, f ree ßhCG, inhibin A and
PAPP-A
1 1110 (85) 84 (74, 91) 95 (94, 96) 5% FPR
NT, PAPP-A, f ree ßhCG and
PGH
1 335 (74) 86 (77, 93) 95 (92, 97) 5% FPR
NT, PAPP-A, f ree ßhCG and
PIGF
2 1443 (221) 88 (70, 95) 95 5% FPR
NT, PAPP-A, f ree ßhCG and
GHBP
1 335 (74) 91 (81, 96) 95 (92, 97) 5% FPR
Ultrasound and quadruple
serum markers
NT, PAPP-A, f ree ßhCG,
ADAM 12 and PlGF
1 998 (151) 79 (72, 86) 95 (93, 96) 5% FPR
Ultrasound and quintuple
serum markers
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NT, PAPP-A, f ree ßhCG,
ADAM 12, total hCG and
PlGF
1 998 (151) 79 (72, 86) 95 (93, 96) 5% FPR
NT, total hCG, inhibin A,
PAPP-A, AFP and uE3
1 1110 (85) 84 (74, 91) 95 (94, 96) 5% FPR
NT, f ree ßhCG, inhibin A,
PAPP-A, AFP and uE3
1 1110 (85) 86 (77, 92) 95 (94, 96) 5% FPR
Ultrasound and sextuple
serum markers
NT, PAPP-A, f ree ßhCG,
ADAM 12, total hCG, PlGF
and PP13
1 998 (151) 80 (73, 86) 95 (93, 96) 5% FPR
*Tests evaluated by at least one study are presented in the table. Where there were two studies at the same threshold,
est imates of summary sensit ivity and summary specif icity were obtained by using univariate f ixed-ef fect logist ic regression
models to pool sensit ivit ies and specif icit ies separately. If the threshold used was a 5% FPR, then only the sensit ivit ies
were pooled. The range of sensit ivit ies and specif icit ies are presented where meta-analysis was not performed because
there were only two or three studies and no common threshold.
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D I S C U S S I O N
Summary of main results
We found a large number of studies evaluating first trimester
Down’s syndrome ultrasound markers with or without first
trimester serum screening tests. Few studies compared two ormore
test strategies in the same population; the majority of studies only
evaluated a single test strategy. However, the comparison between
NT and the combined NT, PAPP-A, free ßhCG test strategy,
both with maternal age, was evaluated in 25 studies. Few studies
were available to assess the performance of test strategies involving
newer serum markers such as ADAM 12. A summary of results
for the 10 most commonly evaluated test strategies is given in
Summary of findings 1, and the remaining 50 test strategies are
given in Summary of findings 2.
Four key findings were noted.
1. The combined test comprised of NT, PAPP-A, free βhCG
and maternal age appears to have significantly better test accuracy
than the tests comprised of NT and maternal age with or without
either PAPP-A or free βhCG. This combined test detects around
nine out of every 10 Down’s affected pregnancies for a fixed 5%
false positive rate (FPR). By comparison, the tests comprised of
NT and maternal age and either PAPP-A or free βhCG, and NT
alone or with maternal age detects between seven and eight out
of every 10 Down’s affected pregnancies for a fixed 5% FPR.
2. While the test combinations that include nasal bone
showed good detection rates when combined with PAPP-A and
free βhCG, the evidence was limited (three studies) and the
variation in threshold precluded meta-analysis.
3. The evidence for combining NT with higher numbers of
serum markers showed similar detection rates to combinations of
NT and double or triple serum markers that include PAPP-A,
but were based on data from only one or two studies. Therefore
further evaluation of these tests is needed. Furthermore, there
were combinations of NT and other ultrasound markers with
serum markers that showed superior detection rates to
combinations of NT with standard double markers commonly
used in clinical practice, which may warrant further study.
4. Detection rates were lower in high-risk pregnancies (mainly
due to advanced maternal age) compared to routine screening
populations. Evidence was available for three tests at a fixed 5%
FPR and showed reductions in detection rates of between 5%
and 25%. Part of this effect may be explained by studies in
routine screening populations missing false negative cases lost
through increased miscarriage in Down’s pregnancies, but this
does not fully explain the effect. We were unable to draw any
conclusions as to why this may be the case, especially since the
analyses were based on few high-risk referral studies. This finding
also contradicts the observation we made in five studies where
data were available to compare the performance of the NT,
PAPP-A, free βhCG and maternal age test strategy between
women younger than 35 years and those 35 years or more within
the same study. In these studies, the ≥ 35 years age group
showed higher detection rates and FPRs compared to the group
less than 35 years old. It should be noted that very few cases
contributed to the analysis of the younger age group.
Strengths and weaknesses of the review
This review is the first comprehensive review of first trimester ul-
trasound and serum screening. We examined papers from around
the world (32 countries), covering a wide cross-section of women
in varying populations. We contacted authors to verify data where
necessary to give as complete a picture as possible while trying to
avoid replication of data.
There were a number of factors that made meta-analysis of the
data difficult, which we tried to adapt for in order to allow for
comparability of data presented in different studies.
1. There were many different cut-points used to define
pregnancies as high or low risk for Down’s syndrome. This
means that direct comparison is more difficult than if all studies
used the same cut-point to dichotomise their populations. This
is less of an issue for first trimester serum screening, compared to
second trimester serum screening, as the majority of authors
chose a cut-point of 5% FPR.
2. There were many different risk equations and software
applications in use for combination of multiple markers, which
were often not described in the papers. This means that risks
may be calculated by different formulae and they may not be
directly comparable for this reason. It is possible that this is
responsible for unexplained heterogeneity in results.
3. Different laboratories and clinics run different assays and
use different machines and methods. This may influence raw
results and subsequent risk calculations. Many laboratories have
a quality assessment or audit trail, however, this may not
necessarily be standard across the board. For example, how many
assays are run, how often medians are calculated and adjusted for
a given population and how quickly samples are tested from
initially being taken.
4. Few studies made direct comparisons between tests, making
it difficult to detect if a real difference exists between tests (i.e.
how different tests perform in the same population). There were
differences in populations, with assay medians being affected, for
example, by race. It is not certain whether it is appropriate to
make comparisons between populations that are inherently
different.
5. We were unable to perform all the investigations of
heterogeneity that we had originally intended to because the data
simply were not available. The vast majority of papers looking at
pregnancies conceived by IVF, affected by diabetes, multiple
gestation or a family history of Down’s syndrome involved
unaffected pregnancies only.
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In addition, the search for this review was last updated in August
2011, and it is possible that new studies may have been published
which have not been included. Since the search was completed
we have kept a watching brief on outputs and are not aware of
any studies with substantial sample sizes which could substantially
affect the findings.
Applicability of findings to the review question
Potentially, when planning screening policy or a clinical screening
programme, clinicians and policy makers need to make decisions
about a finite number of tests or type of tests that can be offered.
These policies are often driven by both the needs of a specific pop-
ulation and by financial resources. Economic analysis was consid-
ered to be outside of the scope of this review. Many of the tests
examined as part of this review are already commercially available
and in use in the clinical setting. The studies were carried out on
populations of typical pregnant women and therefore, the results
should be considered comparable with most pregnant populations
encountered in every day clinical practice.
We were unable to extract information about harms of testing, in-
formation about miscarriage rates and uptake of definitive testing
as the data were not available the majority of the time. While it
is unlikely that major differences between the tests evaluated here
exist in terms of direct harms of testing, as they are all based on
ultrasound, with or without a blood sample, differences in accu-
racy may lead to differences in the use of definitive testing and its
consequent adverse outcomes.
In some countries with a defined screening policy (i.e. the UK),
first trimester serum screening plays amajor role, usually in combi-
nation with first trimester ultrasound scanning. In others however,
there may only be a limited range of tests or markers available-
often second trimester markers, rather than first trimester mark-
ers. The results of this review should be interpreted and applied in
the context of test availability and local restrictions, populations
or policies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence supports the use of the first trimester test comprised
of nuchal translucency (NT), pregnancy-associated plasmaprotein
A (PAPP-A), free beta human chorionic gonadotrophin (βhCG)
and maternal age; there is little evidence to recommend the use
of first trimester ultrasound markers alone, combinations with
single serum tests or those that exclude PAPP-A. However, the
data available on the addition of more that more than two serum
markers to ultrasound markers are limited, and based on generally
small populations of women.Wewould not recommend that these
tests be introduced into wider clinical practice without careful
consideration of cost.
The review has shown that tests involving NT and two or three
markers in combination with maternal age are significantly better
than those involving ultrasound markers alone. We would there-
fore recommend that ultrasound markers alone, or combinations
involving a single serummarker are not used for Down’s syndrome
screening. The choice of multiple serum markers will depend on
the availability of certain assays in local laboratories.On the basis of
this review we would recommend the combination of NT, PAPP-
A, free βhCG and maternal age, as it significantly outperforms
NT and maternal age or NT and maternal age with either of the
two serummarkers, and is widely available. The data for other test
combinations limits our ability to make any other recommenda-
tions about specific test combinations. Alternative screeningmeth-
ods should also be considered when making policy decisions, and
are the subject of other reviews in this suite.
Implications for research
Further evaluation of test combinations involving ultrasound
markers with three or more serum markers are required to deter-
mine whether they offer superior test performance. Further study
of the performance of test combinations in women over 35 is re-
quired, as this age group has the highest incidence of Down’s syn-
drome and has the greatest requirement for tests with high detec-
tion rates.
Future studies should ensure that adequate sample sizes are re-
cruited, and take opportunities to make comparisons of test per-
formance testing several alternative test combinations on the same
population. Such direct comparison removes issues of confound-
ing when making test comparisons, and allows a clear focus on
testing the incremental benefit of increasingly complex and expen-
sive testing strategies. The reporting of studies of test accuracy can
be improved and more closely adhere to the standards for the re-
porting of diagnostic accuracy studies (STARD) guideline. Three
key aspects of this are: 1) formally testing the statistical signifi-
cance of differences in test performance in direct comparisons and
estimating incremental changes in detection rates (together with
confidence intervals); 2) clearly reporting the number of mothers
studied and their results; and 3) reporting the numbers of women
who are lost to follow-up.Many authors reported results of extrap-
olating findings to age-standardised national cohorts to demon-
strate the performance of the test, and failed to report the actual
numbers studied and evaluated.
For the purposes of meta-analysis and to allow for comparisons
to be made between different tests and combinations, we would
recommend the publication of consensus standard algorithms for
estimating risk, and reporting of test performance at a standard set
of thresholds. This would be difficult to achieve and implement,
but an attempt at consensus should be made.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Acacio 2001
Clinical features and settings High-risk referral for invasive testing
Participants 230 participants
Brazil - private centres
Dates not specified
Pregnant women
Mean age 35.8 years (21-45 years)
Singleton pregnancies
Karyotyping performed at same time as NT
10-14 weeks’ gestation
Study design Diagnostic validation study to determine the best ROC cut-off for NT
Retrospective study of patient notes
Target condition and reference standard(s) Down’s syndrome: 12 cases
Reference standards: chorionic villus biopsy, amniocentesis or blood or placenta used for
fetal karyotyping
Index and comparator tests NT with cut-off of 2.5 mm (found to be optimum cut-off from ROC) (Sequoia, Aspen
128XP10-Acuson and Toshiba SH140)
Follow-up 100% karyotyping
Aim of study To define the best fixed cut-off point for NT, and the accuracy of this cut-off for all fetal
aneuploidy screening and for trisomy of chromosome 21
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes Karyotyping
Partial verification avoided?
All tests
Yes All patients received a reference standard
Differential verification avoided?
All tests
No Women had different reference standard
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Acacio 2001 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Audibert 2001
Clinical features and settings Routine screening
Participants 4130 participants
France - single centre
May 1994 to December 1997
Pregnant women
Mean maternal age 30.1 years (all under 38 years), 86% < 35, 14% ≥ 35
Singleton pregnancies
10-14 weeks’ gestation
Crown-rump length between 38 mm and 84 mm
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome: 12 cases
Reference standards: prenatal karyotyping conducted (in 7.6% of patients) depending
on presence of risk > 125, high maternal age, parental anxiety, history of chromosomal
defects or parental translocation or abnormal second trimester scan age
Cytogenetic testing of newborns with suspected abnormalities
Postmortem on terminations of pregnancy or miscarriages
Follow-up to neonatal examination in newborn
Index and comparator tests Maternal age
First trimester NT planned at 12-13 weeks, 3 mm risk cut-off
Second trimester serum hCG between 14 and 17 weeks (Amerlite, Orthoclinical diag-
nostics machine), cut-off 1:250 (Prenata software)
Second trimester serum AFP between 14 and 17 weeks (Amerlite, Orthoclinical diag-
nostics machine), cut-off 1:250 (Prenata software)
Serum tests in 3790 women
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Audibert 2001 (Continued)
Follow-up Delivery and postnatal paediatric examination
35 lost to follow-up and excluded from analysis
Pregnancy loss in 37 women due to spontaneous abortion (n = 21) or intrauterine death
(n = 16)
340 women had first trimester NT but not second trimester serum testing
Aim of study To compare first trimester NT and second trimester maternal serum measurements as
alternative methods of antenatal screening in a low-risk population and to evaluate the
consequence of combining the results in the estimation of risk
Notes Women lost to follow-up are excluded in the final analysis. All antenatally detected cases
were terminated
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT was not measured or not recorded in 219 women and these
patients were excluded from the study
Withdrawals explained?
All tests
Yes 340 women who did not want second trimester serum screening
withdrew from that part of the study
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Babbur 2005
Clinical features and settings Women requesting screening (self-paying service) and women attending on account of
previous pregnancy history of fetal abnormality
Participants 3188 participants
Cambridge, UK - Maternity Hospital
August 2001-March 2004
Singleton pregnancies
Pregnant women
Median age 37 years (19-46 years)
11-14 weeks’ gestation
45-84 mm crown-rump length
Viable fetus
Study design Prospective cohort study
Target condition and reference standard(s) Down’s syndrome: 25 cases
Reference standards: invasive testing offered to women with NT > 3 mm or risk > 1:
250 as defined by combined NT and serum results (chorionic villus sampling from 11
weeks, amniocentesis from 15 weeks). Rapid in situ hybridisation test in patients with
risk > 1:30. No details given of any follow-up to birth
Index and comparator tests First trimester NT in all women (FMF methods)
Second trimester serum biochemistry (AutoDELFIA(TM) time-resolved fluorim-
munoassay (Perkin Elmer)) at 14 weeks. Offered to patients with negative first trimester
NT (2725 accepted, 85%)
Follow-up Details of follow-up to birth not given
Aim of study To determine the detection and false positive rates for trisomy 21 using 2-stage combined
nuchal translucency and triple testing whilst disclosing abnormal NT measurements at
the scan
Notes Women with miscarriages excluded
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference
standard
Differential verification avoided?
All tests
No Choice of reference standard depended on
index test results
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Babbur 2005 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge
of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
Yes 463 patients having NT did not go on to
have serum testing
Barrett 2008
Clinical features and settings Routine screening
Participants 10,273 participants with complete screening and outcome data
Australia - screening programme, independent ultrasound practices
24-month period (dates not specified)
Pregnant women
Mean maternal age 34.9 years (screen positive) and 30.5 years (screen negative)
Singleton pregnancies
11-13 weeks’ gestation
Study design Cohort study
Target condition and reference standard(s) Down’s syndrome: 32 cases
Reference standard: karyotyping or follow-up to birth
Index and comparator tests NT (FMF protocol)
First trimester PAPP-A and free ßhCG (90.2% by time resolved amplified cryptate
emission technology, Kryptor random access immunoassay analyzer, Brahms, 9.8% by
manual Ortho Clinical Diagnostic Immunometric I125 immunoassay for PAPP-A, and
Ortho Clinical Diagnostics Vitros ECi automated analyzer for ßhCG)
Risk cut-off 1:300
Follow-up Linkage to data collected by theMidwives Notification System and theWestern Australia
Birth Defects Registry and by searching laboratory records of all prenatal cytogenetics
services in the state
162 women lost to follow-up were excluded
Pregnancy loss in 54 women due to miscarriage (n = 35), stillbirth (n = 17) and neonatal
death (n = 2)
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Barrett 2008 (Continued)
Aim of study To investigate associations between combined first-trimester screen result, pregnancy
associated plasma protein level and adverse fetal outcomes in women
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Belics 2011
Clinical features and settings High-risk referral for invasive testing
Participants 2032 participants with adequate imaging on ultrasound screening
Budapest - single centre
January 2003 - February 2010
Pregnant women
Mean age 36.4 years (15-46 years) (Down’s syndrome) and 29.8 years (15-49 years) (no
Down’s syndrome)
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Belics 2011 (Continued)
11-20 weeks’ gestation
Study design Cohort study
Target condition and reference standard(s) Down’s syndrome: 52 cases
Reference standards: amniocentesis or CVS (85% of women), or follow-up to birth
Index and comparator tests First and second trimester fetal iliac angle (GE Medical System Kretztechnik GmbH &
Co OHG, AC2-5 transabdominal and IC5-9 transvaginal curved array transducer and
Medison Co., LTD EC4-9ES transvaginal and C3-7IM transabdominal curved array
transducer)
Measurement taken from a transverse section of the fetal pelvis
Cut-off angles of 75-100o
Follow-up Followed up to delivery (no cases were detected at birth)
Aim of study To present results of the sonographic measurement of the fetal iliac angle during the first
and second trimesters of pregnancy
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Different reference standards used
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
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Belics 2011 (Continued)
Uninterpretable results reported?
All tests
Yes 95.2% had adequate imaging
Withdrawals explained?
All tests
No No details of withdrawals given
Benattar 1999
Clinical features and settings Routine screening
Participants 1656 participants
France - single centre
January to December 1995
Singleton pregnancies
Pregnant women
Mean age 32 years (16-46 years), 8.3% > 35 years
Enrolled before 13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 5 cases
Reference standards: amniocentesis due to maternal age > 38 years (6.1% or women)
. Karyotyping encouraged for women with positive result on 1 or more index test. No
details of reference standard for index test negative women
Index and comparator tests Maternal age
NT at 12-14 weeks (Toshiba SSA 270), risk cut-point 1:250
First trimester (12-14 weeks) serum AFP and free ßhCG (Elsa AFP and Elsa free ßhCG;
Cis-Bio International)
Second trimester (15-18 weeks) serum AFP and total hCG (AFP-2T and hCG-60;
Ortho-Clinical Diagnostics)
All women had NT and serum testing
Follow-up Details of follow-up are not stated. Unclear whether women were followed up to birth
Of the 1656 women, 12 (0.7%) were lost to follow-up, 2 hadmiscarriages, 2 had preterm
premature ruptures of the membranes and 2 had intrauterine deaths
Aim of study To evaluate the sequential combination of ultrasound screening for fetal aneoploidy at
11-14 weeks with maternal biochemistry at 12-14 and 15-18 weeks of gestation
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
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Benattar 1999 (Continued)
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Bestwick 2010
Clinical features and settings Routine screening
Participants 22,746 participants
London - 2 antenatal clinics
January 2003 - December 2008
Pregnant women
Median age 39 years (Down’s syndrome) and 34 years (non-Down’s syndrome)
11-13 and 14-22 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 106 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests First trimester NT, PAPP-A and free ßhCG (details not reported)
Second trimester AFP, uE3, free ßhCG and inhibin A (details not reported)
Results in multiple publications
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Bestwick 2010 (Continued)
Follow-up Data obtained from the Hospitals, the regional cytogenetic unit and the National Down
Syndrome Cytogenetic Register
Aim of study To determine whether the standard deviation of NT measurements has decreased over
time and, if so, to revise the estimate and assess the effect of revising the estimate of the
standard deviation on the performance of antenatal screening for Down’s syndrome
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
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Biagiotti 1998
Clinical features and settings High-risk referral for invasive testing
Participants 232 participants (all had NT and serum testing)
32 cases of Down’s and 200 randomly selected controls (selected from series of 3731
women)
Italy - single centre
July 1993 - December 1996
Pregnant women
10 to 13 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 32 cases
Reference standards: CVS or amniocentesis
Index and comparator tests Maternal age
First trimester NT (in longitudinal section of the fetus with caliper measurements to the
nearest 0.1 mm)
First trimester PAPP-A (Amerlex-M PAPP-A IRMA, Ortho-Clinical Diagnostics)
First trimester free ßhCG (Elsa9free ßhCG CIS)
Follow-up 100% karyotyping
Aim of study To evaluate the potential effectiveness of maternal serum PAPP-A and free ßhCG in
combination with NT measurement in the first trimester of pregnancy
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes Karyotyping
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
Yes All women had the same reference standard
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
81First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Biagiotti 1998 (Continued)
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Borenstein 2008
Clinical features and settings High-risk referral for invasive testing
Participants 516 participants
London - hospital birth centre
Dates not reported
Pregnant women
Median maternal age 35 years (range 17-49 years)
11-13 weeks’ gestation
16-24 weeks’ gestation in a sub-sample of 183 women
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 51 cases
Reference standard: CVS
Index and comparator tests First trimester fetal echocardiography (transabdominally with a 4-8 MHz curvilinear
transducer, Voluson 730 Expert, GE Medical Systems) in all women (425 successfully
examined) and in the second trimester in 183 women
Follow-up 100% karyotyping
Aim of study To establish the feasibility of examining the subclavian artery at 11 + 0 to 13 + 6 weeks
of gestation and to determine the prevalence of aberrant right subclavian artery (ARSA)
in chromosomally normal and abnormal fetuses
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant popula-
tion
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Borenstein 2008 (Continued)
Acceptable reference standard?
All tests
Yes Karyotyping
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
Yes All women received the same reference standard
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes 425/516 (82.4%) of women were successfully
examined
Withdrawals explained?
All tests
No No details of withdrawals given
Borrell 2005
Clinical features and settings Routine screening
Participants 3731 participants
Spain
October 1999 - December 2002
Pregnant women
10 to 14 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 25 cases
Reference standards: CVS (high-risk women) or follow-up to birth
Index and comparator tests Maternal age
First trimester (10-14 weeks) Ductus venous Doppler studies
First trimester (10-14 weeks) NT (FMF method)
First trimester (10 weeks) serum PAPP-A and free ßhCG (time-resolved fluorescent
assays, Perkin-Elmer Life Sciences)
Risk cutoffs 1:200, 1:250 or 1:300
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Borrell 2005 (Continued)
DV - Saggital view of quiescent fetus. When optimal record of DV obtained, measured
only once. When reversed end diastolic flow present, 3 separated samples obtained.
Maximum velocity manually drawn in 3 waveforms and PIV automatically obtained by
software linked to equipment
Follow-up Details given in Borrel 2004: follow-up through phone enquiry, contact with attending
obstetrician, births defects registry of Barcelona. Cases with missing follow-up or un-
known karyotype excluded from further analysis
Aim of study To estimate the improvement in screening efficiency when fetal ductus venosus Doppler
studies are added to existing first trimester Down’s syndrome screening protocols
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth (described in Borrel 2004)
Partial verification avoided?
All tests
Yes All patients received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes 4 unaffected pregnancies could not be assessed with NT
Withdrawals explained?
All tests
No No details of withdrawals given
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Borrell 2009
Clinical features and settings Routine screening and high-risk referral
Participants 7250 participants:
6940 women undergoing routine screening (October 1999 - December 2006)
310 women referred for CVS (October 1999 - December 2007)
Barcelona - hospital clinic
Pregnant women
Mean maternal age 32 years
10-13 and 15-20 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 66 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT and ductus venosus pulsivity index (DVPI) (transabdominal ultra-
sound, Eccocee SSA and Power-Vision 400, Toshiba Medical Systems, Voluson PRO,
General Electrics Healthcare)
First trimester PAPP-A and free ßhCG (details not reported)
Second trimester AFP, uE3, free ßhCG and inhibin A (details not reported)
Follow-up From hospital clinic records, telephoning women or from the attending obstetrician.
Obtained in 97.4% of pregnancies
Aim of study To assess the value of ductus venosus blood flow (expressed as pulsatility index, DVPI)
in antenatal Down’s syndrome screening when used with the combined and integrated
tests
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation and selective testing of high-risk
women as done in practice
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference
standard
Differential verification avoided?
All tests
No Choice of reference standard depended on
index test results
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Borrell 2009 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of
reference standard results
Relevant clinical information?
All tests
Yes Information available aswould be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes Ductus venosus measurements were not ob-
tained in 3.3% of pregnancies
Withdrawals explained?
All tests
No No details of withdrawals given
Brameld 2008
Clinical features and settings Routine screening
Participants 22,280 participants with complete screening results and outcome data
August 2001 - October 2003
Australia - State-wide screening programme evaluation
Pregnant women
Median maternal age 31 years (range 14-47 years), 20% ≥ 35
Singleton pregnancies
10-14 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 60 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester PAPP-A, free ßhCG and NT (details not reported)
Risk cut-point 1:300
Follow-up Data on outcome from the Western Australia Midwives data collection, Birth Defects
Registry and hospital morbidity and mortality data
Aim of study To identify first trimester indicators of adverse pregnancy outcomes
Notes
Table of Methodological Quality Table of Methodological
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Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow- up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Brizot 2001
Clinical features and settings Routine screening
Participants 2996 participants
Brazil - University Hospital
Estimated date of delivery pre December 1999
Pregnant women
Median age 28 years (13-46 years), 19.4% ≥ 35 years
Singleton pregnancies
10-14 weeks’ gestation (mean 12 weeks)
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 10 cases
Reference standards: antenatal karyotyping (5.9% of pregnancies: 62% of high-risk,
29% of medium-risk and 3% of the low-risk women) or follow-up to birth (85.3% of
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Brizot 2001 (Continued)
women)
Index and comparator tests Maternal age
First trimester (10-14 weeks) NT
Risk cut-off 1:300
Follow-up 85.3% of women were followed up to birth. Of these, 65 were spontaneous miscarriages
or intrauterine death with no karyotyping
Aim of study To assess the detection rate of chromosomal abnormalities using NT
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
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Centini 2005
Clinical features and settings High-risk patients undergoing routine screening
Participants 408 participants
Italy
Dates not reported
Pregnant women
Singleton pregnancies
Aged ≥ 35 years (range 35-44 years)
10-13 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 6 cases
Reference standards: amniocentesis in women high risk on screening (16.2%) or follow-
up to birth in women who were low risk on screening
Index and comparator tests Maternal age
NT with cut-point 3 mm
Serum free ßhCG (Schering RIA) and PAPP-A (Chematil ELISA)
Risk score cut-point 1:250
Follow-up Follow-up at birth in all by collaboration with mothers
Women who miscarried were excluded from the study
Aim of study To evaluate the combined test of NT, serum markers and age in pregnant women 35
years of age and over to detect Down’s syndrome
Notes No live births were Down’s syndrome. All detected cases were terminated. 7 women were
excluded due to miscarriages
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on
index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test
89First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Centini 2005 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge
of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Chasen 2003
Clinical features and settings Routine screening
Participants 2131 women with 2339 fetuses
New York - single centre
April 2000 to November 2002
Pregnant women
Singleton or multifetal pregnancies
Median age 33 years (interquartile range 31-36), 36.2% ≥ 35 years
Study design Prospective consecutive cohort
Target condition and reference standard(s) Down’s syndrome: 12 cases
Reference standards: karyotyping or follow-up to birth in 96.1% of patients
Index and comparator tests Maternal age
NT (FMF methods)
Combined risk score cut-point 1:300
Each fetus with a separate chorion was considered individually when calculating the
performance of NT but for monochorionic twins, only the fetus with the higher risk
calculation was included
Follow-up Attempted to obtain results for cytogenetic testing following miscarriage or termination
or where Down’s suspected at birth. Karyotype results or documented evidence of phe-
notypically normal baby was recorded in 96.1% of patients
Aim of study To examine the detection rate of chromosomal abnormalities using a combination of
nuchal translucency and maternal age
Notes
Table of Methodological Quality Table of Methodological
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Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
No Reference standard results were available for only 96% of pa-
tients
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes 19 patients could not be imaged
Withdrawals explained?
All tests
No No details of withdrawals given
Chen 2009
Clinical features and settings Routine screening
Participants 242 participants: 22 cases and 220 randomly selected controls
China - hospital screening programme
August 2003 - March 2007
Pregnant women
Median maternal age, cases 30 years (20-44 years) and controls 32 years (19-40 years)
12-14 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 22 cases
Reference standards: karyotyping or follow-up to birth
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Chen 2009 (Continued)
Index and comparator tests First trimester frontomaxillary facial (FMF) angle (transabdominal ultrasound, ATLHDI
5000, Philips Medical Systems or Voluson 730 Pro, GE Medical systems, by clinicians
accredited by the FMF)
Measured with a protractor from printed and filed images
Angle > 95th percentile taken as positive test result
Follow-up Pregnancy outcome obtained from obstetric and neonatal files
Aim of study To evaluate the measurement of FMF angle at 11-13 weeks, 6 days in a Chinese popu-
lation and its applicability in screening for fetal trisomy 21
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if index test interpreted without knowledge of reference
standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Unclear Only the most optimal images were included in the study and
the proportion of images that were not included is not stated
Withdrawals explained?
All tests
No No details of withdrawals given
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Christiansen 2005
Clinical features and settings Screening programmes for syphilis and Down’s syndrome
Participants 108 participants (27 cases of Down’s syndrome, 81 controls)
Denmark - Statens Serum Institute
Dates not specified
Pregnant women
5-11 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 27 affected cases (18 diagnosed in 2nd trimester, 9 at birth)
Reference standard: karyotyping
Index and comparator tests Maternal age
First trimester (week 11-14) NT
Frozen samples tested for:
First trimester (week 5-11) inhibin A (dimer assay kit MCA 950KZZ, Serotec)
First trimester (week 5-11) ßhCG (available for some samples)
First trimester (week 5-11) PAPP-A (available for some samples) (combined PAPP-A
and ßhCG TrIFMA assay)
Risk cutpoints of 1:100, 1:250 and 1:400
Performance assessed with SPlus algorithm
Follow-up All diagnosis were verified by karyotyping
Aim of study To investigate whether inhibin A can be used in the first trimester for Down’s syndrome
screening
Notes Identified through the Danish central cytogenetic registry as part of quality assurance
programme
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation
Acceptable reference standard?
All tests
Yes Karyotyping
Partial verification avoided?
All tests
Yes All women had a reference standard
Differential verification avoided?
All tests
Yes All women had the same reference standard
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test
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Christiansen 2005 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted with-
out knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Christiansen 2009
Clinical features and settings Routine screening
Participants 335 participants: 74 cases and 261 controls matched for length of sample storage and
maternal age
Denmark - screening programme
Dates not reported
Pregnant women
Singleton pregnancies
Median maternal age cases 37.5 years and controls 36.4 years
8-13 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 74 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (details not reported)
Fresh serum samples tested for:
First trimester PAPP-A and free ßhCG (AutoDelfia, PerkinElmer, Turku or Kryptor,
Brahms)
Frozen serum samples tested for:
First trimester placental growth hormone (double monoclonal ELISA, DSL-10-19 200,
Diagnostic Systems Laboratory Inc)
Growth hormone binding protein (enzyme-amplified ELISA, DSL-10-48 100, Diag-
nostic Systems Laboratory Inc)
Follow-up Cross-referencing with the Danish Cytogenetic Central Registry
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Christiansen 2009 (Continued)
Aim of study To examine the potential of placental growth hormone and growth hormone binding
protein as maternal serum screening markers for Down’s syndrome
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Christiansen 2010
Clinical features and settings Routine screening
Participants 531 participants: 28 cases and 503 controls
Denmark - screening programme
Dates not specified
Pregnant women
Singleton pregnancies
Median age cases 36 years (range 25-44 years) and controls 29 years (range 17-45 years)
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Christiansen 2010 (Continued)
8-14 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 28 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (details not reported)
First trimester PAPP-A and free ßhCG (details not reported)
First trimester ADAM12s (AutoDELFIA/Delfia ADAM12 Research kit 4025-0010,
PerkinElmer Life and Analytical Sciences, on the 1235 AutoDELFIA automatic im-
munoassay system)
Follow-up Cross-referencing with the Danish Cytogenetic Central Registry
Aim of study To examine the efficiency of a second generation assay for ADAM12
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
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Christiansen 2010 (Continued)
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Cicero 2004a
Clinical features and settings High-risk referral for invasive testing
Participants 970 fetuses (20 twin and 1 triplet pregnancy)
UK
Dates not specified
Pregnant women
Median age 37 years (16-48 years)
11-14 weeks’ gestation (median 12 weeks)
Study design Prospective cohort study
Target condition and reference standard(s) Down’s syndrome: 88 cases
Reference standard: CVS
Index and comparator tests Maxillary bone length
Mid-saggital view of fetal profile obtained for nasal bone. Transducer angled laterally so
that the maxillary bone and mandible including the ramus and condylar process can be
seen. Maxillary length measured with callipers. Magnified to 0.1 mm increment
Follow-up 100% karyotyping
Aim of study To determine the value of measuring maxillary length at 11-14 weeks’ gestation in
screening for trisomy 21
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes CVS
Partial verification avoided?
All tests
Yes All women had a reference standard
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Cicero 2004a (Continued)
Differential verification avoided?
All tests
Yes All women had the same reference standard
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes Study reports thatmeasurementsweremade suc-
cessfully in all cases
Withdrawals explained?
All tests
No No details of withdrawals given
Cicero 2006
Clinical features and settings Routine screening
Participants 20, 418 participants
UK - Fetal Medicine Centre
October 2001-2004
Pregnant women
Singleton pregnancies
Median age 35 years (18-50 years)
11-13 weeks’ gestation
Study design Prospective cohort study
Target condition and reference standard(s) Down’s syndrome: 140 cases
Reference standards: CVS or amniocentesis in high-risk women, or follow-up to birth
Index and comparator tests Maternal age
Presence of nasal Bone (FMF methods)
First trimester NT (FMF methods)
First trimester serum free ßhCG (Kryptor analyser, Brahms AG)
First trimester serum PAPP-A (Kryptor analyser, Brahms AG)
Follow-up Data on pregnancy outcome from cytogenetics laboratory and by letters and telephone
calls to patients, GPs and maternity units
656 patients excluded because karyotype was not known due to miscarriage (n = 185),
termination of pregnancy (n = 85) or loss to follow-up (n = 386)
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Cicero 2006 (Continued)
Aim of study To investigate the impact of incorporating assessment of the nasal bone into first trimester
combined screening by fetal nuchal translucency thickness andmaternal serumbiochem-
istry
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Reported that fetal NT and serum markers were successfully
measured in all cases
Withdrawals explained?
All tests
Yes Patients lost to follow-up reported
Cocciolone 2008 FTS
Clinical features and settings Routine screening
Participants 18,901 participants
Australia - South Australian Maternal Serum Antenatal Screening Program
Dates not reported
Pregnant women
Median age 31.3 years
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Cocciolone 2008 FTS (Continued)
Maternal and gestational age not reported
Study design Cohort study
Target condition and reference standard(s) Down’s syndrome: 66 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT PAPP-A and free ßhCG (details not reported)
Follow-up Details not reported
Aim of study To compare different screening strategies for the detection of Down’s syndrome and to
consider the practical implications of using multiple screening protocols
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
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Cocciolone 2008 FTS (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given
Cowans 2009
Clinical features and settings Routine screening
Participants 57,057 participants
June 1998 - July 2007
UK - 6 Hospitals
Pregnant women
Singleton pregnancies
Mean age: Down’s syndrome 38 years (range 16-49 years) and healthy 29 years (range
13-56 years)
10-14 weeks’ gestation
Study design Cohort study
Target condition and reference standard(s) Down’s syndrome: 723 cases (307 from original cohort and 416 supplemented cases
screened at the Fetal Medicine centre or Harris Birthright Research Centre for Fetal
Medicine)
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF certified sonographers)
First trimester PAPP-A and free ßhCG (Kryptor analyser, Brahms)
Rick cut-point 1:300
Follow-up Birth data collected at birth by the delivering hospital and stored in several databases
which were merged. Only women with full records for screening and birth outcome
included in the study
Aim of study To investigate if fetal sex has an impact on first trimester combined screening for aenu-
ploidy
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
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Cowans 2009 (Continued)
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Cowans 2010
Clinical features and settings Routine screening
Participants 445 participants: 70 cases and 375 controls matched for storage time and gestational age
January 2007 - October 2008
UK
Pregnant women
Singleton pregnancies
Mean maternal age cases 37.0 years (IQR 32.9 to 40.5 years) and controls 32.4 years
(IQR 29.0 to 35.9 years)
11-13 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 70 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF certified sonographers)
Fresh serum samples tested for:
First trimester PAPP-A and free ßhCG (Kryptor analyser, Brahms)
Frozen serum samples tested for:
First trimester placental growth factor (Solid-phase, 2-site fluoroimmunometric research
assay (4083-0010) on 6000 DELFIA Xpress random access platform, PerkinElmer)
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Cowans 2010 (Continued)
Follow-up Karyotype and results for pregnancy outcome received from cytogenetics laboratories
and maternity units where deliveries took place
Aim of study To examine placental growth factor levels in first trimester maternal serum in trisomy 21
pregnancies and to investigate the potential value of PIGF in a first trimester screening
test
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
103First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Crossley 2002
Clinical features and settings Routine screening
Participants 17,229 participants
UK - 15 centres
Dates not specified
Pregnant women
Median age 29.9 years, 15.4% ≥ 35 years
10-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 45 cases
Reference standards: CVS (offered where women had high NT measurements), amnio-
centesis or follow-up to birth
Index and comparator tests Maternal age
NT (FMF method) in 73% of patients
Clotted blood samples tested for:
Free ßhCG and PAPP-A (Kryptor analyser) in 98.4% of patients
Follow-up Reported that the outcome of all pregnancies was followed up
Aim of study To evaluate the use of NT measurement in combination with biochemical markers as a
first trimester test for Down’s syndrome in routine antenatal setting
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
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Crossley 2002 (Continued)
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Report average success rate of NT (72.9%)
Withdrawals explained?
All tests
Yes Numbers of patients not undergoing NT and biochemical test-
ing given
De Graaf 1999
Clinical features and settings High-risk referral for invasive testing
Participants 292 participants (207 participants before 14 weeks’ gestation)
The Netherlands - single centre
19 84-1997
Pregnant women
Cases: 37 with Down’s syndrome
Controls: 255 matched 5:1 with cases for maternal age (within 2 years), gestational age
(within 2 weeks) and duration of sample storage (within 2 months)
9-15 weeks’ gestation (in a few cases, blood samples for serum testing taken at 15-19
weeks)
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 37 cases (24 affected pregnancies in women with NT testing enrolled
before 14 weeks’ gestation)
Reference standards: CVS and amniocentesis
Index and comparator tests Maternal age
NT (FMF methods) with cut-off > 3 mm
Frozen serum samples tested for:
First trimester free ßhCG and AFP (DELFIA dual labelled time resolved fluorescent
assay)
First trimester serum PAPP-A (DELFIA research assay (CR61-105))
First trimester serum AFP
Follow-up 100% karyotyping
Aim of study To determine the expected detection rate and false positive rate for Down’s syndrome
achievable by early pregnancy screening with combined measurements of serum PAPP-
A, free ßhCG and fetal nuchal translucency, with the addition of AFP
Notes
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De Graaf 1999 (Continued)
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes Karyotyping
Partial verification avoided?
All tests
Yes All women had a reference standard
Differential verification avoided?
All tests
Yes All women had karyotyping
Incorporation avoided?
All tests
Yes Index test did not form part of the reference
standard
Reference standard results blinded?
All tests
No Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Unclear Unclear if index test interpreted without knowl-
edge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes In 11 controls, failed to measure NT
Withdrawals explained?
All tests
No No details of withdrawals given
Ekelund 2008
Clinical features and settings Routine screening
Participants 95,645 participants (40,815 in 2005 and 54,830 in 2006)
Denmark - 19 obstetrics and gynaecology departments
January 2005 - December 2006
Pregnant women
Maternal and gestational age not reported
First trimester
Study design Cohort
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Ekelund 2008 (Continued)
Target condition and reference standard(s) Down’s syndrome: 225 cases (121 in 2005 and 104 in 2006)
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (by nurses, midwives and doctors in accordance with FMF guidelines)
First trimester PAPP-A and free ßhCG (Brahms Kryptor, Brahms Immunodiagnostic
Systems or Delfia Xpress, PerkinElmer)
Risk cut-point 1:300
Follow-up Information obtained from the Danish central cytogenetic registry. No details of follow-
up for women without pre or post-natal chromosome analysis
Aim of study To evaluate the impact of a screening strategy in the first trimester, introduced in Den-
mark during 2004 to 2006, on the number of infants born with Down’s syndrome and
the number of CVS and amniocentesis, and to determine detection and false positive
rates in the screened population in 2005 and 2006
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
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Ekelund 2008 (Continued)
Withdrawals explained?
All tests
Yes Information given on the proportion of women not undergoing
screening
Gasiorek-Wiens 2001
Clinical features and settings Routine screening
Participants 21,959 participants
Germany, Switzerland and Austria - multicentre study
June 1995-May 2000
Pregnant women
Median age 33 years (15-49 years), 36.1% > 35 years
Singleton pregnancies
10-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 210 cases
Reference standards: CVS, amniocentesis or follow-up to birth
Index and comparator tests Maternal age
NT (FMF methods)
Risk cut-points of 1:100 and 1:300
Follow-up Follow-up in 92.2% of women. Loss to follow-up was due to miscarriage (n = 258),
termination of pregnancy (n = 125) or absence of antenatal karyotyping (n = 1463).
Only those with follow-up information included in the study
Aim of study To examine the effectiveness of screening for Down’s syndrome using age and NT at 10-
14 weeks of gestation
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
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Gasiorek-Wiens 2001 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Reported that NT successfully measured in all cases
Withdrawals explained?
All tests
No No details of withdrawals given
Gasiorek-Wiens 2010
Clinical features and settings Routine screening
Participants 4097 participants with complete data on pregnancy outcome
Germany - single examiner
December 1997 - November 2006
Pregnant women
Singleton pregnancies
Median age 35.1 years (range 13.2-46.7 years)
11-13 weeks’ gestation
Study design Cohort study
Target condition and reference standard(s) Down’s syndrome: 34 cases
Reference standards: Karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods)
Mixture model, Delta NT and multiple of the median methods
Follow-up Patient history and ultrasound results were entered into a database and pregnancy out-
come or chromosomal results added as they became available
74 (1.8%) of women were excluded from the study because of incomplete follow-up
information
Aim of study To validate the mixture model in a single operator dataset and to compare the detection
rates for fetal chromosomal defects obtained from themixture model with those obtained
from either the delta NT or log multiple of the median approach
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Gasiorek-Wiens 2010 (Continued)
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Go 2005
Clinical features and settings Routine screening
Participants 1759 participants
The Netherlands - private practice (VU medical centre)
May 2001-October 2003
Pregnant women
49% ≤ 35 years, 51% ≥ 36 years
9-14 weeks’ gestation
Study design Retrospective cohort
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Go 2005 (Continued)
Target condition and reference standard(s) Down’s syndrome: 21 cases
Reference standards: Invasive testing or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods using own medians)
First trimester PAPP-A and free ßhCG (ELIPS Perkin Elmer, Finland)
Follow-up Follow-up data frommedical records and patient reports. Data from 242 patients (12%)
were not available and these patients were excluded from the study
Aim of study Todetermine the diagnostic value of the combination screening test forDown’s syndrome
in the first trimester of pregnancy
Notes Dutch language
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Incomplete investigation reported in 25 patients (1.2%)
Withdrawals explained?
All tests
No No details of withdrawals given
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Gyselaers 2005
Clinical features and settings Routine screening
Participants 13,267 participants (13,207 participant received both NT test and serum testing)
Belgium - multicentre study (35 centres)
Data from January 2004-April 2004 added to previous database from before 2003
Pregnant women
First and second trimester testing
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 26 cases
Reference standards: CVS, amniocentesis or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods)
First trimester PAPP-A (ELISA 2397, DRG International Inc) and free ßhCG (IRMA
K1P1001)
Second trimester PAPP-A and free ßhCG
Risk cut-points of 1:200 and 1:300
Follow-up Follow-up to birth reported by mail by obstetricians. Non-responding obstetricians con-
tacted personally to obtain missing data. Results of follow-up reported by mail by ob-
stetricians. Non-responding obstetricians contacted personally to obtain missing data
Cases of miscarriages (n = 49) and other fetal chromosomal abnormalities excluded from
the study. Unclear if other patients lost to follow-up
Aim of study To evaluate the performance of a first trimester fetal aneuploidy screening programme
Notes Women with miscarriages or cases of other chromosomal defects were excluded from the
study. 9 live births of babies with Down’s syndrome
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
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Gyselaers 2005 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes Numbers of women excluded due to miscarriage or other chro-
mosomal defects and numbers not undergoing NT and bio-
chemical testing reported
Habayeb 2010
Clinical features and settings Routine screening
Participants 1507 participants
UK - fetal medicine unit
September 2007 - December 2008
Pregnant women
Median maternal age 35.4 years (range 18-49 years)
9-10, 11-13 and > 14 weeks’ gestation
Study design Cohort study
Target condition and reference standard(s) Down’s syndrome: 12 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
Early first trimester PAPP-A (9weeks’ gestation) (AutoDELFIAPAPP-Akit, PerkinElmer
LAS (UK) Ltd)
First trimester NT (11-13 weeks’ gestation) (General Electric E8, Voluson 730 Pro, GE
Healthcare)
Second trimester AFP, free ßhCGand uE3 (at or after 14weeks’ gestation) (AutoDELFIA
(TM) time-resolved fluorimmunoassay, PerkinElmer Life Sciences)
Second trimester tests given if first trimester risk low (< 1:100) or invasive testing declined
Cut-point for second-stage risk 1:250
Follow-up Data recorded on a fetal medicine database and combined with data held on separate
databases for pregnancy outcome and the regional cytogenetic laboratory. Cytogenetic
test results available for all women delivering in the region
Aim of study To audit a model combining early PAPP-A with NT and early triple test
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Habayeb 2010 (Continued)
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Hadlow 2005
Clinical features and settings Routine screening
Participants 10,436 participants receiving both NT and serum testing and with complete follow-up
data
Australia
Data from 2-year period (dates not specified)
Pregnant women
Mean age 30.7 years, 21.2% ≥ 35 years
Singleton pregnancies
11-14 weeks’ gestation
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Hadlow 2005 (Continued)
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 32 cases
Reference standards: CVS, amniocentesis or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods)
Clotted blood samples tested for:
First trimester PAPP-A (Kryptor random access immunoassay analyser or manual Ortho
Clinical Diagnostics Immunometric I125 immunoassay)
First trimester free ßhCG (Kryptor random access immunoassay analyser or Ortho Clin-
ical Diagnostics Vitros ECi automated analyser)
Risk cut-point 1:300
Follow-up Data obtained from WA Midwives notification system and WA Birth defects registry.
Missing information sought from referring doctor and ultrasound practice. Data linkage
achieved in 10,436 (99.6%) of patients
In index test negative patients, outcome for 160 women not known
In index test positive patients, outcome in 2 women not known
Aim of study To audit the initial 2 years of conduct of the combined first trimester screening
Notes Women with miscarriages or multiple pregnancies were excluded from the study
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
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Hadlow 2005 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Hafner 1998
Clinical features and settings Routine screening
Participants 4233 participants
Austria - single hospital
June 1993 to July 1996
Pregnant women
Median age 28 years (15-49 years), 6.9% ≥ 35 years
10-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 7 cases
Reference standards: amniocentesis or CVS in patients with previous Down’s pregnancy,
> 35 years or with a positive biochemical test result. Other women underwent scan at 22
weeks and, if NT > 2.5 mm special examination directed to examination of fetal heart.
Follow-up to birth
Index and comparator tests First trimester NT (cut-off 2.5 mm)
NT taken in saggital section. Distance between the end of the echogenic muscles of the
c spine and the inner layer of echogenic skin with callipers on the line
Follow-up No details given of methods of follow-up. 138 women lost to follow-up
Aim of study To determine the value of NT measurement for the detection of aneuploidies and other
malformations in a low-risk population
Notes It appears thatDown’s syndromewas only picked up in cases where CVS or amniocentesis
had been conducted and it s not clear if patients were followed up to birth
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
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Hafner 1998 (Continued)
Acceptable reference standard?
All tests
Unclear Amniocentesis or anomalies scan at 22 weeks. Unclear if women
were also followed up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT measurement was not possible in 2% of cases
Withdrawals explained?
All tests
No No details of withdrawals given
Has 2008
Clinical features and settings Routine screening
Participants 1807 participants with successful scans
Turkey
September 2003 - December 2005
Pregnant women
Singleton pregnancies
Median maternal age 28.3 years (range 17-45 years)
11-14 weeks’ gestation
Study design Cohort study
Target condition and reference standard(s) Down’s syndrome: 9 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods)
First trimester fetal nasal bone (experienced maternal fetal specialists)
First trimester PAPP-A and free ßhCG (details not reported)
Combined cut-point 1:300
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Has 2008 (Continued)
Follow-up Findings recorded in a computer database. Karyotype results obtained directly from
the genetics department. Pregnancy outcomes obtained from hospital records or from
parents via telephone interview. 110 women (5%) with terminations, miscarriages or
malformations and unknown outcome were excluded from the study
Aim of study To evaluate the contribution of nasal bone assessment in first trimester Down’s syndrome
screening
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Evaluation of nasal bone was not possible in 9 (0.5%) cases
Withdrawals explained?
All tests
No No details of withdrawals given
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Hewitt 1996
Clinical features and settings High-risk referral for invasive testing
Participants 1306 women with 1317 fetuses (11 sets of twins)
Australia - 2 hospitals and 2 private practices
September 1993 to September 1994
Pegnant women
Singleton or multifetal pregnancies
Median age 37 years (21-48 years)
10 to 14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 21 cases
Reference standard: CVS
Index and comparator tests First trimester NT (ATL HDI ESP Diagnostic Ultrasound system), cut-point 3 mm or
more
Follow-up 100% karyotyping
Aim of study To evaluate the accuracy of ultrasound measurement of nuchal thickness in first trimester
fetuses for predicting fetal karyotype
Notes No measurement of NT was recorded in 126 cases (9.6%). All down’s syndrome fetuses
terminated
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes CVS
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
Yes All women had the same reference standard
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
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Hewitt 1996 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes No measurement of NT was recorded in 126
cases (9.6%)
Withdrawals explained?
All tests
No No details of withdrawals given
Hormansdorfer 2011
Clinical features and settings Routine screening
Participants 6508 participants with known fetal outcome
Germany - 3 prenatal health centres
August 1999 - May 2007
Pregnant women
Mean maternal age 31.1 years (16-46 years), 22% ≥ 35 years
First trimester
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 40 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF standards)
First trimester PAPP-A and free ßhCG (no details given)
Different software programmes used with and without modification to exclude the role
of maternal age
Follow-up Methods of follow-up not reported. Stated that only women with known fetal outcome
were included in the study
Aim of study To analyse the impact in test performance of 3 widely used first trimester screening
software programs if the maternal age was excluded from their calculation algorithm
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
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Hormansdorfer 2011 (Continued)
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Huang 2010
Clinical features and settings Routine screening
Participants 7118 participants undergoing combined first trimester screening and a fetal abnormality
scan
Taiwan - single hospital
January 2004 - December 2007
Pregnant women
Median maternal age 30 years (range 15-47 years)
8-13 weeks’ gestation
Study design Cohort study
Target condition and reference standard(s) Down’s syndrome: 25 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (11-13 weeks’ gestation) (FMF accredited obstetricians)
First trimester free ßhCG and PAPP-A (8-12 weeks’ gestation) (time resolved amplified
cryptate emission, automated Kryptor Analyser, Brahms)
Combined cut-point 1:300
Second trimester fetal abnormality scan (18-22 weeks’ gestation) for intracardiac
echogenic focus (ICEF) (In accordance with the American Institute of Ultrasound in
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Huang 2010 (Continued)
Medicine Practice Guideline)
Follow-up All neonates examined postnatally and Hospital records reviewed
Aim of study To determine the relation between intracardiac echogenic focus and trisomy 21 in a
population of fetuses previously evaluated by first trimester combined screening
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
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Jaques 2007
Clinical features and settings Routine screening
Participants 16,153 participants
Australia - State screening programme
February 2000 - June 2002
Pregnant women
Mean maternal age 33 years (range 16-51 years), 18.5% ≥ 37 years
10-13 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 63 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF accredited ultrasonologists)
First trimester PAPP-A and free ßhCG (details not reported)
First trimester AFP, inhibin A and uE3 added to first trimester results for women who
were screened at 13 weeks’ gestation (augmented screening, number not reported)
Follow-up Probabilistic record linkage was used to link health records from the Genetic Health
prenatal screening database, Perinatal Data Collection Unit and the Birth Defects Regis-
ter. Written requests for pregnancy outcome were sent to referring health professionals.
Pathology and cytogenetics reports were collected for confirmation of birth defects and/
or karyotype
151 women were lost to follow-up and these were excluded in the analysis
Of the 16,003 women, pregnancy loss in 71 due to miscarriage (n = 68), stillbirth (n =
1) and neonatal death (n = 2)
Aim of study To follow up and evaluate the state-wide first trimester combined screening programme
for Down’s syndrome and trisomy 18 at Genetic Health Services Victoria, Australia
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
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Jaques 2007 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Jaques 2010 FTS
Clinical features and settings Routine screening
Participants 38,584 participants
Australia - State screening programme
2003 - 2004
Pregnant women
Maternal age ≥ 37 years in 16.3% of women
First and second trimester
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 110 cases
Reference standards: karyotyping (CVS = 774, amniocentesis =1644) or follow-up to
birth
Index and comparator tests Maternal age
First trimester NT, PAPP-A and free ßhCG (n = 38,584) (details not reported)
Follow-up Probabilistic record linkage was used to link health records from the Prenatal Screen-
ing Database, prenatal diagnostic data from cytogenetic laboratories, the Victoria Birth
Register (Perinatal Data collection Unit) and the Victoria Birth Defects Register
Aim of study Tomap prenatal screening and diagnostic testing pathways in Victorian pregnant women
during 2003-2004; measure the impact of prenatal diagnostic testing uptake on the
effectiveness of prenatal screening for Down’s syndrome; and assess factors influencing
uptake of diagnostic testing following screening
Notes
124First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jaques 2010 FTS (Continued)
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Invalid results obtained for 7.4% of first and 0.1% of second
trimester screenings
Withdrawals explained?
All tests
Yes 48% of pregnant women in the state did not undergo prenatal
testing
Kagan 2010
Clinical features and settings Routine screening
Participants 56,954 participants with available outcome data
UK - multicentre
July 1999 - April 2007
Pregnant women
Singleton pregnancies
Mean maternal age 35.4 years (range 14.1 to 52.2 years)
11-13 weeks’ gestation
Study design Prospective cohort
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Kagan 2010 (Continued)
Target condition and reference standard(s) Down’s syndrome: 395 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT
First trimester fetal heart rate (pulsed-wave Doppler)
First trimester nasal bone (FMF certified sonographers)
First trimester ductus venous flow (FMF certified sonographers)
First trimester flow across tricuspid valve (FMF certified sonographers)
First trimester PAPP-A and free ßhCG (Kryptor, Brahms AG or Delfia Express, Perkin
Elmer)
Multiple publications with different test evaluations
Follow-up Karyotype results and details of pregnancy outcome added to databases as they became
available. Women without complete screening and outcome data (n = 3053, 5.1%) were
excluded from the study
Aim of study To examine the performance of first-trimester screening for trisomies 21, 18 and 13 by
maternal age, fetal nuchal translucency thickness, fetal heart rate and maternal serum
free ßhCG and PAPP-A
Other objectives in related publications
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
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Kagan 2010 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Kim 2006
Clinical features and settings Routine screening
Participants 2570 participants with available outcome data
Korea - hospital and womens healthcare centre
January 2001 to December 2001
Pregnant women
Mean age 29.9 years (SD 3.3 years)
Singleton pregnancies
10-14 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 31 cases
Reference standard: amniocentesis or CVS in 419 patients considered high risk (NT > 2.
5, aged > 35 years, positive biochemical test result, history of chromosomal abnormality,
fetal structural abnormality at ultrasound or other reason). Follow-up to birth
Index and comparator tests First trimester NT (FMF methods) (HDI 3000, ATL, Bothell, WA, USA)
3 measurements taken, largest one used for risk calculation
Cut-off 2.5 mm, 3.0 mm or 95th percentile of each CRL
Follow-up Pregnancy outcomes ascertained from obstetric and neonatal medical records of live or
stillborn babies
Only patients with known pregnancy outcome included in the study
8 patients who terminated their pregnancies because of structural abnormalities on ul-
trasound with no karyotyping results were excluded. Karyotyping was performed in in-
trauterine fetal death (n = 4) cases
Aim of study To determine the value of NT with different cut-offs for the detection of chromosomal
aberrations
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
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Kim 2006 (Continued)
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Koster 2011
Clinical features and settings Routine screening
Participants 998 participants: 151 cases and 847 controls matched for gestational age, maternal
weight, maternal age and storage time
The Netherlands - National institute for Public Health and the Environment
2004 - 2006
Pregnant women
Singleton pregnancies
Median maternal age 37 years (interquartile range 36-39 years)
8-13 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 151 cases
Reference standards: karyotyping or follow-up to birth
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Koster 2011 (Continued)
Index and comparator tests Maternal age
First trimester NT
Fresh serum samples tested for:
First trimester free ßhCG and PAPP-A (AutoDELFIA, PerkinElmer)
Frozen serum samples tested for:
First trimester ADAM 12s, total hCG, placental protein 13 (PP13) and placental growth
factor (PlGF) (AutoDELFIA or DelfiaXpress, PerkinElmer)
Follow-up Pregnancy outcome was recorded via questionnaires and self-reporting by the participat-
ing women. Only samples for pregnancies with known outcome were selected as controls
Aim of study To evaluate the modelled predictive value of 3 current screening markers (PAPP-A, free
ßhCG and NT) and 4 potential screening markers (ADAM 12, total hCG, PP13 and
PIGF) for Down’s syndrome using different screening strategies
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
129First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Koster 2011 (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given
Kozlowski 2007 GC
Clinical features and settings Routine referral
Participants 6906 participants with complete outcome data
Germany - gynaecologists practices
January 2000 - December 2003
Pregnant women
Median maternal age 32 years (15-48 years), 26.4% ≥ 35 years
11-14 weeks’ gestation
Study design Cohort study
Target condition and reference standard(s) Down’s syndrome: 19 cases in gynaecologists practices
Reference standard: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF certified gynaecologists)
First trimester free ßhCG and PAPP-A (Kryptor analyser, Brahms)
Risk cut-point 1:300
Follow-up Data on pregnancy outcome were obtained by contacting the patient or their general
gynaecologist. Women without complete outcome data (36%) were excluded from the
study
Aim of study To evaluate and compare the screening performance for fetal trisomy 21 in the first
trimester of pregnancy in general gynaecologists practices and specialised centres for
prenatal care in Germany
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
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Kozlowski 2007 GC (Continued)
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes 146 women (including 11 with down’s syndrome) excluded as
results could not be assigned to gynaecologists’ or prenatal centre
group
Kozlowski 2007 PC
Clinical features and settings Routine referral
Participants 3862 participants with complete outcome data
Germany - tertiary level prenatal centres
January 2000 - December 2003
Pregnant women
Median maternal age 34 years (range 14-46 years), 43.2% ≥ 35 years
11-14 weeks’ gestation
Study design Cohort study
Target condition and reference standard(s) Down’s syndrome: 26 cases
Reference standard: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF certified sonographers)
First trimester free ßhCG and PAPP-A (Kryptor analyser, Brahms)
Risk cut-point 1:300
Follow-up Data on pregnancy outcome were obtained by contacting the patient or their general
gynaecologist. Women without complete outcome data (8%) were excluded from the
study
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Kozlowski 2007 PC (Continued)
Aim of study To evaluate and compare the screening performance for fetal trisomy 21 in the first
trimester of pregnancy in general gynaecologists practices and specialised centres for
prenatal care in Germany
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes 146 women (including 11 with down’s syndrome) excluded as
results could not be assigned to gynaecologists’ or prenatal centre
group
Krantz 2000
Clinical features and settings Routine screening
Participants 10,251 participants
USA
September 1995 to June 1998
Pregnant women
132First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Krantz 2000 (Continued)
34.7% ≥ 35 years
Singleton pregnancies
No diabetes
9-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 50 cases (33 had undergone biochemical testing)
Reference standards: not reported
Index and comparator tests Maternal age
First trimester NT in 5,809 (2018 ≥ 35 years).patients (FMF methods)
Dried blood samples tested for:
First trimester free ßhCG and PAPP-A in 10,251 patients (enzyme-linked immunosor-
bent asay procedures)
Follow-up No details of follow-up reported
Aim of study To assess the effectiveness of free ßhCG, PAPP-A and NT for first trimester screening
for Down’s syndrome and trisomy 18
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Unclear Unclear reference standard
Partial verification avoided?
All tests
Unclear Unclear if all patients had a reference standard
Differential verification avoided?
All tests
Unclear Unclear if choice of reference depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
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Krantz 2000 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Kublickas 2009
Clinical features and settings Routine screening
Participants 3907 participants
Sweden
2005 - 2006
Pregnant women
51% of women aged ≥ 35 years
9-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 29 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF trained sonographers)
First trimester free ßhCG and PAPP-A (AutoDELFIA, PerkinElmer)
Follow-up The dataset used contained outcomes for all pregnancies
Aim of study To provide the necessary mathematical formulae to construct a risk calculation package
for Down’s syndrome using maternal serum free ßhCG, PAPP-A and NTmeasurements
in the first trimester for use in a web-based system
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
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Kublickas 2009 (Continued)
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Kuc 2010
Clinical features and settings Routine screening
Participants 27,291 participants: 223 cases and 22,157 controls (not matched)
TheNetherlands - The Dutch National Institute for Public Health and the Environment
Dates not specified
Pregnant women
Maternal age not reported
8-13 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 223 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF trained sonographers)
First trimester free ßhCG and PAPP-A (automated dissociation-enhanced lanthanide
fluorescent immunoassay, AutoDELFIA, PerkinElmer)
Follow-up Known outcomes for cases and controls
Aim of study To estimate the effect of timing of serum collection on screening performance
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Kuc 2010 (Continued)
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Lam 2002
Clinical features and settings Routine screening
Participants 16,237 participants
Hong Kong - multicentre study
1997 to 2000
Pregnant women
Mean age 30.5 years (19% ≥ 35 years) (unaffected pregnancies)
10-14 weeks and 15-18 weeks’ gestation
Study design Prospective cohort
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Lam 2002 (Continued)
Target condition and reference standard(s) Down’s syndrome: 35 cases
Reference standards: women considered high risk offered CVS (0.7%) or amniocentesis
(11.8%). Follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods)
Second trimester free ßhCG and AFP (methods not stated)
(All women underwent both NT and biochemical testing)
Follow-up By review of hospital and laboratory records and by directly telephoning women.
Participants who defaulted the second trimester serum tests (n = 1015) and those who
miscarried after NT but before serum testing (n = 91) were excluded from the study.
Outcome obtained in only 15,253 patients (93.9%)
Aim of study To report data on participants undergoing both first and second trimester methods of
screening to assess the relative efficacy of different methods of screening
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
No Not all women received a reference standard (6.1% had no as-
certainment of pregnancy outcome)
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT successful in 99.8% of cases
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Lam 2002 (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given
Leung 2009
Clinical features and settings Routine screening
Participants 10,185 participants (178 twin pregnancies; 10,363 fetuses)
Hong Kong - University Hospital
June 2003 - March 2007
Pregnant women
Singleton or multifetal pregnancies
Median maternal age 32 years (IQR 30-35 years), 27.4% of women aged ≥ 35 years
11-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 34 cases
Reference standards: amniocentesis or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF accredited doctors, HDI 5000 or HDI 3000, Philips Medical
System)
First trimester nasal bone assessment (7925 women) (FMF accredited doctors, HDI
5000 or HDI 3000, Philips Medical System)
First trimester PAPP-A and free ßhCG (Kryptor analyser, Brahms Diagnostica GmbH)
Risk cut-point 1:300
For twin pregnancies, a risk was calculated for each fetus based on the individual NT
and maternal serum biochemistry corrected for twin pregnancies
Follow-up Specific staff were allocated to contact all women for pregnancy and fetal outcome.
Women were contacted by phone and mail. 5 screen positive and 50 screen negative
cases had unknown outcome
Aim of study To examine the effectiveness of first trimester fetal trisomy 21 screening using a com-
bination of maternal age, NT and maternal serum free ßhCG and PAPP-A levels in a
predominantly Chinese population in Hong Kong
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
138First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Leung 2009 (Continued)
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Nasal bone status could not be determined in 176 women (2.
2%) (2 with Down’s syndrome)
Withdrawals explained?
All tests
No No details of withdrawals given
MacRae 2008
Clinical features and settings Routine screening
Participants 18,965 pregnancies
UK - University Hospital
July 1998 - January 2004
Maternal age not reported
10-13 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 37 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (trained sonographers)
Risk cut-point 1:300
Follow-up Information on birth outcome from Harris birthright Research Centre database, the
North East Regional Cytogenetic Laboratory, theNationalDown’s syndrome register and
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MacRae 2008 (Continued)
the Basildon and Thurrock University Hospital database and, in some cases, maternal
and paediatric records. For each case, screening results were linked to cytogenetic results/
pregnancy outcome
Aim of study To evaluate NT scans with a view to comparing findings with other research centres
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Index tests did not form part of the reference standard
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Maiz 2007
Clinical features and settings High-risk referral for invasive testing
Participants 227 participants
UK - single centre
Pregnant women
140First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Maiz 2007 (Continued)
Singleton pregnancies
Median maternal age 35 years (17-49 years)
11-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 20 cases
Reference standard: CVS
Index and comparator tests First trimester presence of mitral gap (Doppler flow traces)
Follow-up 100% karyotyping
Aim of study To investigate the possible association between a particular pulsed Doppler waveform
pattern, mitral gap and trisomy 21 at 11 + 0 to 13 + 6 weeks
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant popula-
tion
Acceptable reference standard?
All tests
Yes Karyotyping
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
Yes Choice of reference standard did not depend on
index test results
Incorporation avoided?
All tests
Yes Index tests did not form part of the reference
standard
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable
measurements
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Maiz 2007 (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given
Maiz 2009
Clinical features and settings Routine screening
Participants 19,614 participants with complete screening and outcome data
UK - multicentre
January 2006 - May 2007
Pregnant women
Singleton pregnancies
Median maternal age 34.5 years (14.1-50.1 years)
11-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 122 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT and fetal heart rate
First trimester ductus venous blood flow velocity waveforms (FMF certified sonogra-
phers)
First trimester PAPP-A and free ßhCG (Delfia Xpress, PerkinElmer)
Follow-up Karyotype results and details on pregnancy outcome were added to the database as soon
as they became available.Women without complete outcome data (5.3%) were excluded
from the study
Aim of study To investigate the performance of first trimester screening for aneuploidies by including
assessment of ductus venosus flow in the combined test of maternal age, fetal NT thick-
ness, fetal heart rate and serum free ßhCG and PAPP-A
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
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Maiz 2009 (Continued)
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Malone 2004
Clinical features and settings Routine screening
Participants 6324 participants
USA - multicentre study (15 centres)
May 2002 to December 2002
Pregnant women
Mean age 30.1 years (16-47 years), 22.1% ≥ 35 years
Singleton pregnancies
10-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 11 cases
Reference standards: karyotyping in 587 (amniocentesis n = 510; neonatal cord blood n
= 41; products of conception and autopsy material n = 31), or follow-up to birth
Index and comparator tests Nasal bone imaging
Fetal image in a perfect saggital plane with fetal spine down. Angle of insonation of
ultrasound beam with fetal profile close to 45 degrees. Image magnified significantly
until 2 echogenic lines are visible in region of fetal nose. Transducer tilted from side to
side to distinguish fetal skin from nasal bone. Deeper echogenic line noted to become
more echolucent at its distal end
Follow-up A tracking programme with up to 10 contact options for each patient used for follow-
up
Follow-up to birth in 6228 patients (98.5%) and adequate nasal bone imaging in 4801
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Malone 2004 (Continued)
(75.9%)
Aim of study To evaluate first trimester nasal bone imaging as a screening tool for aneuploidy
Notes Only 17% of patients who had miscarriage or termination of pregnancy had karyotype
information available
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
No Not all women received a reference standard (1.5% had no as-
certainment of pregnancy outcome)
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Nasal bone screening successful in 4801 cases (75.9%)
Withdrawals explained?
All tests
No No details of withdrawals given
Malone 2005
Clinical features and settings Routine screening
Participants 38,033 participants
USA - multicentre study (15 centres)
October 1999 to December 2002
Pregnant women
144First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Malone 2005 (Continued)
Mean maternal age 30.1 years (SD 5.8 years.); 8199 (21.6%) aged ≥ 35 years
Singleton pregnancies
Live fetuses
10-13 and 15-18 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 92 cases
Reference standards: amniocentesis offered to women with positive results from any
screening test or follow-up to birth
Index and comparator tests Maternal age
First trimester NT in 36,306 patients (92.9%)
First trimester PAPP-A and free ßhCG in 37,843 patients (99.5%)
Second trimester AFP, total hCG, uE3 and inhibin A in 35,236 patients (92.6%)
All data in 33,546 patients (88.2%)
Follow-up Follow-up with computerised tracking system. Medical records were reviewed in cases of
1) possible medical problem suspected 2) positive screening test results with no karyotype
data, 3) 10% random sample of all enrolled patients
Follow-up to birth in 36,378 patients (97%)
Aim of study To evaluate first trimester and/or second trimester screening tool for Down’s syndrome
Notes Unclear which types of patients did not have follow-up data. Appears that aborted/
miscarried fetuses did not have follow-up
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
No Not all women received a reference standard (3% had no as-
certainment of pregnancy outcome, patients not excluded from
study)
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
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Malone 2005 (Continued)
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT failed or rejected at review in only 7.1%
Withdrawals explained?
All tests
Yes Details given for patients who did not undergo different index
tests
Marchini 2010
Clinical features and settings Routine screening
Participants 1521 participants (18 twin and 2 triplet pregnancies; 1543 fetuses)
Italy
Pregnant women
Singleton or multifetal pregnancies
Median maternal age 31.3 years (range 18-45 years), 19.7% ≥ 35 years
11-14 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 8 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF accredited sonographers)
First trimester serum free ßhCG and PAPP-A (Kryptor analyser, Brahms)
Risk cut-point 1:300
Follow-up Follow-up obtained by analysis of fetal karyotype, from patient notes and by telephoning
patients
Aim of study To evaluate the performance of the combined test compared to the NT measurement
alone, in fetal aneuploidy screening in the general population and in pregnant women
aged 35 years and over
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
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Marchini 2010 (Continued)
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Marsis 2004
Clinical features and settings Screening of patients ≥ 35 years of age
Participants 262 participants
Indonesia - 4 hospitals
January 2001 to January 2003
Pregnant women
Mean age 37.7 years (35-43 years)
Singleton pregnancies
11-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 8 cases
Reference standards: amniocentesis (unclear in which patients this was conducted) or
follow-up to birth
Index and comparator tests First trimester NT (all patients) with > 3.0 mm cut-off (FMFmethods, Apoge 800-ATL,
SSD 680-Aloka, Logic alpha 200 GE, Veluson 730 Pro GE)
First trimester nasal bone assessment (97 (55%) patients who also had NT)
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Marsis 2004 (Continued)
Follow-up Follow-up to birth in patients with no nasal bone and NT > 3 mm. Unclear if screen-
negative patients had follow-up to birth
Aim of study Evaluation of a non-invasive method to screen for Down’s syndrome at a maternal age
of 35 years or more
Notes No cases of Down’s detected that were not picked up in screening tests
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done
in practice
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference stan-
dard
Differential verification avoided?
All tests
No Choice of reference standard depended on in-
dex test results
Incorporation avoided?
All tests
Yes Reference standardwas independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of
reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
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Marsk 2006
Clinical features and settings Routine screening
Participants 139 participants: 31 cases and 108 controls (3:1 with cases, matched for time of study,
geographic location and to be within 5-year age interval)
Sweden - data from Swedish Nuchal Translucency Trial
Dates not reported
Pregnant women
Mean age cases 38.5 years (SD 4.0 years) and controls 35.5 years (SD 4.0 years)
Singleton pregnancies
8-14 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 31 cases
Reference standards: not reported
Index and comparator tests Maternal age
First trimester NT (12-14 weeks) (method not specified)
Frozen serum samples
PAPP-A and free ßhCG in sample taken at 8-14 weeks (Auto Delfia Instrument)
Risk cut-points of 1:250 and 1:350 (Lifecycle software used to calculate risk)
Follow-up No details of methods used to follow women-up
Aim of study To determine to what extent adding first trimester serum screening to NTwould change
the detection rate and test positive rate for Down’s syndrome
Notes Part of NUPP trial
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
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Marsk 2006 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes Details given for women who did not agree to take part
Matias 1998
Clinical features and settings High-risk referral for invasive testing
Participants 486 participants
UK and Portugal
Dates not reported
Pregnant women
Singleton pregnancies
Median age 35 years (17-46 years)
10-14 weeks’ gestation
Study design Prospective cohort study
Target condition and reference standard(s) Down’s syndrome: 38 cases
Reference standard: fetal karyotyping. In cases where NT above 95th percentile or ab-
normal ductus venousus flow, follow-up scan conducted at 14-16 weeks
Index and comparator tests Maternal age
First trimester NT (SSD, Aloka)
First trimester ductus venosus flow velocity: measured transabdominally (5-MHz curvi-
linear probe, Ecocee, Toshiba) or transvaginally (SSD 2000, Aloka)
Follow-up 100% karyotyping
Aim of study To assess the possible role of Doppler ultrasound assessment of ductus venous blood flow
in screening for chromosomal abnormalities at 11 to 14 weeks of gestation
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
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Matias 1998 (Continued)
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes Karyotyping
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
Yes All women had the same reference standard
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes Reported that measurements made successfully
in all cases
Withdrawals explained?
All tests
No No details of withdrawals given
Matias 2001
Clinical features and settings High-risk referral for invasive testing
Participants 515 participants
Portugal
Dates not reported
Pregnant women
Median age 35 years (17-46 years)
Singleton pregnancies
11-14 weeks’ gestation
Study design Prospective cohort study
Target condition and reference standard(s) Down’s syndrome: 43 cases
Reference standards: fetal karyotyping. In cases where NT above 95th percentile, follow-
up scan conducted at 14-16 weeks
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Matias 2001 (Continued)
Index and comparator tests Maternal age
First trimester NT (SSD, Aloka)
First trimester ductus venous Doppler evaluation - ductus venosus flow velocity - abnor-
mal flow is defined as absent or reversed flow of blood in the ductus venosus, normal flow
defined as presence. Measurement made by obtaining the right ventral midsaggital plane
of the fetal trunk in fetal quiescence. Pulsed Doppler gate placed in distal portion of um-
bilical sinus. 5 consecutive high-quality waveforms used to measure peak velocity during
ventricular systole and diastole, the lowest forward velocity during atrial contraction in
late diastole and the pulsatility index. Up to 10 minutes allowed for measurements
Follow-up All women received karyotyping. Unclear if patients followed up to birth
Aim of study To review the role of Doppler ultrasound in screening for chromosomal abnormalities
at 11 to 14 weeks of gestation
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes Karyotyping
Partial verification avoided?
All tests
Yes All women had a reference standard
Differential verification avoided?
All tests
Yes All women had the same reference standard
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes Reported thatDopplermeasurementsmade suc-
cessfully in all cases
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Matias 2001 (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given
Mavrides 2002
Clinical features and settings High-risk referral for invasive testing
Participants 256 participants whowere referred to unit for fetal karyotyping and hadNT andDoppler
studies
UK - tertiary referral fetal medicine unit
Conducted over 18 months, dates not reported
Pregnant women
Median age 35 years (15-42 years)
11-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 30 cases
Reference standard: CVS or follow-up
Index and comparator tests Maternal age
First trimester NT
First trimester ductus venous Doppler studies (ATI HDL 5000 US machine with curvi-
linear TV probe)
Follow-up Follow-up based on ultrasounds findings, examination at birth, postmortem examination
in cases of intrauterine death or termination of pregnancy and by telephone interviews
with parents
Aim of study To assess the role of first trimester Doppler assessment of the ductus venosus in screening
for fetal aneuploidy in pregnancies at 11-14 weeks of gestation
Notes 2 live births with Down’s syndrome. Appears to be a high-risk invasive testing study
but some people did not appear to get karyotyping but were followed up. Probably the
majority got karyotyping
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes Karyotyping
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Mavrides 2002 (Continued)
Partial verification avoided?
All tests
Yes All participants had a reference standard
Differential verification avoided?
All tests
Yes All participants had the same reference standard
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes Doppler studies failed in 4 cases (1.5%)
Withdrawals explained?
All tests
No No details of withdrawals given
Maxwell 2011 FTS
Clinical features and settings Routine screening
Participants 32,478 participants with available outcome data
Australia - screening programme
2005 - 2006
Pregnant women
Singleton pregnancies
Median maternal age 31 years (14-48 years), 24.3% of women aged ≥ 35 years
10-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 94 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT PAPP-A and free ßhCG (details not reported)
Risk cut-point 1:300
Follow-up Diagnostic data collected from cytogenetic laboratories. Screening data linked toWestern
Australia diagnostic data, hospital morbidity and mortality data, midwives notification
data and the Birth Defects Registry data through the Department of Health Western
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Maxwell 2011 FTS (Continued)
Australias Data Linkage Branch. Outcome data available for 92.3% of screened women
Aim of study To investigate socio-demographic characteristics in the uptake of prenatal aneuploidy
screening in Western Australia and to identify potential barriers to screening access
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Maymon 2005
Clinical features and settings Routine screening
Participants 595 participants
Israel
January 1999 - January 2004
Pregnant women
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Maymon 2005 (Continued)
Mean age, healthy 30.3 years (SD 4.5), Down’s syndrome 33.7 years (SD 4.9)
Singleton pregnancies
11-14 weeks’ gestation and second trimester screening
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 24 cases
Reference standards: amniocentesis (recommended for women with higher risk on first
or second trimester testing) or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (11-14 weeks)
First trimester PAPP-A and free ßhCG (methods detailed in Maymon 2001) (some
analysed retrospectively from banked samples)
Second trimester PAPP-A and free ßhCG (methods detailed in Maymon 2001)
Follow-up Delivery outcome obtained by telephone interview or medical records. Information was
available for all uneventful pregnancies and delivery outcomes. It is unclear whether
information on terminations of pregnancy or miscarriages was available.
Aim of study To evaluate the cross-trimester multiple marker correlation and the minimum marker
combination needed for detecting various chromosomal aneuploides
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
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Maymon 2005 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Maymon 2008
Clinical features and settings Routine screening
Participants 243 participants: 19 cases and 224 consecutive controls
USA - antenatal sonographic unit
October 2005 - May 2007
Pregnant women
Singleton pregnancies
11-13 and 14-28 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 19 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (according to FMF criteria)
Second trimester nuchal skin-fold (according to published criteria)
First trimester free ßhCG and PAPP-A (details not reported)
Follow-up Cases detected through karyotyping. Stated that controls had normal pregnancies
Aim of study To assess whether there is a correlation between nuchal translucency and nuchal skin-
fold measurements in Down’s syndrome and in normal pregnancies
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
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Maymon 2008 (Continued)
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Different reference standards used
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Merz 2011
Clinical features and settings Routine referral
Participants 124,205 participants
Germany
Dates not reported
Pregnant women
Maternal age not reported
Singleton pregnancies
First trimester
Study design Retrospective cohort study
Target condition and reference standard(s) Down’s syndrome: 500 cases
Reference standard: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (only data obtained by level II or III certified sonographers included)
First trimester free ßhCG and PAPP-A (Brahms Kryptor system)
FMF Germany risk calculation
Risk cut-point 1:150
Follow-up Details not reported
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Merz 2011 (Continued)
Aim of study To demonstrate that the variability of the FPR can be reduced through adjusting the
concentrations of free ßhCGandPAPP-Ameasured in thematernal serumbymeaning of
a nonlinear regression function modelling the dependence of these variables on maternal
weight
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Michailidis 2001
Clinical features and settings Routine screening
Participants 7447 participants
UK - hospital maternity unit
January 1995 to January 2000
Pregnant women
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Michailidis 2001 (Continued)
Mean age 30.1 years (13-50 years), 21.1% ≥ 35 years, 11.9% ≥ 37 years
10-14 weeks’ gestation
Study design Prospective cohort study
Target condition and reference standard(s) Down’s syndrome: 23 cases
Reference standards: karyotyping in women considered at risk due to index test results,
age or family history or those with considerable anxiety (632 women, 8.5%). Follow-up
to birth
Index and comparator tests Maternal age
First trimester NT in all patients (fetus in mid-sagittal section. Maximum thickness of
subcutaneous translucency between skin and soft tissue overlying the C-spine with the
fetus in the ventral position)
Second trimester AFP, free ßhCG in 65% of patients with NT (radio-immunoassay and
immunoradiometric assays)
Follow-up Outcome at birth assess from hospital database, labour ward records or directly from
patients
Follow-up data in 7447 patients (87% of initial patient cohort). Patients without follow-
up excluded
Aim of study To asses the effectiveness of antenatal screening for trisomy 21 by first trimester sonog-
raphy followed by second trimester biochemical screening
Notes 2nd trimester data not analysed
4 live births: 1 diagnosed before birth and chose not to abort. 3 diagnosed after birth
(no invasive testing was conducted)
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
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Michailidis 2001 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Molina 2010 high risk
Clinical features and settings High-risk referral for invasive testing
Participants 333 participants
Spain - fetal medicine unit
February 2007 - January 2009
Pregnant women
Singleton pregnancies
Mean maternal age 32.7 years (range 16.7-47.5 years)
11-14 weeks’ gestation
Study design Cohort
Target condition and reference standard(s) Down’s syndrome: 20 cases
Reference standard: CVS
Index and comparator tests First trimester nasal bone (FMF certified sonographer)
First trimester ductus venosus (FMF certified sonographer)
First trimester tricuspid regurgitation (FMF certified sonographer)
Follow-up 100% karyotyping
Aim of study To evaluate detection and false positive rates of the ultrasound markers - nasal bone,
ductus venosus flow and tricuspid regurgitation, during the first trimester in a population
at high-genetic risk and to study the influence of a 2-stage screening policy after previous
combined screening on the rate of invasive procedures
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
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Molina 2010 high risk (Continued)
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes Karyotyping
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
Yes Choice of reference standard did not depend on
index test results
Incorporation avoided?
All tests
Yes Index tests did not form part of the reference
standard
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes 5 (1.5%) women did not have measurements
obtained for nasal bone and tricuspid regurgi-
tation and 10 (3%) did not have measurements
obtained for ductus venosus
Withdrawals explained?
All tests
No No details of withdrawals given
Molina 2010 screening
Clinical features and settings Routine screening
Participants 6831 participants
Spain - fetal medicine unit
February 2007 - January 2009
Pregnant women
Maternal age not reported
9-11 weeks’ gestation
Study design Cohort
Target condition and reference standard(s) Down’s syndrome: 23 cases
Reference standard: karyotyping or follow-up to birth
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Molina 2010 screening (Continued)
Index and comparator tests Maternal age
First trimester NT (FMF certified sonographer)
First trimester PAPP-A and free ßhCG (DELFIA Xpress random access platform,
PerkinElmer)
Follow-up Details not reported
Aim of study To evaluate detection and false positive rates of the ultrasound markers - nasal bone,
ductus venosus flow and tricuspid regurgitation, during the first trimester in a population
at high-genetic risk and to study the influence of a 2-stage screening policy after previous
combined screening on the rate of invasive procedures
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Index tests did not form part of the reference standard
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
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Monni 2005
Clinical features and settings Routine screening
Participants 16,654 participants
Italy - single centre
2001-2004
Pregnant women
Median age 32 years (14-49 years)
Singleton pregnancies
10-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 96 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods, No information given regarding machines used)
First trimester nasal bone examination (transabdominal ultrasound in mid-sagittal view)
Annual audit of screening performance (medians)
Follow-up Outcome at birth as recorded in hospital database (provided by outcome sheets or tele-
phone interviews). Of 32,000 cases in the database, 16,654 (52%) patients had NT,
nasal bone assessment and follow-up data available. Patients without follow-up data were
excluded from the study
Aim of study To evaluate the feasibility and diagnostic accuracy of fetal NT and nasal bone assessment
at 11-14 weeks for screening of trisomy 21
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
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Monni 2005 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes In 13 cases (1.3%) not possible to ascertain if nasal bone was
visible
Withdrawals explained?
All tests
No No details of withdrawals given
Montalvo 2005
Clinical features and settings Routine screening
Participants 4538 participants who had follow-up data available
Spain - tertiary hospital
July 1999 - October 2004
Pregnant women
Mean age 31.1 years (14-49 years), 25.9% of patients ≥ 35 years
Singleton pregnancies
10-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 19 cases
Reference standards: invasive testing offered to women considered high risk from screen-
ing results or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (Methods described by Nicholaides)
First trimester PAPP-A and free ßhCG (Kryptor Trace system, CIS Bio International)
Risk cut-point 1:270
Follow-up Only patients with postnatal results available are included in the study
Aim of study To report the experience of using of use of the combined first trimester screening test
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
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Montalvo 2005 (Continued)
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Moon 2007
Clinical features and settings Routine screening
Participants 6471 fetuses with available outcome data
Korea
July 2004 - March 2006
Pregnant women
Singleton or multifetal pregnancies
Mean maternal age: Down’s syndrome 35.5 years (SD 4.8 years), non-Down’s syndrome
31.7 years (SD 3.4 years)
11-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 15 cases
Reference standard: karyotyping or follow-up to birth
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Moon 2007 (Continued)
Index and comparator tests First trimester fetal nasal bone assessment (Voluson 730, LOGIQ 400 or 5, GEMedical
Systems orHDI 500, PhilipsMedical systems) (AmericanRegistry ofDiagnosticMedical
Sonographers certified Sonographers)
Follow-up Obstetric andneonatal outcome obtained frommedical records, karyotyping reports and,
when needed, telephone conversations with parents or physicians. A total of 7834 fetuses
were included in the study but 1047 fetuses (13.4%) without available outcome data
were excluded. The remaining 6787 fetuses included 154 twin pregnancies. Assessment
of fetal nasal bone was possible in 6490 (95.6%) of the 6787 fetuses. Comparison of
nasal assessments between the control population and Down’s cases was performed in
6471 fetuses
Aim of study To evaluate the role of nasal bone assessment in first-trimester screening for Down’s
syndrome in the Korean population
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Index tests did not form part of the reference standard
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Assessment of fetal nasal bone was not possible in 297 women
(4.4%)
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Moon 2007 (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given
Muller 2003
Clinical features and settings Routine screening
Participants 5694 participants who had first trimester NT and biochemical testing
France - 9 centres serving 12 maternity units
January 1998 - June 2001
Pregnant women
Singleton pregnancies
Maternal age not reported
11-13 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 26 cases
Reference standards: invasive testing (offered to women with high NT measurement) or
follow-up to birth
Index and comparator tests Maternal age
First trimester nuchal translucency in 98% of patients (methods not specified. 60 sono-
graphers - 2 trained by Fetal Medicine Foundation, who trained 30 in turn. 8 received
specific training in France, and 20 were self-taught. Machines not specified)
Frozen serum tested for:
First trimester PAPP-A (99% of patients), free ßhCG 99% of patients and AFP (93%
of patients) (time-resolved fluorescent assay, Perkin-Elmer Life sciences)
Risk cut-point 1:250
Follow-up Data from the French national screening programme used for follow-up at birth. 211
women (3.7%) who did not return after NT or were found to be > 14 weeks were
excluded. It is unclear how many patients had follow-up to birth
Aim of study Prospective study of NT and retrospective evaluation of serum (in same patient popu-
lation) to evaluate whether or not to move the national French Down’s screening pro-
gramme to a first trimester programme
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
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Muller 2003 (Continued)
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Women with NT too small to measure assumed to have NT of
< 0.5 mm
Withdrawals explained?
All tests
Yes Women failing to return or who more than 14 weeks pregnant
were excluded (214)
Nicolaides 1992
Clinical features and settings High-risk referral for invasive testing
Participants 827 participants
UK - research centre for fetal medicine
January 1990 - October 1991
Pregnant women
Median age 38 years (22-47 years)
10-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 13 cases
Reference standards: fetal karyotyping by amniocentesis (52%) or CVS (48%)
Index and comparator tests Maternal age
First trimester NT (curvilinear 5MHz transducer, Aloka 650 CO Limited)
Follow-up 100% karyotyping
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Nicolaides 1992 (Continued)
Aim of study To examine the significance of fetal NT at 10-14 weeks’ gestation in the prediction of
abnormal fetal karyotype
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes Amniocentesis or CVS
Partial verification avoided?
All tests
Yes All women had a reference standard
Differential verification avoided?
All tests
No Women had different reference standards
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Nicolaides 2005
Clinical features and settings Routine screening
Participants 75,821 participants with available information on outcome
UK - Various hospitals and a fetal medicine centre
June 1998 - December 2003
Pregnant women
Median age 31 years (13-49 years)
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Nicolaides 2005 (Continued)
Singleton pregnancies
11-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 325 cases
Reference standards: amniocentesis or CVS (patients considered high risk based on
screening). First trimester presence/absence of nasal bone, presence/absence of tricuspid
regurgitation or normal/abnormal Doppler studies (patients of intermediate risk on first
trimester screening and did not undergo CVS or amniocentesis. With the addition of
information from these tests, if adjusted risk was high, CVS was performed). Follow-up
to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods)
First trimester free ßhCG and PAPP-A (Kryptor analyser, Brahms AG)
Risk cut-point 1:300
Follow-up Follow-up data from cytogenetics laboratories, patients, GPs or maternity units where
they delivered. Patients without follow-up information due tomiscarriage or termination
(n = 490) or loss to follow-up (n = 2117) were excluded from the study
Aim of study To evaluate the performance of first trimester screening for trisomy 21 by a combination
of maternal age, fetal NT and maternal serum free ßhCG and PAPP-A. In addition, the
impact of a new individual risk orientated 2-stage approach to first trimester screening
was examined
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
171First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nicolaides 2005 (Continued)
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes Exclusions due to loss to follow-up and missing information
for women with miscarriages or terminations of pregnancy ex-
plained
Niemimaa 2001
Clinical features and settings Routine screening
Participants 2515 participants
Finland - primary care centres and maternity clinics of hospitals
During 1999
Pregnant women
17.5% aged ≥ 35 years
10-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 8 cases
Reference standards: invasive testing (patients considered high risk based on NT screen-
ing) or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (≥ 3 mm) (64% of women) (method not described)
Fresh serum tested for:
First trimester free ßhCG and PAPP-A (Wallac analytes and 1st trimester risk calculation
programme maternal weight correction)
Risk cut-point 1:250
Follow-up Follow-up data from maternity clinics and the National Research and Development
Centre for Welfare and Health. Test negative patients followed up by contacting all
maternity clinics and the National Research and Development Centre for Welfare and
Health. Unclear if follow-up information was obtained in all cases
Aim of study To evaluate efficacy of combining first trimester maternal serum and fetal NT measure-
ment in screening for Down’s syndrome in Finland
Notes
Table of Methodological Quality Table of Methodological
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Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Noble 1995
Clinical features and settings Routine screening in a high-risk population
Participants 2529 participants
UK
October 1994 to April 1995
Pregnant women
Singleton pregnancies
Median age 34 years (15-47 years), 47% ≥ 35 years
10-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 61 cases
Reference standards: karyotyping performed (27% of women) due to increased NT
(14%), advanced maternal age (10%), previous chromosomally abnormal child (0.5%)
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or parental anxiety (2%).Ultrasound examination at 20weeks (65%of patients). Follow-
up to birth (9% of women)
Index and comparator tests Maternal age
First trimester NT (methods not stated)
Fresh serum (or serum frozen over a weekend) tested for:
First trimester free ßhCG (immunoradiometric assay, CIS)
Follow-up Pregnancy outcome obtained from maternity units or the patients themselves. Follow-
up information only appears to have been obtained in 9% of cases (second trimester
ultrasound used as reference standard for other women)
Aim of study Tomeasure the contribution of maternal serum free beta hCG in a screening programme
for fetal trisomy 21 based on fetal NT in the first trimester of pregnancy
Notes No proper results data are presented for this study
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation
Acceptable reference standard?
All tests
No Invasive testing, ultrasound at 20 weeks or
follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference
standard
Differential verification avoided?
All tests
No Choice of reference standard depended on
index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge
of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
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Withdrawals explained?
All tests
No No details of withdrawals given
O’Callaghan 2000
Clinical features and settings Routine screening
Participants 1000 participants
Australia - public and private sector venues
September 1997 to September 1999
Pregnant women
Singleton or multifetal pregnancies (2000 fetuses including 25 sets of dichorionic twins,
7 sets of monochorionic twins and 4 sets of triplets but the numbers amongst the 1000
fetuses reported in the paper were not stated)
Median age 32 years
11-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 8 cases
Reference standards: CVS, amniocentesis, neonatal karyotyping or follow-up to birth
Index and comparator tests Maternal age
NT (FMF methods)
Follow-up Follow-up from cytogenetics laboratory records but the completeness of follow-up is not
reported
Aim of study To evaluate a risk assessment tool based on first trimester NT
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women had a reference standard
Differential verification avoided?
All tests
Unclear Unclear if the choice of reference standard depended on index
test results
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Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
O’Leary 2006
Clinical features and settings Routine screening
Participants 22,340 participants
Australia - 13 ultrasound practices
August 2001 to October 2003
Singleton pregnancies
Pregnant women
Median age 31 years (14-47 years), 20% ≥ 35 years
11-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 60 cases
Reference standards: CVS or amniocentesis (women assessed to be high risk on screening)
or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods)
First trimester free ßhCG and PAPP-A (machine not stated)
All study participants underwent all tests
Risk cut-point 1:300
Follow-up Follow-up data obtained by review of the Midwives Notification System and the Birth
Defects Registry. 415 patients (1.8%) excluded due to no follow-up data. Patients with
multiple pregnancies or incomplete screens (n = 3946) were also excluded from the study
Aim of study To assess fetal outcomes for pregnancies identified at increase risk for Down’s syndrome
by first trimester combined ultrasound examination and maternal serum biochemistry
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Notes Appears likely that patients with miscarriages and terminations excluded
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes Details given of patients excluded due to incomplete screening
data or loss to follow-up
Okun 2008 FTS
Clinical features and settings Routine screening
Participants 14,487 participants undergoing first trimester screening (a separate cohort of 30,792
pregnancies were evaluated for integrated screening)
November 2002 - December 2005
Canada - 2 hospitals
Pregnant women
Singleton pregnancies
Mean maternal age 34 years
11-14 weeks’ gestation
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Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 62 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (most sonographers had FMF certification)
First trimester free ßhCG and PAPP-A (DSX Four Plate Automated ELISA Processing
system,DynexTechnologies andDPCImmulite 2000 automated immunoassay analyser,
Siemens Medical Solutions Diagnostics)
Risk cut-point 1:200 or NT ≥ 3.5 mm
Results presented with and without adjustment for bias due to miscarriages (viability
bias)
Follow-up From cytogenetics databases in both Hospitals, the Canadian Institute for Health Infor-
mation, labour and delivery databases, written and phone follow-up with care providers
and phone follow-up with women after birth
Aim of study To evaluate the performance of integrated prenatal screening and first trimester combined
screening for trisomy 21 in a large Canadian urban centre
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
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Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Orlandi 1997
Clinical features and settings Routine screening of general and high-risk women
Participants 2010 participants (744 in subgroup undergoing NT testing)
Italy
Dates not reported
Recruited through private physician or genetic counselling program for women of ad-
vanced maternal age
Pregnant women
Aged 15-46 years, 35% ≥ 35 years
Singleton pregnancies
9-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 11 cases (7 in subgroup with NT testing)
Reference standards: not reported
Index and comparator tests Maternal age
First trimester NT (37% of patients) (FMF methods, Toshiba SSA 250A or Acuson XP
10)
First trimester free ßhCGandPAPP-A (all patients) (dried blood samples, enzyme-linked
immunosorbent assays)
Risk cut-point 1:380
Follow-up Not reported
Aim of study To evaluate first trimester combined screening for Down’s syndrome
Notes Unclear as to what reference standard (if any) was used. All cases of Down’s syndrome
identified had been picked up by screening
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation
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Acceptable reference standard?
All tests
Unclear Reference standard not reported
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference
standard
Differential verification avoided?
All tests
Unclear Unclear if the choice of reference standard
depended on screening results
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge
of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
Yes Details given of women undergoing NT
but not biochemical testing
Orlandi 2003
Clinical features and settings Routine screening (2 centres) or in referred patients (1 centre)
Participants 1089 participants undergoing fetal nasal bone assessment
Italy/The Netherlands - 3 centres
February 2002 to April 2002
Pregnant women
Singleton pregnancies
Median age 31.7 years (SD 4.0) in unaffected cases and 36.5 years (SD 4.1) in affected
cases
11-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 15 cases
Reference standards: CVS or amniocentesis (women considered high risk on screening on
the basis of NT and biochemical results, but not on nasal bone screening, or if requested
due to age or anxiety), or follow-up to birth
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Index and comparator tests Maternal age
First trimester nasal bone assessment
First trimester NT
First trimester free ßhCG
First trimester PAPP-A
Follow-up Reported that karyotyping was performed postnatally. It is unclear in which cases this
was conducted
Aim of study To assess the feasibility of measuring nasal bone length in first trimester pregnancy and
to confirm if the absence of fetal nasal bone is a marker for Down’s syndrome
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference
standard
Differential verification avoided?
All tests
No Choice of reference standard depended on
index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge
of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
Yes Nasal bone assessment was successfully
conducted in 94.3% of women
Withdrawals explained?
All tests
No No details of withdrawals given
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Clinical features and settings Routine screening
Participants 2411 participants
Italy
Dates not reported
Pregnant women
Median age 30.5 years (SD 8.2)
First trimester (gestational weeks not reported)
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 15 cases
Reference standard: not reported
Index and comparator tests Maternal age
First trimester nasal bone assessment (FMF methods)
First trimester NT, free ßhCG and PAPP-A
Data from other studies used to generate statistical parameters to estimate performance
of first trimester screening with and without nasal bone evaluation)
Risk cut-point 1:250
Follow-up No details reported for any follow-up to birth
Aim of study To determine the benefit of including nasal bone assessment in addition to standard first
trimester markers as a screening test for Down’s syndrome
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
Unclear Unclear if the choice of reference standard depended on screen-
ing results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
Unclear Reference standard interpreted with knowledge of index test
results
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Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Otaño 2002
Clinical features and settings High-risk referral for invasive testing
Participants 194 participants
Argentina
October 2001 - January 2002
Pregnant women
Median age 36 years (19-44 years)
Singleton pregnancies
11-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 5 cases
Reference standard: CVS
Index and comparator tests First trimester nasal bone assessment (frontal saggital section of the fetal face. Angle of
insonation of fetal nose close to 90 degree angle)
Follow-up 100% karyotyping
Aim of study To evaluate the association of nasal bone on ultrasound and Down’s syndrome fetuses at
11-14 weeks’ gestation
Notes States in text that there were 6 cases of trisomy 21
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes CVS
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Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
Yes All women had the same reference standard
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
Unclear Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes Unsuccessful nasal bone assessment in 6%
Withdrawals explained?
All tests
No No details of withdrawals given
Pajkrt 1998
Clinical features and settings Routine screening
Participants 1473 participants
The Netherlands tertiary maternity unit
June 1994 to March 1997
Pregnant women
Mean age 31.4 years (SD 5.7), 24% ≥ 35 years
Singleton pregnancies
10-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 9 cases
Reference standards: prenatal karyotyping offered to patients considered high risk or
maternal anxiety (conducted in 24%) or follow-up to birth
Index and comparator tests Maternal age
NT (FMFmethod,Hitachimachines, 6 sonographers instructed to take ’sufficient time’)
Risk cut-point ≥ 3 mm
Follow-up Follow-up to outcome assessment in the delivery room. 68 women (4.4%) were excluded
from the study due to loss to follow-up
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Aim of study To evaluate the effectiveness of NT measurement in the detection of trisomy 21 in a
low-risk population
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
Unclear Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Unsuccessful NT measurement in 4.3%
Withdrawals explained?
All tests
No No details of withdrawals given
Pajkrt 1998a
Clinical features and settings High-risk referral for invasive testing
Participants 2247 participants undergoing NT and fetal karyotyping
The Netherlands - prenatal diagnostic centre
February 1994 to July 1997
Singleton pregnancies
Pregnant women
Mean age 37.6 years (22-46 years)
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10-14 weeks’ gestation
Study design Consecutive cohort
Target condition and reference standard(s) Down’s syndrome: 36 cases
Reference standard: prenatal karyotyping
Index and comparator tests Maternal age
FT NT (maximal saggital thickness of NT, corrected for gestational age)
Follow-up 100% karyotyping
Aim of study To examine the discriminatory capacity of NT measurement in the detection of trisomy
21 and other chromosomal anomalies
Notes No follow-up information on 12 miscarriages
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes Karyotyping
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
Yes All women had the same reference standard
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
Yes Unsuccessful NT measurement in 2.4%
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Withdrawals explained?
All tests
Yes Patients excluded due to sonographically de-
tected fetal abnormalities at NT measurement,
no karyotyping or miscarriages
Palomaki 2007 FTS
Clinical features and settings Routine screening
Participants 10,775 participants
Canada - General Hospital
October 2003 - November 2004
Pregnant women
Mean maternal age 32.3 years (SD 4.6 years)
10-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 23 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
FT NT (encouraged to only accept measurements from sonographers with FMF certi-
fication)
FT PAPP-A (AutoDELFIA, PerkinElmer)
FT hyperglycosylated-hCG (Nichols Advantage Specialty system, Nochols Institute Di-
agnosics)
Follow-up From electronic record searches of local patient and cytogenetic records and case finding
of local and regional birth records
Aim of study To validate Down’s syndrome screening protocols that include hyperglycosylated-hCG
measurements
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
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Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Perni 2006
Clinical features and settings Routine screening
Participants 4615 participants
USA - single institution
January 2003 to September 2004
Pregnant women
Singleton pregnancies
Mean age 33.0 years (IQR 31.0-36.0)
10-13 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 22 cases
Reference standards: CVS or amniocentesis. Cytogenetic testing in cases of miscarriage.
Follow-up to birth
Index and comparator tests Maternal
First trimester NT (FMF methods)
First trimester PAPP-A and free ßhCG (dried blood spots, methodology described else-
where)
Follow-up Outcome information from computerised medical record review. Numbers of patients
lost to follow-up not reported
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Aim of study To evaluate the performance of maternal age, fetal NT, PAPP-A and free ßhCG for
aneuploidy screening
Notes Appears that all cases of Down’s were diagnosed prenatally by karyotyping
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Prefumo 2005
Clinical features and settings High-risk referral for invasive testing
Participants 544 participants
UK - tertiary referral fetal medicine unit
December 2001 to November 2003
Pregnant women
Median age 37 years (19-46 years)
Singleton pregnancies
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11-14 weeks’ gestation
Study design Prospective cohort study
Target condition and reference standard(s) Down’s syndrome: 47 cases
Reference standard: CVS
Index and comparator tests Maternal age
First trimester NT (methods not reported), risk cut-point 1:300
First trimester nasal bone examination (mid-sagittal view with beam of the ultrasound
transducer being parallel to the nasal bones, previously described)
First trimester ductus venous flow (abnormal defined as absent or reversed flow. Angle
of insonation < 30 degrees. 3 minutes allotted time. NB previously described)
Follow-up 100% karyotyping
Aim of study To assess the role of fetal ductus venous and nasal bone evaluation in first trimester
screening for Down’s syndrome
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice
Acceptable reference standard?
All tests
Yes CVS
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
Yes All women had the same reference standard
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
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Uninterpretable results reported?
All tests
Yes Not possible to satisfactorily assess ductus ve-
nous flow in 4 cases (0.6%) and nasal bones in
52 cases (8.3%)
Withdrawals explained?
All tests
Yes 158 patients not included in the study due to
time restrictions or due to the patient declining
taking part
Prefumo 2006
Clinical features and settings Routine screening
Participants 7116 participants
UK - single institution
December 2001 to November 2003
Pregnant women
Singleton pregnancies
Mean age 31.4 years (14.5-50.2 years)
10-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 12 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (all patients) (mid-sagittal view)
First trimester nasal bone assessment
Follow-up Outcome information from computerised hospital records. Results cross-matched with
the registry of the Regional Genetics Service. No report of how many patients lost to
follow-up
Aim of study To assess the role of fetal nasal bone evaluation in first trimester screening for trisomy
21 in selected and unselected pregnancies
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
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Prefumo 2006 (Continued)
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Nasal bones could not be satisfactorily assessed in 9.9%of fetuses
Withdrawals explained?
All tests
No No details of withdrawals given
Ramos-Corpas 2006
Clinical features and settings Routine screening
Participants 1800 participants
Spain - hospital fetal medicine department
June 2003 to April 2004
Pregnant women
Singleton pregnancies
Mean age 30.1 years (15-46 years) (SD 5.37), 18% ≥ 35 years
First trimester (before week 14)
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 7 cases
Reference standards: invasive testing offered to patients considered high risk at screening
(> 1:300) or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF method (Accuson XP10, Mountain View, California) Maxi-
mum allotted time of 20 minutes)
First trimester nasal bone assessment (in 93.4% of patients)
Risk cut-point 1:300
PAPP-A and free ßhCG (Delfia Xpress 6000 immunoanalyzer, Perkin Elmer) - not used
in study
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Ramos-Corpas 2006 (Continued)
Published population parameters used (Wald 2003)
Follow-up Follow-up in all patients without invasive testing by 1) monitoring all births and mis-
carriages at the hospital, 2) continued contact with the genetics departments and 3)
telephone follow-up. States in abstract that only fetuses with complete follow-up results
included in the study
Aim of study To evaluate the utility of determining the presence or absence of nasal bone in a low-risk
fetal population
Notes 5 cases diagnosed by invasive testing, 2 by follow-up
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Nasal bones could not be satisfactorily assessed in 6.6%of fetuses
Withdrawals explained?
All tests
No No details of withdrawals given
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Rissanen 2007
Clinical features and settings Routine screening
Participants 4776 participants undergoing NT and/or biochemical screening
Finland - hospitals or health care centres
1999 - 2000
Pregnant women
Singleton pregnancies
Mean maternal age 29.5 years, 17.7% ≥ 35 years
10-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 13 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (Trained personnel)
First trimester PAPP-A and free ßhCG (AutoDelfia kits, PerkinElmer)
Risk cut-point 1:250
Follow-up Outcomes obtained from all maternity clinics, the Finnish Register of Congenital Mal-
formations and theNational Research and Development Centre for Welfare and Health.
Follow-up was complete in 99% of live-born infants. Data on miscarriages (n = 68)
received from the National Research and Development Centre for Welfare and Health
Aim of study To evaluate whether first trimester screening markers are altered in pregnancies af-
fected both by other chromosomal defects than trisomy 21 and structural anomalies and
whether it is possible to detect these pregnancies by combined ultrasound and biochem-
ical screening
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
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Rissanen 2007 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Rozenberg 2002
Clinical features and settings Routine screening
Participants 9118 participants
France - 2 tertiary and 4 primary referral centres
March 1994 to December 1997
Pregnant women
Median age 30.5 years (18-37 years)
Singleton pregnancies
12-14 and 14-17 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 21 cases
Reference standards: amniocentesis offered to patients withNT > 3mm or serummarker
risk was > 1:250, or follow-up to birth
Index and comparator tests Maternal age
First trimester NT in 98.6% of women (FMF methods)
Second trimester free ßhCG (beta hCG ELISA immunoradiometric assay) and AFP
(AFP ELISA immunoradiometric assay) in 91.1% of women
Both NT and biochemical testing in 60.4% of women
Follow-up Details of the method of follow-up not given. 3.4% of patients were lost to follow-up
and were excluded from the study. This included 113 women (1.2%) with miscarriages
Aim of study To assess the performance of combined first trimester sonographic screening and second
trimester serum screening
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Rozenberg 2002 (Continued)
Notes Includes cost-effectiveness analysis
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women had a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT was not able to be measured in 93 women (1.5%)
Withdrawals explained?
All tests
No No details of withdrawals given
Rozenberg 2007
Clinical features and settings Routine screening
Participants 14,934 participants
Canada - multicentre study
Pregnant women
Singleton pregnancies
Mean maternal age 30.9 (SD 4.5) years
11-13 weeks’ gestation
Study design Prospective cohort study
196First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rozenberg 2007 (Continued)
Target condition and reference standard(s) Down’s syndrome: 51 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (trained assessors following protocol)
First trimester PAPP-A and free ßhCG (PerkinElmer Life Sciences)
Second trimester ultrasound and/or serum markers (free ßhCG and AFP or total hCG,
AFP and uE3) performed in some cases
Risk cut-point 1:250
Follow-up Notebooks in maternity hospitals used to record information on patient characteris-
tics, screening and outcome at birth. Data obtained from cytogenetic laboratories and
DASDY database (contains results of birth examinations). Letters sent to women with
missing outcome information and, after 3 months, if there was no response, they were
contacted by telephone
Aim of study To evaluate the performance, acceptability and cost-effectiveness ratio of a pragmatic
approach to screening for Down’s syndrome based on the combined first trimester test
supplemented by routine ultrasound at 20-22 weeks in the general population
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
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Rozenberg 2007 (Continued)
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes 554 women (3.7%) did not undergo screening
Sahota 2010
Clinical features and settings Routine screening
Participants 10,854 pregnancies with complete outcome data
China - University Hospital
January 2005 - May 2008
Pregnant women
Singleton pregnancies
Median maternal age 33.1 years, 30.1% of women aged ≥ 35 years
10-13 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 32 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF accredited sonographers, HDI 5000, Philips Medical System)
First trimester PAPP-A and free ßhCG (kryptor analyser, Brahms Diagnostica GmbH)
Contingent screening strategies
• Strategy-NT-BC: combined screening and if risk intermediate, nasal bone
assessment added
• Strategy-BC: screening with PAPP-A and free ßhCG and if intermediate risk, NT
added. If risk still intermediate, nasal bone assessment added
• Strategy-NT: screening with NT and if intermediate risk, PAPP-A and free ßhCG
added. If risk still intermediate, nasal bone assessment added
Intermediate risk cut-points 1:50 to 1:1000
Follow-up Fetal karyotypes entered into database when available. Data on pregnancy outcomes
obtained either from local maternity database for those who delivered in the unit or via
telephone calls to patients
Aim of study To assess the relative performance of a multi-stage first trimester screening protocol for
fetal Down’s syndrome
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
198First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sahota 2010 (Continued)
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Salomon 2010
Clinical features and settings Routine screening
Participants 21,492 participants
France - Single Health Authority district
January 2001 - December 2003
Pregnant women
Median maternal age 30.7 years (18.0-46.3 years)
11-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 80 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (sonographers trained to FMF standards)
First trimester PAPP-A and free ßhCG (time resolved fluorescent assay, PerkinElmer Life
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Salomon 2010 (Continued)
Sciences)
Routine abnormality scan for structural malformations (20-24 weeks)
Femur length at routine abnormality scan
Follow-up Case report forms completed by attending obstetrician ormidwife throughout pregnancy
and delivery.Databases of certified laboratories cross-checked with delivery and outcome
data in all maternity units, the databases of all cytogenetic laboratories, the database of
the health authority (DASDY), contact with women by mail 3 months after expected
delivery and direct telephone with women
Aim of study To evaluate the performance of the contingent use of femur length at routine mid-
trimester scan in screening for Down’s syndrome in women having previously undergone
first trimester screening with disclosure of risk estimates
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
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Santiago 2007
Clinical features and settings Routine screening
Participants 4248 participants
Spain - Screening database managed by the Fetaltest project
To December 2005
Pregnant women
Singleton pregnancies
Mean maternal age 30.6 years (14-46 years)
11-13 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 13 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (trained sonographers)
First trimester PAPP-A and free ßhCG (details not reported)
Cut-point 1:300 and detection rate at 5% FPR
Follow-up Follow-up by supervising the live births and miscarriages at the Hospital together with
continuous contact with the genetics department. 24 pregnancies ended in miscarriage
and were lost to follow-up. In 269 women not giving birth at that Hospital, only those
karyotyped were followed up. In total, 287 women (6.8%) were lost to follow-up
Aim of study To determine whether delta-NT could be extrapolated successfully from 1 centre-specific
NT reference curve to another and thus to empirically calculate the likelihood ratios of
delta-NT
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
201First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Santiago 2007 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Sau 2001
Clinical features and settings Routine screening
Participants 3185 participants
UK - single hospital
November 1996 to November 1998
Pregnant women
Mean age 28 years (SD 5)
11-14 and 6-20 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 8 cases
Reference standards: invasive testing (women with high risk on screening) or follow-up
to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods, transabdominal route) in 84% of women. NT risk
cut-point of 1:100 or if NT measurement > 95th centile for that particular CRL con-
sidered screen positive. Confirmatory NT test conducted in all women positive on first
NT screening
Second trimester AFP, ßhCG and uE3 in 49% of women. Serum risk cut-point 1:250
Follow-up Follow-up from computerised maternity records, the neonatal database and the hospital
termination of pregnancy and miscarriage record books
Aim of study To present data on the performance of biochemical screening in a population with a
prior low-risk screening result
Notes
Table of Methodological Quality Table of Methodological
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Sau 2001 (Continued)
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes In 122 (4.3%) of women, a second NT scan was needed since
the first 1 failed to obtain a measurement
Withdrawals explained?
All tests
Yes Of 3704 women booked for hospital delivery, 3185 had at least
1 screening test and were included in the study
Schaelike 2009
Clinical features and settings Routine screening
Participants 10,668 participants with complete outcome data
Germany - private centre
November 2000 - December 2006
Pregnant women
Singleton pregnancies
Maternal age ≥ 35 years in 31.0% of women
11-13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 59 cases
Reference standards: karyotyping or follow-up to birth
203First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Schaelike 2009 (Continued)
Index and comparator tests Maternal age
First trimester NT (FMF certified physicians)
First trimester PAPP-A and free ßhCG (Kryptor analyser, Brahms GmbH)
Cut-point 1:300
Follow-up Information provided by either obstetric departments or obstetricians. Results fromCVS
and amniocentesis, as well as karyotypes from aborted fetal tissue or from postnatal
investigations were used. 3.9% of women were lost to follow-up and were excluded from
the study
Aim of study To assess the performance of a combined first trimester screening concept for trisomies
21, 18 and 13 applied to a low- and high-risk patient sample in a specialised private
centre for prenatal medicine
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
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Schielen 2006
Clinical features and settings Routine screening
Participants 4033 participants
The Netherlands - multicentre (44 centres) study
July 2002 to May 2004
Singleton pregnancies
Pregnant women aged 18-47 years (median 36.5 years)
10-14 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 21 cases
Reference standards: invasive testing or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods)
First trimester free ßhCG and PAPP-A (AutoDELFIA analyser)
Follow-up Women were asked to fill in a questionnaire about outcome of pregnancy. A second
request was sent by mail if necessary
784 patients were lost to follow-up (16.2%) and were excluded from the study
Aim of study To report the results of a first trimester combined-test screening programme in a multi-
centre routine clinical setting
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
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Schielen 2006 (Continued)
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Schuchter 2001
Clinical features and settings Routine screening
Participants 9342 participants
Austria - single institution
January 1994 to December 1998
Pregnant women
Singleton pregnancies
Mean age 28 years (15-46 years), 10.7% ≥ 35 years
10-13 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 19 cases
Reference standards: CVS (offered to patients with first trimester NT > 3.5 mm), am-
niocentesis (offered to patients with first trimester NT 2.5-3.4 mm, high risk on second
trimester serum testing (> 1:250) and those > 35 years) or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (5-MHz transducer, Acuson Corp)
Second trimester AFP, uE3 and hGC (triple test) offered to patients not undergoing first
trimester invasive testing (99.7% of women) (AMERLEX-M 2nd Trimester kits, Ortho
Clinical Diagnostics)
Follow-up Patients included in study if they were delivered in the same hospital where they were
screened. All newborns were examined formalformations by a paediatrician after delivery
Aim of study To evaluate screening for trisomy 21 in a low-risk population utilising a combination of
NT measurement in the first trimester and the triple test in the second trimester
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
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Schuchter 2001 (Continued)
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Schuchter 2002
Clinical features and settings Routine screening
Participants 4802 participants
Austria - single institution
December 1997 to April 2000
Singleton pregnancies
Pregnant women
13.0% > 35 years
10-12 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 14 cases
Reference standards: CVS and amniocentesis (offered to patients with increased risk (>
1:400) at first trimester screening. CVS recommended when NT > 3.5 or when women
did not want to wait until the 15th week for amniocentesis), or follow-up to birth
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Schuchter 2002 (Continued)
Index and comparator tests Maternal age
First trimester NT (transabdominal transducer, 5-MHz curvilinear Transducer, Acuson,
Mountain View), cut-point 2.5 mm
First trimester PAPP-A and free ßhCG (done radioimmunologically, kits by Ortho Clin-
ical Diagnostics)
Combined risk cut-point 1:250
Follow-up Patients without follow-up information (n = 92, 2%) were excluded from the study. 27
women with spontaneous abortions were also excluded from the study
Aim of study To determine the detection rate of the combined test, NT alone and maternal age alone
in a non-selected population at a false positive rate of about 5%
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All patients received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes Women not attending visits were excluded from the study
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Schwarzler 1999
Clinical features and settings Routine screening
Participants 4523 participants
UK - single institution
July 1996 to November 1997
Pregnant women
Mean age 29.4 years (16-47 years)
10-14 weeks’ gestation
Study design Prospective consecutive cohort
Target condition and reference standard(s) Down’s syndrome: 12 cases
Reference standards: invasive testing (women considered high risk on screening) or fol-
low-up to birth
Index and comparator tests Maternal age
NT (Sagittal plane by transabdominal (92.7%) and transvaginal (7.3%) sonography)
Adjusted risk cut-point 1:270
Follow-up Pregnancy outcome obtained via questionnaires, examination by neonatologist and out-
come cross-referenced with regional cytogenetics registry. 26 test-negative patients lost
to follow-up and excluded from the study
Aim of study To evaluate first trimester pregnancy screening for fetal aneuploidy and congenital heart
defects by maternal age and NT measurement in an unselected population
Notes 3 live births, 9 termination of pregnancy
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
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Schwarzler 1999 (Continued)
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Scott 2004
Clinical features and settings Routine screening
Participants 2053 participants
Australia - private practice (Sydney Ultrasound for Women)
July 2000 to May 2002
Pregnant women
Median age 32 years (15-44 years), 29% ≥ 35 years
Singleton pregnancies
11-14 weeks’ gestation
Study design Prospective cohort study
Target condition and reference standard(s) Down’s syndrome: 5 affected cases
Reference standards: invasive testing or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods, sagittal plane, ATL 5000; Philips)
First trimester free ßhCG and PAPP-A (kryptor analyser, Brahms Diagnostics)
All participants had all tests
Risk cut-point 1:300
Follow-up Data obtained from referring doctors or patients via letter, phone or completed feedback
form given at the time of consultation. Only cases of known outcome included in the
study. 68 (1.3%) lost to follow-up, largely due to miscarriage (n = 20) and loss to follow-
up (n = 40)
Aim of study To report the sensitivity of combined first trimester biochemistry and ultrasound screen-
ing for Down’s syndrome in an Australian private practice specialising in obstetric ultra-
sound
Notes Only women having biochemical testing before NT were included in the study. This was
done to avoid bias from women declining biochemical testing following negative NT.
Table of Methodological Quality Table of Methodological
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Scott 2004 (Continued)
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Sepulveda 2007
Clinical features and settings Routine screening
Participants 1287 participants
Chile - fetal medicine centre
January 2003 - January 2006
Pregnant women
Median maternal age 33 years (range 14-47 years), 35.4% ≥ 35 years
Singleton pregnancies
11-14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 31 cases
Reference standards: CVS, amniocentesis, cordocentesis or follow-up to birth
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Sepulveda 2007 (Continued)
Index and comparator tests Maternal age
First trimester NT and nasal bone assessment (Accuvix XQ, Medison or Voluson 730,
GE Healthcare) (only included in study if scanned by 1 of 2 fetal medicine specialists
following FMF guidelines)
Follow-up Cases of chromosomal abnormality were identified from the cytogenetics laboratory log-
book, which recorded all the cytogenetic studies performed prenatally, after a sponta-
neous abortion or fetal death, or in neonates with physical abnormalities. Information
from the remaining cases was obtained from the delivery records and neonatal discharge
summaries, which recorded the condition of the neonate at birth and the physical ex-
amination performed by a neonatologist
Aim of study To report their experience with first trimester screening for trisomy 21 by using the
combination of NT thickness and nasal bone assessment
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
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Sepulveda 2007 (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given
Snijders 1998
Clinical features and settings Routine screening
Participants 96,127 participants
UK - multicentre study (22 centres)
Women due to deliver before June 1997
Pregnant women
Median age 31 years (14-49 years)
Singleton pregnancies
10 to 14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 326 cases
Reference standards: CVS and amniocentesis (9.6% of women) or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (sagittal section)
Risk cut-point 1:300
Follow-up Each women given a request form to complete about the outcome of pregnancy. 4184
women (4.2%) were excluded due to loss to follow-up or due to miscarriages that were
not karyotyped
Aim of study To investigate the assessment of risk by a combination of maternal age and fetal NT
thickness, measured by ultrasonography at 10-14 weeks of gestation
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
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Snijders 1998 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Sorensen 2011
Clinical features and settings Routine screening
Participants 19,694 participants
Denmark - 2 centres
July 2005 - June 2007
Pregnant women
Singleton pregnancies
Maternal age: healthy mean age 30.4 years (16-45 years), 16.5% ≥ 35 years, Down’s
syndrome median age 34 years (23-44 years)
8-13 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 100 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF certified sonographers)
First trimester PAPP-A and free ßhCG (TRACE technology, Kryptor instrument,
Brahms AG)
Follow-up Details not reported. It was stated that, for non-Down’s syndrome pregnancies, only
those with known healthy fetus were included
Aim of study To develop 2 alternative risk calculation programmes to assess whether the screening
efficacies for T13, T18 and T21 could be improved by using our locally estimated
medians
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Sorensen 2011 (Continued)
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Spencer 1999
Clinical features and settings Women referred for invasive testing or self-referred for screening
Participants 1156 participants: 210 cases and 946 controls matched for gestational and maternal age
UK - fetal medicine research centre
Dates not specified
Pregnant women
Median maternal age 38 years (19-46 years) (cases) and 36 years (15-47 years) (controls)
10-14 weeks’ gestation
Study design Case-control study
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Spencer 1999 (Continued)
Target condition and reference standard(s) Down’s syndrome: 210 cases
Reference standards: invasive testing (high-risk women) or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (methods not reported)
Frozen serum samples tested for:
First trimester free ßhCGandPAPP-A (Kryptor analyser, time resolved amplified cryptate
emission (TRACE))
Follow-up Stated that pregnancy outcome was ascertained in all women
Aim of study To examine the potential impact of combining maternal age with fetal NT thickness and
maternal serum free ßhCG and PAPP-A in screening for trisomy 21 at 10-14 weeks of
gestation
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as
done in practice
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on
index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted with-
out knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
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Spencer 1999 (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given
Spencer 2002
Clinical features and settings Routine screening
Participants 278 participants: 54 cases and 224 controls (no details of how selected)
UK - OSCAR screening program
Samples collected since 1998
Pregnant women
Median maternal age 36 years (20-44 years) (cases) and 30 years (16-41 years) (controls)
11-13 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 54 cases
Reference standards: details not reported
Index and comparator tests Maternal age
First trimester NT (FMF methods)
Frozen serum samples tested for:
First trimester free ßhCG, PAPP-A and ThCG (Kryptor Analyser (TRACE) and auto-
mated immunofluorescent assays)
Follow-up Methods for follow-up to birth not reported
Aim of study To assess serum hyperglycosylated hCG for use in the first trimester of pregnancy as a
marker of Down’s syndrome
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth (Nicolaides 2005(OSCAR
screening program))
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
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Spencer 2002 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear of all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Spencer 2008
Clinical features and settings Routine screening
Participants 622 participants: 55 cases and 567 controls matched for gestational age
Denmark - screening programme
Dates not reported
Pregnant women
Median maternal age cases 35.8 years, controls 29.3 years
8-13 weeks’ gestation (results modelled on only cases where testing conducted before 10
weeks’ gestation)
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 55 cases (31 tested before 10 weeks’ gestation)
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (details not reported)
Fresh serum samples tested for:
First trimester PAPP-A and free ßhCG (Kryptor analyser, Brahms)
Frozen samples tested for:
First trimester ADAM 12 (measured blind to clinical outcome) (manual DELFIA assay,
PerkinElmer Life & Analytical Sciences)
Follow-up Details not reported
Aim of study To establish the effectiveness or otherwise of ADAM 12 as an early screening marker
Notes
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Spencer 2008 (Continued)
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Stenhouse 2004
Clinical features and settings Routine screening
Participants 5000 participants
UK - maternity clinic
Over a 3 year period - dates not specified
Pregnant women
Singleton pregnancies
Median age 32 years (14-45 years), 27% ≥ 35 years
11 to 14 weeks’ gestation
Study design Prospective cohort
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Stenhouse 2004 (Continued)
Target condition and reference standard(s) Down’s syndrome: 15 cases
Reference standards: invasive testing offered to women with screening risk of > 1:250 or
follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods, ATL HDI 3500, ATL HDI 3000, Toshiba SSA-
340A and Kretz Voluson)
First trimester free ßhCG and PAPP-A (Clotted venous blood samples, AutoDELFIA
immunoassy, Perkin Elmer)
Follow-up Details not reported
Aim of study To assess the effectiveness of combined ultrasound and biochemical screening for chro-
mosomal abnormalities in singleton pregnancies in a routine antenatal clinic and labo-
ratory setting
Notes Fetal loss rate for invasive testing was 1.4% (3/212)
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT not successfully measured in 25 patients (0.5%)
220First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stenhouse 2004 (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given
Strah 2008
Clinical features and settings Routine screening
Participants 7096 participants with information available on pregnancy outcome
Slovenia - 2 outpatient clinics
November 1999 - May 2006
Pregnant women
Singleton pregnancies
Median maternal age 28.6 years (range 15-42 years), 2.5% ≥ 36 years
11-14 weeks’ gestation
Study design Cohort
Target condition and reference standard(s) Down’s syndrome: 12 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimesterNT (2 FMF certified sonographers) (3.5-5MHz and 8-4MHz transducers
Toshiba Corevision Pro and 2-5 MHz and 9.3-3.7 MHz transducers GE Healthcare
Voluson 730 Pro)
Cut-off 1/300
Follow-up Pregnancy outcomes were obtained from participating women, referring gynaecologists,
paediatricians and maternity units and were missing in 3% (n = 225) of cases. Karyotype
results were reported from the cytogenetics laboratory. Only women with known out-
come were included in the study analysis
Aim of study To evaluate screening for trisomy 21 by maternal age and NT in a low-risk population
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
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Strah 2008 (Continued)
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Theodoropoulos 1998
Clinical features and settings Routine screening
Participants 4611 women due to deliver before July 1996
Greece - 4 medical centres
Dates not specified
Singleton pregnancies
Median maternal age 29 years (16-48 years), 7.8% ≥ 37 years
10 to 14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 10 cases
Reference standards: CVS or amniocentesis or follow-up to birth. Unclear reference
standard in cases of intrauterine death, miscarriages and terminations
Index and comparator tests Maternal age
First trimester NT (FMF methods, transabdominally with 5 or 3.5 MHz curvilinear
translucer or transvaginally with 5 MHz transducer)
Pandya’s risk criteria
Follow-up Results of fetal karyotyping and pregnancy outcome were entered into the database when
they became available
Aim of study To evaluate first trimester screening for chromosomal defects by fetal NT thickness at
10-14 weeks of gestation in 4 medical centres in Greece
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Theodoropoulos 1998 (Continued)
Notes 1 set of parents continued with diagnosed Down’s pregnancy to birth, 9 terminated. 1
case of Down’s syndrome only detected at birth
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Thilaganathan 1999
Clinical features and settings Routine screening
Participants 9802 participants
UK - district general hospital
November 1994 to November 1998
Pregnant women
Singleton pregnancies
Mean age 29 years (15-45 years)
10 to 14 weeks’ gestation
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Thilaganathan 1999 (Continued)
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 21 cases
Reference standards: CVS (offered to patients considered high risk on screening) or
follow-up to birth
Index and comparator tests Maternal age
First trimester NT (transabdominally, Toshiba SSA-250, Accuson 128XP/4 or Aloka
650CL with 3.5-7.5 curvilinear transducers)
Follow-up Pregnancy outcomes from hospital records and general practitioners. Karyotype results
or postnatal tests were provided by the local Regional Cytoenetics laboratory. The pro-
portion of patients who were followed up is not reported (49 patients had not given
birth at the time of analysis of outcomes)
Aim of study To evaluate the effectiveness of 10-14 week NT measurement in routine ultrasounds
screening for Down’s syndrome
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
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Thilaganathan 1999 (Continued)
Uninterpretable results reported?
All tests
Yes Unsuccessful NT in 10.1% of patients
Withdrawals explained?
All tests
Yes Patients not included due to ineligibility described
Timmerman 2010
Clinical features and settings High-risk referral
Participants 445 fetuses with increased risk based on NT or biochemical testing and information
available on pregnancy outcome
The Netherlands - fetal medicine unit
September 1996 - March 2008
Mean maternal age 34.5 years (19-45 years)
First trimester
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 72 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests First trimester ductus venosus pulsatility index and Ductus venosus a-wave (methods
reported elsewhere)
Follow-up Pregnancy outcome was obtained from standard follow-up forms filled in and returned
by patients, maternity wards or midwife practices and by reviewing neonatal, pathology
and clinical paediatric notes. When the baby was born without structural defects or
dysmorphic features, the chromosomeswere assumed tobe normal. In all cases of enlarged
NT or antenatal suspicion of abnormal development, the infant was investigated by a
neonatologist, paediatric cardiologist or geneticist.
Aim of study To investigate if ductus venosus pulsatility index for veins and a-wave measurements
can increase the accuracy of first trimester Down’s syndrome screening in a high-risk
population
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in practice
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
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Timmerman 2010 (Continued)
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Satisfactory waveform measurements made in 98% of cases
Withdrawals explained?
All tests
No No details of withdrawals given
Torring 2010
Clinical features and settings Routine screening
Participants 691 participants: 46 cases and 645 controls
Denmark - nationwide screening programme
Dates not reported
Pregnant women
Singleton pregnancies
Mean maternal age cases 35 years, controls 31 years
8-11 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 46 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (11-13 weeks’ gestation) (FMF certified sonographers)
First trimester PAPP-A and free ßhCG (fresh serum, 8-11 weeks’ gestation) (Kryptor
analyser, Brahms)
First trimester ADAM 12 (frozen serum, 8-11 weeks’ gestation) (Kyptor analyser, assay
by Cezanne SAS, TRACE technology)
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Torring 2010 (Continued)
Follow-up Not reported
Aim of study To determine whether ADAM 12 is a useful serum marker for fetal trisomy 21 using the
mixture model
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of some index
test results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Vadiveloo 2009
Clinical features and settings Routine screening
Participants 10,189 participants
UK - screening programme
July 2000 - October 2005
Pregnant women
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Vadiveloo 2009 (Continued)
Median maternal age 33.1 years, 36.9% ≥ 35 years
9-14 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 44 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (trained sonographers)
First trimester PAPP-A and free ßhCG (DELFIA fluoroimmunoassay, PerkinElmer LAS)
Contingent: biochemistry high risk cut-off 1:42, low risk cut-off 1:1000. If biochem-
ical/maternal age risk between 1:42 and 1:1000, NT results added and combined risk
calculated. Final cut-point 1:250
Follow-up Not reported
Aim of study To assess the performance of a 2-stage screening protocol for Down’s syndrome based on
initial serum marker analysis for all women and NT measurement only in women with
intermediate risks
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
228First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vadiveloo 2009 (Continued)
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Valinen 2007
Clinical features and settings Routine screening
Participants 7534 participants
Finland - screening programme
2002-2004
Pregnant women
Singleton pregnancies
Mean maternal age 29.6 years, 18.6% ≥ 35 years
10-12 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 30 cases (24 underwent NT as well as biochemical testing)
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (trained nurses, midwives and doctors) (4765 women)
First trimester PAPP-A and free ßhCG (details not reported) (all women)
Cut-point 1:250
Follow-up Contacted chromosome laboratory at the department of clinical genetics in the Oulu
university clinic and the Finish Register of Congenital Malformation and the National
Research and Development Centre for Welfare and Health
Aim of study To compare the efficacy of both separate and combined maternal serum testing and
fetal NT measurement in the first trimester screening for Down’s syndrome in northern
Finland
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
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Valinen 2007 (Continued)
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Viora 2003
Clinical features and settings Routine screening
Participants 1752 participants
Italy - ultrasound and prenatal diagnosis unit
December 2001 to June 2002
Pregnant women
Median age 32 years (18-47 years)
11 to 14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 10 cases
Reference standards: CVS or follow-up to birth
Index and comparator tests Maternal age
Nasal bone assessment (ultrasound examinations with Aloka SSD-1700 or ATL-Philips
5000 HCD)
Follow-up Follow-up to birth in all cases of abnormalities. Not reported if there was follow-up in
screen-negative patients
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Viora 2003 (Continued)
Aim of study To evaluate the significance of nasal bone ossification as a marker fir trisomy 21 at 11 to
14 weeks’ gestation in an unselected population
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes In 154 cases (8.1%) fetal profile was not obtained
Withdrawals explained?
All tests
No No details of withdrawals given
Wald 2003
Clinical features and settings Routine screening
Participants 39,983 participants
UK and Austria - multicentre trial
September 1996 to April 2000
Pregnant women
9-13 and 14-20 weeks’ gestation
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Wald 2003 (Continued)
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 85 cases
Reference standards: invasive testing (following second trimester screening) or follow-
up to birth
Index and comparator tests First trimesterNT (midsaggital section, optimalmagnification of thickness of translucent
space between inner skin surface and fascia covering cervical spine (white black interface
(oute) - black white interface (inner), 41 models of ultrasound machine, 20 minutes
allotted scanning time)
First and second trimester serum AFP, hCG, uE3, PAPP-A, free ßhCG (time resolved
fluoroimmunoassay, AutoDELFIA)
First and second trimester inhibin A (Sandwich enzyme linked immunosorbent assay,
Oxford bioinnovation)
First and second trimester urinary beta core fragment, total hCG, ITA and free ßhCG
(ITA and beta core fragment, Quest diagnostics USA)
Follow-up Follow-up by: 1) staff at local hospitals completed a study outcome form at, or just
after delivery, 2) study records of CVS, amniocentesis or karyotype at birth linked to
information from cytogenic laboratories, 3) study records linked to records of cases
of Down’s syndrome from the National Down’s Syndrome Cytogenetic Register, 4)
information obtained from local obstetrical outcome records, 5) forms sent to all women
with a request to return details of the outcome of their pregnancy, 6) individual searches
in respect of women whose outcomes of pregnancy had not been obtained by any of the
previous methods. 4% of total patient cohort did not have a documented outcome of
pregnancy. Unclear if any of these were included in the nested case-control study
Aim of study To identify the most effective, safe and cost-effective strategy for antenatal screening for
Down’s syndrome using NT, maternal serum and urine markers in the first and second
trimesters of pregnancy and maternal age in various combinations
Notes Performance of screening assessed at 17 weeks’ gestation. Study tried to be non-interven-
tional in the first trimester - second trimester testing was aimed to be used as the basis
for any referral for invasive testing
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
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Wald 2003 (Continued)
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Unclear Unclear if all index tests interpreted without knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Rates of NT failure on average 9%. Pre-10 weeks’ gestation, >
33% failure rate, declined to 7% at 12 weeks
Withdrawals explained?
All tests
No No details of withdrawals given
Wapner 2003
Clinical features and settings Routine screening
Participants 8216 participants
USA multicentre study (12 prenatal diagnostic centres)
Dates not specified
Singleton pregnancies
Pregnant women
Mean age 35 years (SD 4.6), 50% ≥ 35 years
11 to 14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 61 cases
Reference standards: invasive testing. Miscarriage with cytogenetic testing. Follow-up to
birth
Index and comparator tests Maternal age
First trimester NT (FMF methods)
Dried blood samples tested for:
First trimester free ßhCG and PAPP-A (dried blood samples, enzyme-linked immunoad-
sorbent assay as previously described)
Risk cut-point 1:270
Follow-up Follow-up to birth by directly following up women and reviewing delivery records. An
effort was also made to obtain information on terminated or miscarried pregnancies.
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Wapner 2003 (Continued)
196 (2.3%) of patients without follow-up information were excluded and women with
a previous trisomy 18 or 21 pregnancy were also excluded
Aim of study To evaluate the use of combined first trimester markers for aneuploidy in clinical practice
Notes 16 live Down’s syndrome births
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Wax 2009
Clinical features and settings Routine screening
Participants 2231 participants
USA
January 2005 - January 2008
Pregnant women
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Wax 2009 (Continued)
Singleton pregnancies
Mean maternal age 36.7 years (SD 3.2 years)
First and second trimester
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 8 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (Sonographers credited by FMF or Nuchal Translucency Quality
Review Program)
First trimester PAPP-A and free ßhCG (details not reported)
Second trimester ultrasound (in 884 women)
Cut-point for combined test 1:220
Follow-up Down’s syndrome cases ascertained from pre-natal genetic database, including prenatal
and newborn testing or physical examination at birth
Aim of study To evaluate the trisomy 21 screening performance of the first trimester combined test
followed by second trimester genetic sonography
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
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Wax 2009 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Wojdemann 2005
Clinical features and settings Referrals for screening
Participants 8622 participants
Denmark - 3 obstetrics departments
March 1998 to June 2001
Pregnant women
Mean age 29 years, 10.8% ≥ 35 years
Singleton pregnancies
11 to 14 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 12 cases
Reference standards: invasive testing (in cases of increased risk) or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods, Logic 700 MR machine) (all women)
First trimester free ßhCCG (AFP/ßhCG Auto Delfia kit) and PAPP-A (In-house ELISA
(Sandwich)) in 6,441 women (75%)
Risk cut-point 1:250
Follow-up Cross-checking with all the chromosome laboratories in Denmark. Follow-up in 96.2%
of pregnancies through patients records
Aim of study To determine the performance of screening for Down’s syndrome and other major chro-
mosomal abnormalities using NT, free ßhCG and PAPP-A in a prospective study of a
non-selected population
Notes Uptake of screening was 73% (9,941 accepted out of 13,621 offered screening)
Women with miscarriages excluded from the study
3 live Down’s syndrome births
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
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Wojdemann 2005 (Continued)
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT could not be measured in 2.5% of cases
Withdrawals explained?
All tests
No No details of withdrawals given
Wortelboer 2009
Clinical features and settings Routine screening
Participants 20,293 participants with complete outcome data
The Netherlands - nationwide screening programme
May 2004 - July 2006
Pregnant women
Singleton pregnancies
Median maternal age 34.9 years (15-48 years)
8-14 weeks’ gestation
Study design Cohort
Target condition and reference standard(s) Down’s syndrome: 87 cases
Reference standards: karyotyping or follow-up to birth
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Wortelboer 2009 (Continued)
Index and comparator tests Maternal age
First trimester NT (FMF protocols)
First trimester PAPP-A and free ßhCG (AutoDELFIA analyser, PerkinElmer, Turku)
Cut-point for combined test 1:250
Follow-up Pregnancy outcome was evaluated by questionnaire and collected through self-reporting
of the participating women. Due to strict privacy rules of the Dutch Personal Data
Protection Act, the researchers were allowed to send a reminder letter to collect missing
data only once. Women without complete information on outcome were excluded from
the study
Aim of study To study the performance of the first-trimester combined test between 2004 and 2006
compared to a previous period to investigate changes in time and identify reasons for
sub-optimal performance
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
238First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wortelboer 2009 (Continued)
Withdrawals explained?
All tests
Yes Only 65% of biochemistry screened women (n = 41,782) had
NT results
Wright 2008
Clinical features and settings Routine screening
Participants 37,488 participants with complete outcome data
UK - single centre
July 1999 - July 2005
Pregnant women
Singleton pregnancies
Median maternal age 35.2 years (16-52 years)
11-13 weeks’ gestation
Study design Cohort
Target condition and reference standard(s) Down’s syndrome: 264 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT
First trimester PAPP-A and free ßhCG (Kryptor system, Brahms AG)
Follow-up Maternal characteristics and test results were recorded in a computer database and kary-
otype results and details on pregnancy outcomes added as they became available.Women
without complete outcome data (n = 1231, 3.2%) were excluded from the study
Aim of study To examine the validity of methods used to derive patient-specific risks form NT mea-
surements
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
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Wright 2008 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Wright 2010
Clinical features and settings Routine screening
Participants 223,361 pregnant women
UK, Denmark and Cyprus - multicentre
Some data from UK and Denmark in previous publications
Dates not reported
Singleton pregnancies
Median maternal age 31.9 years (IQR 27.7-35.8 years)
7-14 weeks’ gestation
Study design Cohort
Target condition and reference standard(s) Down’s syndrome: 886 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (details not reported)
First trimester PAPP-A and free βhCG (Kryptor system, Brahms AG or Delfia Express
sustem, PerkinElmer, Waltham)
Follow-up Karyotype results and details on pregnancy outcomes were added to databases as soon
as they became available
Aim of study To establish an algorithm for first trimester combined screening for trisomy 21 with
biochemical testing from 7 to 14 weeks’ gestation and ultrasound testing at 11-13 weeks
Notes Taken results modelled for PAPP-A and free ßhcg at 12 weeks as that was most common
time for testing (44% of women)
240First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wright 2010 (Continued)
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No
Withdrawals explained?
All tests
No
Zoppi 2001
Clinical features and settings Routine screening
Participants 10,001 participants
Italy - genetic diagnosis centre
May 1996 to unspecified date
Pregnant women
Median age 33 years (14-48 years)
Singleton pregnancies
10 to 14 weeks’ gestation
Study design Prospective cohort
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Zoppi 2001 (Continued)
Target condition and reference standard(s) Down’s syndrome: 64 cases
Reference standards: amniocentesis, CVS or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods)
Risk cut-points of 1:100, 1:200 and 1:300
Follow-up Outcome obtained from women themselves. 1422 patients (11%) with no data on
follow-up outcome and 202 patients with miscarriages were excluded from the study
Aim of study To examine the distribution of fetal NT thickness in normal and abnormal fetuses in
Sardinia and to determine its effectiveness as a screening tool
Notes Study design unclear (maybe a case-control study)
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT could not be measured in 25 (0.2%) of cases
Withdrawals explained?
All tests
No No details of withdrawals given
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AFP:alpha-fetoprotein
ßhCG: beta human chorionic gonadotrophin
CVS: chorionic villus sampling
DELFIA: dual labelled time resolved fluorescent assay
DVPI: ductus venosus pulsivity index
FMF: frontomaxillary facial
hCG: human chorionic gonadotrophin
NT: nuchal translucency
PAPP-A: pregnancy-associated plasma protein A
PIGF: placental growth factor
uE3: unconjugated oestriol
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbas 1995 Unable to extract useful data
Abdul-Hamid 2004 No Down’s syndrome pregnancies
Abraha 1999 Unable to extract useful data
Abu-Rustum 2010 Not Down’s syndrome specific
Achiron 2010 Study only includes cases of Down’s syndrome
Adekunle 1999 Unable to extract useful information
Agaard-Tillery 2010 Results presented in another study
Aitken 1993 Unable to extract useful data
Aitken 1996 Fewer than 80% of pregnancies had gestational age confirmed by USS
Aitken 1996a Fewer than 80% of pregnancies had gestational age confirmed by USS
Ajayi 2011 No diagnostic data
Akbas 2001 Less than 5 Down’s syndrome pregnancies
Alexioy 2009 Study only includes test-positives
Allingham-Hawkins 2011 Quantitative fluorescent polymerase chain reaction study
American College 2009 Discussion article
Antona 1998 Likely fewer than 80% of pregnancies dated by USS
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Antsaklis 1999 Women screened at greater than 24 weeks’ gestation
Anuwutnavin 2009 Second trimester ultrasound
Ashwood 1987 Unable to extract useful data
Asrani 2005 Review article
Audibert 2001b Unable to ascertain whether part of screening population in Rozenberg et al. No response from
authors, therefore excluded to reduce risk of data replication
Axt-Fleidner 2006 Unable to extract useful data
Azuma 2002 Unable to extract useful data
Baghagho 2004 Unable to obtain paper
Bahado-Singh 1995 USS markers greater than 14 weeks’ gestation
Bahado-Singh 1996 USS markers greater than 14 weeks’ gestation
Bahado-Singh 1999b USS markers greater than 14 weeks’ gestation
Bahado-Singh 2002 USS markers greater than 14 weeks’ gestation
Bahado-Singh 2003 Review article
Ball 2007 Data from the FASTER trial
Bar-Hava 2001 No Down’s pregnancies in study population
Barkai 1996 No Down’s pregnancies in study population
Barnabei 1995 No Down’s pregnancies in study population
Bartels 1988 Unable to extract useful data
Bartels 1993 No Down’s pregnancies in study population
Barth 1991 Second trimester ultrasound study
Bas-Budecka 2007 No diagnostic data
Baviera 2004 Unclear method of confirmation of gestational age
Bazzett 1998 Male versus female fetuses
Beke 2008 Results are not specific to Down’s syndrome
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Bellver 2005 No Down’s syndrome pregnancies in study
Benn 1995 Less than 80% follow-up
Benn 1996 Less than 80% follow-up
Benn 1997 No Down’s pregnancies in study population
Benn 1998 Less than 80% follow-up
Benn 2001 Statistical modelling (computer simulation)
Benn 2002 Modelled data
Benn 2003 Less than 80% of pregnancies dated by USS
Benn 2003a Editorial
Benn 2005 No Down’s pregnancies included
Benn 2005a Mathematical model
Benn 2007 No follow-up information
Berry 1995 Less than 80% of pregnancies USS dated
Berry 1997 Less than 80% of pregnancies USS dated
Bersinger 1994 Gestational age not USS estimated
Bersinger 2000 Unable to extract useful data
Bersinger 2001 No Down’s syndrome pregnancies in study population
Bersinger 2003 Unable to extract useful data
Bersinger 2004 No Down’s syndrome pregnancies in study population
Bersinger 2005 No Down’s syndrome pregnancies in study population
Bestwick 2008 All healthy pregnancies
Biggio 2004 Cost-effectiveness analysis
Bilardo 2011 Not a proper sample - most had elevated NT
Bindra 2002 Review article
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Blundell 1999 Unable to extract useful data
Boormans 2010 Study of testing on amniocentesis samples
Boots 1989 Population risk factor calculations
Bornstein 2009 No diagnostic data
Bornstein 2009a No diagnostic data
Bornstein 2010 No diagnostic data
Borowski 2007 No diagnostic data
Borrell 2007 No follow-up data
Borrell 2009a Based on SURUSS data - second trimester serum parameters not actually measured
Borruto 2002 Unable to extract useful data
Bottalico 2009 Second trimester ultrasound
Boue 1990 Review article
Bradley 1994 Screen-negative population gestations not confirmed by ultrasound
Braithwaite 1996 Review article
Brambati 1995 USS screening inclusive of women greater than 14 weeks’ gestation
Brambati 1996 Review article
Brizot 1995 Unable to extract useful data
Brizot 1995a Unable to extract useful data
Brizzi 1989a Second trimester ultrasound
Brock 1990 Unable to extract useful data
Calda 2010 No data for false positive rates
Campogrande 2001 Unable to extract useful data
Canick 1988 Unable to extract useful data
Canick 1995b Unable to extract useful data
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Canini 2002 No Down’s syndrome pregnancies in study population
Cans 1998 Second trimester ultrasound
Carreras 1991 Second trimester ultrasound
Caughey 2007 No diagnostic data
Cebesoy 2008 No diagnostic data
Chelli 2008 No follow-up for false negatives
Chen 1999 Review article
Chen 2002 No Down’s syndrome pregnancies in study population
Chen 2004 Less than 5 Down’s cases in study population
Chen 2005 Unable to extract useful data
Chen 2008 No diagnostic data
Cheng 1993 Likely that fewer than 80% of gestational age confirmed by USS
Cheng 1999 Case series
No Down’s syndrome pregnancies in study population
Cheng 2004 No Down’s syndrome pregnancies in study population
Cheng 2004a No Down’s syndrome pregnancies in study population
Chitayat 2002 Less than 5 Down’s cases in study population
Chiu 2011 Study of maternal DNA testing
Cho 2009 Study of testing amniotic fluid
Chou 2009 Not possible to calculate specificity
Christiansen 2002 Unable to extract useful data
Christiansen 2007a Unable to extract useful data
Christiansen 2008 No diagnostic data
Chung 2000 Less than 5 Down’s syndrome pregnancies in study population
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CNGOF 1996 Unable to obtain translation
Cocciolone 2008 Unable to extract useful data - attempted to contact author
Cole 1996 Review article
Comas 2001 USS at greater than 14 weeks
Comas 2002 USS at greater than 14 weeks
Comas 2002a USS at greater than 14 weeks
Comstock 2006 Unable to extract useful data
Conde-Agudelo 1998 Review article
Cowans 2011 No diagnostic data
Crossley 1991 Less than 80% of pregnancies had gestational age confirmation by ultrasound
Crossley 1993 Less than 80% of pregnancies had gestational age confirmation by ultrasound
Crossley 1996 No Down’s syndrome pregnancies in study population
Crossley 2002a Adjustment factors for smokers
Cuckle 1984 Gestational age not confirmed by USS
Cuckle 1987 Gestational age not confirmed by USS
Cuckle 1987a No gestational age limits given
Cuckle 1990 Paper presenting adjustment factors
Cuckle 1996 Data modelled on 4 meta-analysed studies
Cuckle 1999b Unable to extract useful data
Cuckle 1999c Review article
Cullen 1990 Abnormal scans only in study population
Cusick 2004 Less than 5 Down’s syndrome pregnancies in study population
Cusick 2007 ST ultrasound
Dancoine 2001 No Down’s syndrome pregnancies in study population
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Dane 2008 Not specific to Down’s syndrome
De Biasio 2000 Unable to extract useful information
De Biasio, 1999 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Biasio, 2001 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Graaf 1991 Unable to extract useful data
Del Carmen Saucedo 2009 No follow-up information
DeVore 2001 Second trimester ultrasound
Dhaifalah 2007 Unable to obtain translation
Dhaifalah 2007a Unable to obtain translation
Dhallan 2007 DNA testing of blood samples from parents
Dickerson 1994 Comment
Dimaio 1987 Gestational age by USS only in screen-positive population
Doran 1986 Ultrasound confirmation of gestational age performed in screen-positive women only
Dreux 2008 No information for specificity
Drugan 1996 Second trimester ultrasound
Drugan 1996a Unable to extract useful data
Drysdale 2002 Fewer than 5 Down’s syndrome pregnancies in population
Dugoff 2008 Not specific to Down’s syndrome
Ebell 1999 Review article
Economides 1998 Unable to extract useful data
Erickson 2004 No Down’s syndrome pregnancies in population
Evans 1996 No Down’s syndrome pregnancies in population
Evans 2007 Data previously presented in another study
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Falcon 2005 Unable to extract useful data
Falcon 2006 Unable to extract useful data
Ford 1998 Audit
Frishman 1997 No Down’s syndrome pregnancies in population
Fukada 2000 Unable to extract useful data
Gaudry 2009 Study of karyotyping
Gebb 2009 Study only examines screen-positives
Geerts 2008 Study only examines abnormal fetuses
Geipel 2010 ST ultrasound
Gekas 2009 Diagnostic data from other studies
Gekas 2011 Diagnostic data from other studies
Gekas 2011a Diagnostic parameters from other studies
Gerovassili 2007 No diagnostic data
Ghidini 1998 Comparison of male versus female fetuses
Goetzinger 2010 Second trimester ultrasound
Goldie 1995 Fewer than 80% of study population had gestational age confirmed by USS
Gollo 2008 Only 1 case of Down’s syndrome
Gonçalves 2004 Greater than 14 weeks USS screening
Goodburn 1994 Likely that fewer than 80% of pregnancies had gestational age estimated by USS
Gorduza 2007 Study of FISH technique
Grace 2010 ST ultrasound
Grati 2010 No diagnostic data
Gray 2009 ST ultrasound
Gregor 2007 Unable to obtain translation
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Gregor 2009 Unable to obtain translation
Grether 2009 Systematic review and guidelines
Grozdea 2002 Unable to extract useful data
Guo 2010 Study of fetal samples
Gyselaers 2004 Less than 80% follow-up
Gyselaers 2004a Less than 80% follow-up
Gyselaers 2006 Unaffected pregnancies only
Gyselaers 2006a Unable to extract useful data
Hackshaw 1995 No Down’s syndrome pregnancies in population
Hackshaw 2001 No Down’s syndrome pregnancies in population
Haddow 1992 Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Hadzsiev 2007 Study of FISH technique
Hafner 1995 Less than 5 Down’s pregnancies in study population
Hallahan 1998 Gestational age greater than 24 weeks
Han 2008 Study of findings on amniocentesis
Harper 2010 Second trimester ultrasound
Harrison 2006 Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Harry 2006 Editorial
Hayashi 1995 Unable to extract useful data
Hayashi 1996 Less than 5 Down’s pregnancies in study population
Heikkila 1997 Fewer than 80% of pregnancies had gestational age confirmed by USS
Heinig 2007 No Down’s syndrome data
Heinonen 1996 No Down’s syndrome pregnancies in population
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Herman 2000 No Down’s syndrome pregnancies in study population
Herman 2003 Correlation between markers, not evaluation of screening tests
Herrou 1992 Unable to extract useful data
Hershey 1985 Gestation unclear
Hershey 1986 Gestation based on LMP
Hewitt 1993 Unable to extract useful data
Hills 2010 Study of testing on CVS and amniocentesis samples
Ho 2010 Study of FISH diagnosis
Hogdall 1992 Unclear method of determination of gestational age
Unable to extract useful data
Hong Kong Practitioner CME
Hoogendoorn 2008 Diagnostic data from other studies used
Howe 2000 Second trimester ultrasound scans
Hsiao 1991 Unable to obtain translation
Hsieh 1999 No Down’s syndrome pregnancies in study population
Hsu 1997a Adjustment factors
Hsu 1998a No Down’s syndrome pregnancies in study population
Hsu 1999b No Down’s pregnancies
Hu 2007 Same data as Liu 2010
Huang 2003 No Down’s syndrome pregnancies in study population
Huang 2007 Not possible to obtain detection rate
Huang 2007a No diagnostic data
Huggon 2004 Study of cardiac function in pregnancies with normal and abnormal NT results
Hui 2003 No Down’s syndrome pregnancies in population
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Hui 2005 No Down’s syndrome pregnancies in population
Hultén 2004 Editorial/commentary
Hung 2003 Modelling
Hung 2008 Second trimester ultrasound
Hurley 1993 Unable to extract useful data
Huttly 2004 No Down’s syndrome pregnancies in population
Hwa 2004 Less than 5 Down’s pregnancies in population
Iles 1996 Review
Ind 1994 Unable to extract useful data
Ivorra-Deleuze 2010 No diagnostic data
Jakobsen 2011 Not Down’s syndrome specific
Jean-Pierre 2005 Review article
Johnson 1991 Gestational age estimated by USS in fewer than 80% of cases
Johnson 1993 Normal pregnancies only
Jorgensen 1999 Gestation greater than 14 weeks for USS
Jorgez 2007 Study of DNA testing on maternal blood
Josefsson 1998 No Down’s syndrome pregnancies in study population
Jou 2001 Less than 5 Down’s syndrome pregnancies in study population
Jun-Tao 2003 Unable to obtain translation
Jung 2007 ST ultrasound
Kagan 2006 Screen-positive pregnancies only
Kagan 2007 No diagnostic data
Kagan 2008 Not Down’s syndrome detection
Kalelioglu 2007 ST ultrasound
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Kautzmann 1995 Fewer than 80% pregnancies had gestational age estimated by USS
Kazerouni 2009 Not possible to obtain complete diagnostic data
Keith 1992 Summary article
Kelekci 2004 Less than 5 Down’s syndrome pregnancies in population
Kellner 1995 Less than 5 Down’s syndrome pregnancies in population
Kellner 1995a Less than 80% follow-up
Unable to ascertain proportion of population with gestational age confirmed by USS
Kellner 1997 Assumption of normal karyotype without reference standard in significant proportion of control
pregnancies
Kirkegaard 2008 FPR only calculated for subset of the cohort
Kjaergaard 2008 Unable to obtain translation
Knight 1990 Review article
Knight 2001 Validation of a specific assay
Knight 2005 Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Koos 2006 Review article
Kornman 1996 Less than 5 Down’s syndrome pregnancies in population
Kornman 1997 Unable to extract useful information
Kotaska 2007 No new data
Kramer 1998 No Down’s syndrome pregnancies in study population
Krantz 1996 Modelled data
Krantz 2005 Adjustment factor
Krantz 2007 Uses data from other published studies
Kulch 1993 No Down’s cases in population
Lai 1998 Modelled population
Lai 2003 No Down’s syndrome pregnancies in study population
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Laigaard 2006 Unable to extract useful data
Laigaard 2006b Simulation
Lam 1997 Unable to extract useful data
Lam 1998 Fewer than 80% pregnancies had gestational age estimated by USS
Lam 1999 No Down’s syndrome pregnancies in population
Lam 1999a Unable to extract useful data
Lam 2000 Study of women’s decisions about screening
Lam 2001 Male versus female fetuses
Lambert-Messerlian 1996 Fewer than 80% of pregnancies USS dated
Lambert-Messerlian 1998 Unable to extract useful data
Lauria 2007 No diagnostic data
Lehavi 2005 Down’s syndrome pregnancies only
Leung 2006 Unable to separate twins from singletons therefore unable to extract useful data
Leymarie 1993 Appears to be a review article (French)
Li 1998 Unable to obtain translation
Li 1999 Unable to obtain translation
Li 2010 No diagnostic data
Liao 1997 Unable to obtain translation
Liao 2001 Unable to extract useful data
Lim 2002 Second trimester ultrasound
Lippman 1987 Editorial
Liu 2010 Not possible to separate out data for cases of Down’s syndrome
Lo 2010 Pooled test results
Lustig 1988 Gestational age by LMP only
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Luthgens 2008 FPR and DR obtained from different cohorts
MacDonald 1991 Fewer than 80% of gestational ages estimated by USS
Macintosh 1994 Unable to extract useful data
Macintosh 1997 Unable to extract useful data
MacRae 2010 Pooled test results
Macri 1994 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Macri 1996 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Malone 1998 Review article
Malone 2003 Review article
Mandryka-Stankewycz 2009 No diagnostic data
Mangione 2001 Abnormal screening results only
Markov 2008 Unable to obtain paper
Maymon 2001 No Down’s syndrome pregnancies in study population
Maymon 2001a No normal test results included therefore unable to extract meaningful data
Maymon 2002 No Down’s syndrome pregnancies in study population
Maymon 2004a No Down’s syndrome pregnancies in study population
Maymon 2005a Modelled data
McDuffie 1996 USS dating on screen positive women only
Meier 2002 Observed versus expected cases of Down’s syndrome in a population
Merkatz 1984 Gestational age not confirmed by ultrasound scan
Merz 2005 Editorial
Merz 2008 Part of Merz 2011 cohort
Metzenbauer 2001 Normal pregnancies only
Metzenbauer 2002 Unable to extract useful data
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Mikic 1999 No Down’s syndrome pregnancies in study population
Miller 1991 Unable to extract useful data
Milunsky 1989 Fewer than 80% gestational age estimated by USS
Milunsky 1996 Fewer than 80% gestational age estimated by USS
Minobe 2002 Gestational age greater than specified limits
Miron 2008 No diagnostic data
Miron 2009 No diagnostic data
Miron 2010 No diagnostic data
Miyamura 1999 Unable to extract useful data
Moghadam 1998 Unable to extract useful data
Monni 2000 Less than 5 Down’s syndrome pregnancies
Monni 2002 Review article
Mooney 1994 Greater than 24 weeks’ gestation
Muhcu 2008 No diagnostic data
Muller 1994 No Down’s syndrome pregnancies in study population
Muller 1996a Unable to extract useful data
Muller 1999 Unable to extract useful data
Muller 2002 Gestational age greater than 24 weeks
Muller 2002a Unable to extract meaningful data - unable to separate double and triple test data
Muller 2003b No Down’s syndrome pregnancies in study population
Murta 2002 Unable to extract useful data
Musone 2000 Unable to extract useful data
Musto 1986 Fewer than 80% USS dated
Myrick 1990 Unable to extract useful data
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Naidoo 2008 Not specific Down’s syndrome results
Nau 2009 No diagnostic data
Nau 2009a No diagnostic data
Neveux 1996 No Down’s syndrome pregnancies in population
Neveux 1996a Unable to extract useful data
Ng 2004 Unable to extract useful data
Nicolaides 1992a Study of outcomes of abnormal NT results
Nicolaides 2000 Review article
Nicolaides 2004 Review article
Nicolaides 2005a Unable to obtain translation - appears to be a review article
Nicolaides 2005b Unable to obtain translation - appears to be a review article
Nicolaides 2005c Unable to obtain translation - appears to be a review article
Nicolaides 2005d Unable to obtain translation - appears to be a review article
Nicolaides 2005e Unable to obtain translation - appears to be a review article
Nicolaides 2005f Review article
Niemimaa 2001b No Down’s pregnancies in study population
Niemimaa 2002 No Down’s syndrome pregnancies in population
Niemimaa 2003 No Down’s syndrome pregnancies in population
Noble 1997b Unable to extract useful data
Norgaard 1990 Less than 80% of gestational ages confirmed by USS
Norton 1992 Unable to extract useful data
Novakov-Mikic 2007 Out of FT screening time frame
O’Brien 1997a No Down’s syndrome pregnancies in population
O’Brien 1997b No Down’s syndrome pregnancies in population
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Odibo 2004 Gestational age of greater than 14 weeks in USS population
Odibo 2007 ST ultrasound
Odibo 2008 ST ultrasound
Odibo 2009 No results presented
Offerdal 2008 ST ultrasound
Ognibene 1999 Unable to extract useful data
Oh 2007 No diagnostic data
Olajide 1989 Unable to extract useful data
Onda 1996 Unable to extract useful data
Onda 1998 Unable to extract useful data
Onda 2000 Less than 80% follow-up
Orlandi 2002 No Down’s syndrome pregnancies in study population
Ottavio 1997 Second trimester USS
Ozkaya 2010 Only healthy pregnancies
Paladini 2007 No diagnostic data
Palka 1998 Twin data used in calculation of the median
Palomaki 1989 Fewer than 80% USS dated
Palomaki 1993 No Down’s syndrome pregnancies in population
Palomaki 1994 No Down’s syndrome pregnancies in population
Palomaki 1996 Meta-analysis
Palomaki 2005 Unable to extract meaningful data
Panburana 2001 Less than 5 Down’s syndrome pregnancies in population
Pandya 1994 Study of outcomes of abnormal NT results
Pandya 1995b Review article
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Papadopoulou 2008 No diagnostic data
Parra-Cordero 2007 ST ultrasound
Paterlini-Brechot 2007 Editorial, no new data
Paul 2001 Unable to extract useful data
Peralta 2005 Unable to extract useful data
Perenc 1998 No Down’s syndrome pregnancies in study population
Perheentupa 2002 No Down’s syndrome pregnancies in population
Perona 1998 Smokers versus non smokers
Persico 2008 ST ultrasound
Petervari 2000 Unable to extract useful data
Petrocik 1989 Likely fewer than 80% USS dated
Phillips 1992 Gestational age confirmed by USS in less than 80% of population
Phillips 1993 Gestational age confirmed by USS in less than 80% of population
Pihl 2008 Only 2 cases of Down’s syndrome
Pinette 2003 Women screened prior to recruitment
Platt 2004 Unable to extract useful data
Podobnik 1995 Abnormal results only
Poon 2009 No diagnostic data
Prefumo 2002 Comparison of prevalence and predicition
Prefumo 2004 Comparison of a marker in women of different ethnic origins
Price 1998 Unable to extract useful data
Páez 2004 Unable to obtain translation
Raty 2000 No Down’s syndrome pregnancies in population
Rembouskos 2004 Unable to extract useful data
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Ren 1992 Review article
Renier 1998 Method of ascertainment of gestational age unclear
Twin gestations included in general population
Resta 1990 Second trimester USS
Reynders 1997 Fewer than 5 Down’s cases
Reynolds 1989 Explanation of mathematical techniques
Reynolds 1999 Unable to extract useful data
Reynolds 2008 Not full diagnostic data
Ribbert 1996 No Down’s syndrome pregnancies in study population
Rice 2005 Down’s syndrome pregnancies excluded from study
Rich 1991 Unable to extract useful data
Roberts 1995 No Down’s syndrome pregnancies in study population
Robertson 1991 Editorial
Rode 2003 No Down’s pregnancies
Ronge 2006 Editorial - summary of FASTER results
Rose 1995 Review article
Ross 1997 Review article
Rotmensch 1996 Unable to extract useful data
Rotmensch 1999 No Down’s syndrome pregnancies in study population
Rozenberg 2006 USS greater than 14 weeks’ gestation
Rudnicka 2002 No Down’s syndrome pregnancies in population
Ryall 1992 Unable to determine method of confirmation of gestational age
Ryall 2001 High-risk results only included (i.e. no screen-negative group for comparison)
Räty 2002 No Down’s pregnancies in population
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Sabriá 2002 Unable to ascertain how numbers calculated and from which populations
Sacchini 2003 Unable to extract useful data
Sahota 2009 No diagnostic data
Sahota 2010a Included in Sahota 2010
Salazar 2007 Unable to obtain paper
Salazar 2008 Only 1 case of Down’s syndrome
Saller 1997 Down’s syndrome secondary to Robertsonian translocation only. No controls
Salomon 2001 No Down’s syndrome pregnancies in population
Salonen 1997 Fewer than 80% had gestational age estimated by USS
Saltvedt 2005 Gestation greater than 14 weeks for nuchal scanning
Saridogan 1996 Down’s syndrome and Edward’s syndrome affected pregnancies only
Savoldelli 1993 Unable to extract useful data
Schielen 2009 Full study information not given
Schiott 2006 Unable to extract useful data
Schmidt 2007a Not specific to Down’s syndrome
Schmidt 2007b No separate Down’s syndrome data
Schmidt 2007c No diagnostic data
Schmidt 2008a Not specific to Down’s syndrome
Schmidt 2008b Not specific to Down’s syndrome
Schmidt 2008c Not specific to Down’s syndrome
Schmidt 2010 No follow-up data for test negatives
Schuchter 1998 No Down’s pregnancies in study population
Scott 1995 Less than 5 Down’s syndrome pregnancies in study population
Seeds 1990 Review article
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Seki 1995 No Down’s syndrome pregnancies in study population
Shenhav 2003 No Down’s syndrome pregnancies
Shintaku 1989 Unable to extract useful data
Shulman 2003 No Down’s syndrome pregnancies in population
Sieroszewski 2008 No Down’s syndrome specific information for specificity
Simon-Bouy 1999 Review article
Simpson 1986 Gestational age confirmed by USS in less than 80% of population
Smith 1990 Analysis of screen-positive results
Smith 1996 Review/meta-analysis
Smith 1999 Unable to extract useful data
Smith-Bindman 2001 Meta-analysis of second trimester ultrasound markers
Smith-Bindman 2003 Population study, not examining DTA
Snijders 1995 Study of prevalence, not screening
Snijders 1999 Study of prevalence, not screening
Soergel 2006 Less than 80% follow-up
Sokol 1998 Observation of Down’s prevalence stratified by age
Sonek 2003 Editorial
Sonek 2007 ST ultrasound
Sood 2010 No diagnostic data
Sooklim 2010 ST ultrasound
Spencer 1985 Fewer than 80% USS dated
Spencer 1991a Likely fewer than 80% USS dated
Spencer 1991b Unable to extract useful data
Spencer 1992 Unable to extract useful data
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Spencer 1993a Fewer than 80% USS dated
Spencer 1993b No Down’s pregnancies in study population
Spencer 1993c Unable to extract useful data
Spencer 1993d Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1993e Unable to extract useful data
Spencer 1995a No Down’s pregnancies in population
Spencer 1996b Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1997 Statistical modelling, aneuploid pregnancies only in study population
Spencer 1998a No Down’s pregnancies in population
Spencer 1998b Unable to extract useful data
Spencer 1999a Review
Spencer 1999b Statistical methods paper
Spencer 2000a Examination of median shifts rather than an evaluation of screening
Spencer 2000b No Down’s syndrome pregnancies in population
Spencer 2000c No Down’s syndrome pregnancies in population
Spencer 2000d No Down’s cases
Spencer 2000e Male versus female fetuses
Spencer 2000f No Down’s cases in population
Spencer 2000g No Down’s pregnancies in population
Spencer 2000h No Down’s pregnancies in population
Spencer 2000i Comparsison of fetal sex
Spencer 2001a No Down’s syndrome pregnancies in population
Spencer 2001b Unable to extract useful data
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Spencer 2001c Unable to extract useful data
Spencer 2001d Unable to extract useful data
Spencer 2001e No Down’s syndrome pregnancies in population
Spencer 2002a No Down’s pregnancies
Spencer 2002b Risk validation study
Spencer 2002c No Down’s syndrome pregnancies in population
Spencer 2002d Demonstration of median changes with time, rather than evaluation of screening
Spencer 2003a No Down’s pregnancies in population
Spencer 2003b No Down’s pregnancies in population
Spencer 2003c Calculation of weight correction factor
Spencer 2003d Fewer than 5 Down’s syndrome pregnancies
Spencer 2004 Calculation of smoking correction factor
Spencer 2005a No Down’s pregnancies
Spencer 2005b No Down’s pregnancies
Spencer 2005c Comparison of 2 different assays - not actual screening evaluation
Spencer 2008a Unable to extract appropriate data for unaffected pregnancies
Spong 1999 Comparison of male and female fetuses
Staboulidou 2009 No diagnostic data
Stevens 1998 Literature review
Stoll 1992 Review article
Stressig 2011 ST ultrasound
Su 2002a Unable to extract useful data
Suchet 1995 Review article
Suchy 1990 Unable to ascertain method of confirmation of gestational age
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Summers 2003a Only 55% gestational ages estimated by USS
Summers 2003b No Down’s syndrome pregnancies in study population
Suntharasaj 2005 Examination of inter-observer variation in NT scanning
Susman 2010 No diagnostic data
Sutton 2004 Unable to extract useful data
Suzuki 1998 Unable to extract useful data
Tabor 1987 Gestational age not confirmed by USS
Tanski 1999 Information on screen-positive pregnancies only
Thilaganathan 1998 No Down’s syndrome pregnancies in study population
Thilaganathan 1999b Editorial
Tislaric 2002 No Down’s syndrome pregnancies in population
Torok 1997 Unable to extract useful data
Torring 2009 Not possible to obtain full diagnostic data
Trninic-Pjevic 2007 Unable to obtain translation
Tsai 2001 Less than 5 Down’s syndrome pregnancies in study population
Valerio 1996 Fewer than 80% pregnancies had gestational age estimated by USS
Van Blerk 1992 Unable to extract useful data
Van Dyke 2007 Not possible to obtain full diagnostic data
Van Heesch, 2006 No Down’s syndrome pregnancies in study population
Software comparison study
Van Lith 1991 Unable to extract useful data
Van Lith, 1993 Unable to extract useful data
Van Lith, 1994 Unable to extract useful data
Veress 1986 Unable to extract useful data
Veress 1988 Unable to extract useful data
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Vergani 2008 ST ultrasound
Vintzileos 2003 Second trimester USS
Wald 1988a Less than 80% had gestational age confirmed by ultrasound
Wald 1988b Gestational age not confirmed by USS
Wald 1991 No Down’s pregnancies in study
Wald 1992a Less than 80% had gestational age confirmed by ultrasound
Wald 1992b No Down’s pregnancies in study
Wald 1992c No Down’s pregnancies in study
Wald 1993 No USS dating
Wald 1994a No Down’s syndrome pregnancies in population
Wald 1994b Review article
Wald 1996a No Down’s pregnancies
Wald 1996b Dated by LMP
Wald 1996c No Down’s syndrome pregnancies in population
Wald 1996d Gestational age greater than 24 weeks
Wald 1997 Data modelled on 3 separate populations of women
Wald 1998 Unable to extract useful data
Wald 1999a Unable to extract useful data
Wald 1999b Gestational age not confirmed by USS
Wald 1999c No Down’s syndrome pregnancies
Wald 1999d Modelled on several studies, some of which have no USS dating
Wald 2003b No cases
Wald 2003c Less than 80% had gestational age confirmed by USS
Wald 2006 Modelled on SURRUS data
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Wallace 1994 Unable to extract useful data
Wallace 1997 No Down’s syndrome pregnancies in study population
Wang 2010 ST ultrasound
Ward 2005 Review article
Watt 1996a No Down’s syndrome pregnancies in study population
Watt 1996b No Down’s syndrome pregnancies in study population
Wax 2007 No diagnostic data
Weinans 2001 Unable to extract useful data
Weinans 2004 Study of women’s views on screening
Weisz 2007 Cohort split into people having different tests and non-representative samples of women assessed for
each test
Welborn 1994 Abnormal results only (cystic hygroma)
Wenstrom 1993 Less than 80% of pregnancies had gestational age confirmed by USS
Wenstrom 1995a Adjustment factors
Wenstrom 1995b Less than 80% of pregnancies had gestational age confirmed by USS
Wetta 2011 No diagnostic data
Whitlow 1998a Unable to extract useful data
Whitlow 1998b Unable to extract useful data
Whitlow 1999 Unable to extract useful data
Williamson 1994 Likely fewer than 80% USS dated
Wilson 2000 Review
Wojdemann 2001 No Down’s syndrome pregnancies in study population
Wong 2003 Less than 5 Down’s syndrome pregnancies in population
Wright 2006 Mathematical model
Wright 2007 Simulation study, no new data
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Xie 2010 Only cases of false negatives and true negatives included
Yagel 1998 Second trimester USS
Yamamoto 2001a Unable to extract useful data
Yamamoto 2001b Method of determination of gestational age unclear
Yamamoto 2001c Unable to extract useful data
Yaron 2001 Male versus female fetuses
Ye 1995 Unable to obtain translation
Yoshida 2000 Fewer than 80% pregnancies had gestational age estimated by USS
Zalel 2008 No diagnostic data
Zeitune 1991 Only aneuploid pregnancies included in study
Zelop 2005 No Down’s cases in population
Zhang 2011 No diagnostic data
Zhao 1998 Unable to obtain translation
Zhong 2011 Second trimester ultrasound
Zoppi 2003a Inappropriate study design
CVS: chorionic villus sampling
DR: detection rate
FPR: false positive rate
LMP: last menstrual period
NT: nuchal translucency
USS: ultrasound scan
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Aberrant right subclavian artery 1 425
2 Frontomaxillary facial angle >95
percentile
1 242
3 Presence of mitral gap 1 217
4 Maxillary bone length, 5%
percentile
1 927
5 Tricuspid regurgitation 1 312
6 Iliac angle 90 degrees 1 2032
7 Ductus venosus a-wave reversed 1 378
8 Ductus venosus pulsivity index >
95 percentile
1 378
9 Nasal bone, mixed cut-points 11 48279
10 NT, 2.5 mm 4 11835
11 NT, 3 mm 6 10381
12 NT, 5FPR 3 63885
13 NT, mixed cut-points 13 90978
14 NT and age, risk 1:100 1 10668
15 NT and age, risk 1:250 10 79412
16 NT and age, risk 1:300 23 252811
17 NT and age, 1FPR 4 98453
18 NT and age, 3FPR 4 98453
19 NT and age, 5FPR 22 288853
20 NT and age, mixed cut-points 50 530874
21 NT and nasal bone, Absent NB
+ NT ≥ 95th centile
1 486
22 Ductus and age, risk 1:250 1 3731
23 Ductus and age, 5FPR 2 3965
24 Ductus and age, mixed
cut-points
5 5331
25 Ductus, NT and age, risk 1:100 1 19736
26 Ductus, NT and age, risk 1:250 1 3727
27 Ductus, NT and age, 5FPR 2 3961
28 Ductus, NT and age, mixed
cut-points
3 23697
29 Age and nasal bone, mixed
cut-points
4 25303
30 Age, NT and tricuspid blood
flow, risk 1:100
1 19736
31 Age, NT and nasal bone, risk
1:100
1 19736
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32 Age, NT and nasal bone, risk
1:300
4 9963
33 Age, NT and nasal bone, mixed
cut-points
5 29699
34 Age, NT, nasal bone and
ductus, risk NT>1:300 AND
abnormal DV flow AND
absent NB
1 544
35 Age, NT, nasal bone, free
ßhCG and PAPP-A, 1st
trimester, 5FPR
1 20305
36 Age, NT, nasal bone, free
ßhCG and PAPP-A, 1st
trimester, mixed cut-points
3 41842
37 Age, NT and free ßhCG, 1st
trimester, 5FPR
4 4986
38 Age, NT and free ßhCG, 1st
trimester, risk 1:240
1 5809
39 Age, NT and free ßhCG, 1st
trimester, mixed cut-points
5 10795
40 Age, NT and PAPP-A, 1st
trimester, risk 1:100
1 1507
41 Age, NT and PAPP-A, 1st
trimester, risk 1:185
1 5809
42 Age, NT and PAPP-A, 1st
trimester, 5FPR
3 2498
43 Age, NT and PAPP-A, 1st
trimester, mixed cut-points
5 9814
44 Age, NT and total hCG, 1st
trimester, 5FPR
1 1110
45 Age, NT and AFP, 1st trimester,
5FPR
1 1110
46 Age, NT and ITA, 1st trimester,
5FPR
1 278
47 Age, NT and inhibin, 1st
trimester, risk 1:100
1 40
48 Age, NT and inhibin, 1st
trimester, risk 1:250
1 40
49 Age, NT and inhibin, 1st
trimester, risk 1:400
1 40
50 Age, NT and inhibin, 1st
trimester, 5FPR
1 1110
51 Age, NT and inhibin, 1st
trimester, mixed cut-points
2 1150
52 Age, NT, PAPP-A and free
ßhCG, 1st trimester, risk 1:100
10 102332
53 Age, NT, PAPP-A and free
ßhCG, 1st trimester, risk 1:150
5 177643
54 Age, NT, PAPP-A and free
ßhCG, 1st trimester, risk 1:200
8 135768
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55 Age, NT, PAPP-A and free
ßhCG, 1st trimester, risk 1:220
1 2231
56 Age, NT, PAPP-A and free
ßhCG, 1st trimester, risk 1:250
25 174712
57 Age, NT, PAPP-A and free
ßhCG, 1st trimester, risk 1:300
29 544681
58 Age, NT, PAPP-A and free
ßhCG, 1st trimester, 1FPR
7 88874
59 Age, NT, PAPP-A and free
ßhCG, 1st trimester, 3FPR
9 312680
60 Age, NT, PAPP-A and free
ßhCG, 1st trimester, 5FPR
24 391874
61 Age, NT, PAPP-A and free
ßhCG, 1st trimester, mixed
cut-points
69 1173853
62 Age, NT, PAPP-A and uE3, 1st
trimester, 5FPR
1 576
63 Age, NT, PAPP-A and ITA, 1st
trimester, 5FPR
2 11053
64 Age, NT, PAPP-A and inhibin,
1st trimester, risk 1:100
1 40
65 Age, NT, PAPP-A and inhibin,
1st trimester, risk 1:250
1 40
66 Age, NT, PAPP-A and inhibin,
1st trimester, risk 1:400
1 40
67 Age, NT, PAPP-A and inhibin,
1st trimester, 5FPR
1 1110
68 Age, NT, PAPP-A and inhibin,
1st trimester, mixed cut-points
2 1150
69 Age, NT, PAPP-A and
ADAM12, 1st trimester, 5FPR
2 1042
70 Age, NT, PAPP-A and
ADAM12, 1st trimester, risk
1:250
1 691
71 Age, NT, free ßhCG and
ADAM12, 1st trimester, 5FPR
1 351
72 Age, NT, AFP and free ßhCG,
1st trimester, risk 1:250
1 1656
73 Age, NT, AFP and free ßhCG,
1st trimester, 5FPR
1 1110
74 Age, NT, AFP and free ßhCG,
1st trimester, mixed cut-points
2 2766
75 Age, NT, AFP and PAPP-A, 1st
trimester, 5FPR
1 1110
76 Age, NT, total hCG and
PAPP-A, 1st trimester, 5FPR
1 1110
77 Age, NT, total hCG and
inhibin, 1st trimester, 5FPR
1 1110
78 Age, NT, free ßhCG and
inhibin, 1st trimester, 5FPR
1 1110
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79 Age, NT, PAPP-A, free ßhCG,
1st trimester serum, ductus
venosus pulsivity index, 5FPR
1 7250
80 Age, free ßhCG and PAPP-A,
if risk 1:42-1:1000, NT, final
1:250 risk
1 10189
81 Age, NT, ductus, free ßhCG
and PAPP-A, 1st trimester, risk
1:100
2 26986
82 Age, NT, ductus, free ßhCG
and PAPP-A, 1st trimester, risk
1:250
2 10325
83 Age, NT, ductus, free ßhCG
and PAPP-A, 1st trimester,
5FPR
2 10325
84 Age, NT, ductus, free ßhCG
and PAPP-A, 1st trimester,
mixed cut-points
3 30061
85 Age, NT, nasal bone, free
ßhCG and PAPP-A, 1st
trimester, risk 1:100
1 19736
86 Age, NT, nasal bone, free
ßhCG and PAPP-A, 1st
trimester, risk 1:300
1 1801
87 Age, NT, tricuspid blood flow,
free ßhCG and PAPP-A, 1st
trimester, risk 1:100
1 19736
88 Age, NT, fetal heart rate,
free ßhCG and PAPP-A, 1st
trimester, 5FPR
2 76385
89 Age, NT, fetal heart rate, nasal
bone, free ßhCG and PAPP-A,
1st trimester, risk 1:200
1 19736
90 age, NT, fetal heart rate, ductus,
free ßhCG and PAPP-A, 1st
trimester, 5FPR
1 19614
91 Age, NT, fetal heart rate,
tricuspid blood flow, free ßhCG
and PAPP-A,1st trimester,
5FPR
1 19736
92 Age, NT, AFP, free ßhCG and
PAPP-A, 1st trimester, risk
1:250
1 5483
93 Age, NT, AFP, free ßhCG and
PAPP-A, 1st trimester, 5FPR
2 1306
94 Age, NT, AFP, free ßhCG and
PAPP-A, 1st trimester, mixed
cut-points
3 6789
95 Age, NT, total hCG, inhibin
and PAPP-A, 1st trimester,
5FPR
1 1110
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96 Age, NT, PAPP-A, free ßhCG
and PGH, 1st trimester, 5FPR
1 335
97 Age, NT, PAPP-A, free ßhCG
and GHBP, 1st trimester, 5FPR
1 335
98 Age, NT, PAPP-A, free ßhCG
and PIGF, 1st trimester, 5FPR
2 1443
99 Age, NT, PAPP-A, free ßhCG
and total hCG, 1st trimester,
5FPR
1 998
100 Age, NT, PAPP-A, free ßhCG
and PP13, 1st trimester, 5FPR
1 998
101 Age, NT, PAPP-A, free ßhCG
and ADAM12, 1st trimester,
5FPR
4 2571
102 Age, NT, PAPP-A, free ßhCG
and ADAM12, 1st trimester,
risk 1:250
2 1222
103 Age, NT, PAPP-A, free ßhCG
and ADAM12, 1st trimester,
mixed cut-points
4 2571
104 Age, NT, free ßhCG, PAPP-A
and inhibin, 1st trimester, risk
1:100
1 40
105 Age, NT, free ßhCG, PAPP-A
and inhibin, 1st trimester, risk
1:250
1 40
106 Age, NT, free ßhCG, PAPP-A
and inhibin, 1st trimester, risk
1:400
1 40
107 Age, NT, free ßhCG, PAPP-A
and inhibin, 1st trimester,
5FPR
1 1110
108 Age, NT, PAPP-A, free
ßhCG, ADAM12 and PlGH,
1st trimester, 5FPR
1 998
109 Age, NT, total hCG, inhibin,
PAPP-A, AFP and uE3, 1st
trimester, 5FPR
1 1110
110 Age, NT, free ßhCG, inhibin,
PAPP-A, AFP and uE3,1st
trimester, 5FPR
1 1110
111 Age, NT, PAPP-A, free
ßhCG, ADAM12, total hCG
and PlGF, 1st trimester, 5FPR
1 998
112 Age, NT, PAPP-A, free ßhCG,
ADAM12, total hCG, PlGF
and PP13, 1st trimester, 5FPR
1 998
113 NT, free ßhCG and PAPP-A,
1st trimester incidence rate
63.3%
1 6508
274First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
114 NT, PAPP-A, free ßhCG and
maternal age - maternal age <
35 years
5 19057
115 NT, PAPP-A, free ßhCG and
maternal age - maternal age ≥
35 years
5 10980
Test 1. Aberrant right subclavian artery.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 1 Aberrant right subclavian artery
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borenstein 2008 4 2 47 372 0.08 [ 0.02, 0.19 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. Frontomaxillary facial angle >95 percentile.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 2 Frontomaxillary facial angle >95 percentile
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chen 2009 4 5 18 215 0.18 [ 0.05, 0.40 ] 0.98 [ 0.95, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. Presence of mitral gap.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 3 Presence of mitral gap
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Maiz 2007 4 26 16 171 0.20 [ 0.06, 0.44 ] 0.87 [ 0.81, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Maxillary bone length, 5% percentile.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 4 Maxillary bone length, 5% percentile
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cicero 2004a 21 42 67 797 0.24 [ 0.15, 0.34 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. Tricuspid regurgitation.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 5 Tricuspid regurgitation
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Molina 2010 high risk 10 6 10 286 0.50 [ 0.27, 0.73 ] 0.98 [ 0.96, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 6. Iliac angle 90 degrees.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 6 Iliac angle 90 degrees
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Belics 2011 31 44 21 1936 0.60 [ 0.45, 0.73 ] 0.98 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 7. Ductus venosus a-wave reversed.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 7 Ductus venosus a-wave reversed
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Timmerman 2010 49 92 23 214 0.68 [ 0.56, 0.79 ] 0.70 [ 0.64, 0.75 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 8. Ductus venosus pulsivity index > 95 percentile.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 8 Ductus venosus pulsivity index > 95 percentile
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Timmerman 2010 58 129 14 177 0.81 [ 0.70, 0.89 ] 0.58 [ 0.52, 0.63 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 9. Nasal bone, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 9 Nasal bone, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cicero 2006 87 151 53 20127 0.62 [ 0.54, 0.70 ] 0.99 [ 0.99, 0.99 ]
Has 2008 3 7 6 1785 0.33 [ 0.07, 0.70 ] 1.00 [ 0.99, 1.00 ]
Leung 2009 13 164 13 7735 0.50 [ 0.30, 0.70 ] 0.98 [ 0.98, 0.98 ]
Malone 2004 0 22 9 4770 0.0 [ 0.0, 0.34 ] 1.00 [ 0.99, 1.00 ]
Molina 2010 high risk 12 10 7 282 0.63 [ 0.38, 0.84 ] 0.97 [ 0.94, 0.98 ]
Moon 2007 8 16 7 6440 0.53 [ 0.27, 0.79 ] 1.00 [ 1.00, 1.00 ]
Orlandi 2003 10 15 5 997 0.67 [ 0.38, 0.88 ] 0.99 [ 0.98, 0.99 ]
Orlandi 2005 8 9 7 2387 0.53 [ 0.27, 0.79 ] 1.00 [ 0.99, 1.00 ]
Ota o 2002 3 1 2 174 0.60 [ 0.15, 0.95 ] 0.99 [ 0.97, 1.00 ]
Ramos-Corpas 2006 2 19 4 1657 0.33 [ 0.04, 0.78 ] 0.99 [ 0.98, 0.99 ]
Sepulveda 2007 13 2 18 1219 0.42 [ 0.25, 0.61 ] 1.00 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 10. NT, 2.5 mm.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 10 NT, 2.5 mm
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Acacio 2001 9 33 3 185 0.75 [ 0.43, 0.95 ] 0.85 [ 0.79, 0.89 ]
Hafner 1998 3 71 4 4155 0.43 [ 0.10, 0.82 ] 0.98 [ 0.98, 0.99 ]
Kim 2006 21 161 10 2378 0.68 [ 0.49, 0.83 ] 0.94 [ 0.93, 0.95 ]
Schuchter 2002 7 91 7 4697 0.50 [ 0.23, 0.77 ] 0.98 [ 0.98, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 11. NT, 3 mm.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 11 NT, 3 mm
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Babbur 2005 16 57 9 3106 0.64 [ 0.43, 0.82 ] 0.98 [ 0.98, 0.99 ]
Hewitt 1996 12 52 9 1239 0.57 [ 0.34, 0.78 ] 0.96 [ 0.95, 0.97 ]
Kim 2006 17 89 14 2450 0.55 [ 0.36, 0.73 ] 0.96 [ 0.96, 0.97 ]
Marsis 2004 8 3 2 259 0.80 [ 0.44, 0.97 ] 0.99 [ 0.97, 1.00 ]
Nicolaides 1992 10 41 3 773 0.77 [ 0.46, 0.95 ] 0.95 [ 0.93, 0.96 ]
Pajkrt 1998a 15 35 21 2141 0.42 [ 0.26, 0.59 ] 0.98 [ 0.98, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 12. NT, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 12 NT, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bestwick 2010 72 1132 34 21508 0.68 [ 0.58, 0.77 ] 0.95 [ 0.95, 0.95 ]
Spencer 1999 134 47 76 899 0.64 [ 0.57, 0.70 ] 0.95 [ 0.93, 0.96 ]
Wald 2003 43 1994 42 37904 0.51 [ 0.40, 0.62 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 13. NT, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 13 NT, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Acacio 2001 9 33 3 185 0.75 [ 0.43, 0.95 ] 0.85 [ 0.79, 0.89 ]
Babbur 2005 16 57 9 3106 0.64 [ 0.43, 0.82 ] 0.98 [ 0.98, 0.99 ]
Bestwick 2010 72 1132 34 21508 0.68 [ 0.58, 0.77 ] 0.95 [ 0.95, 0.95 ]
Hafner 1998 3 71 4 4155 0.43 [ 0.10, 0.82 ] 0.98 [ 0.98, 0.99 ]
Hewitt 1996 12 52 9 1239 0.57 [ 0.34, 0.78 ] 0.96 [ 0.95, 0.97 ]
Kim 2006 22 146 9 2393 0.71 [ 0.52, 0.86 ] 0.94 [ 0.93, 0.95 ]
Marsis 2004 8 3 2 259 0.80 [ 0.44, 0.97 ] 0.99 [ 0.97, 1.00 ]
Michailidis 2001 13 97 10 7327 0.57 [ 0.34, 0.77 ] 0.99 [ 0.98, 0.99 ]
Nicolaides 1992 10 41 3 773 0.77 [ 0.46, 0.95 ] 0.95 [ 0.93, 0.96 ]
Pajkrt 1998a 15 35 21 2141 0.42 [ 0.26, 0.59 ] 0.98 [ 0.98, 0.99 ]
Schuchter 2002 7 91 7 4697 0.50 [ 0.23, 0.77 ] 0.98 [ 0.98, 0.98 ]
Spencer 1999 134 47 76 899 0.64 [ 0.57, 0.70 ] 0.95 [ 0.93, 0.96 ]
Wald 2003 43 1994 42 37904 0.51 [ 0.40, 0.62 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 14. NT and age, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 14 NT and age, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Schaelike 2009 27 158 32 10451 0.46 [ 0.33, 0.59 ] 0.99 [ 0.98, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 15. NT and age, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 15 NT and age, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Audibert 2001 8 178 4 3940 0.67 [ 0.35, 0.90 ] 0.96 [ 0.95, 0.96 ]
Benattar 1999 4 84 1 1567 0.80 [ 0.28, 0.99 ] 0.95 [ 0.94, 0.96 ]
Borrell 2005 17 89 8 3613 0.68 [ 0.46, 0.85 ] 0.98 [ 0.97, 0.98 ]
Crossley 2002 20 628 17 11932 0.54 [ 0.37, 0.71 ] 0.95 [ 0.95, 0.95 ]
Marsk 2006 29 22 2 86 0.94 [ 0.79, 0.99 ] 0.80 [ 0.71, 0.87 ]
Muller 2003 16 273 10 5184 0.62 [ 0.41, 0.80 ] 0.95 [ 0.94, 0.96 ]
Niemimaa 2001 3 186 2 1411 0.60 [ 0.15, 0.95 ] 0.88 [ 0.87, 0.90 ]
Pajkrt 1998 8 249 1 1215 0.89 [ 0.52, 1.00 ] 0.83 [ 0.81, 0.85 ]
Wald 2003 60 2394 25 37504 0.71 [ 0.60, 0.80 ] 0.94 [ 0.94, 0.94 ]
Wojdemann 2005 9 154 3 8456 0.75 [ 0.43, 0.95 ] 0.98 [ 0.98, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 16. NT and age, risk 1:300.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 16 NT and age, risk 1:300
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2005 18 111 7 3591 0.72 [ 0.51, 0.88 ] 0.97 [ 0.96, 0.98 ]
Brizot 2001 9 213 1 2773 0.90 [ 0.55, 1.00 ] 0.93 [ 0.92, 0.94 ]
Chasen 2003 10 185 2 2142 0.83 [ 0.52, 0.98 ] 0.92 [ 0.91, 0.93 ]
Gasiorek-Wiens 2001 184 3039 26 18710 0.88 [ 0.82, 0.92 ] 0.86 [ 0.86, 0.86 ]
Gyselaers 2005 11 635 15 12546 0.42 [ 0.23, 0.63 ] 0.95 [ 0.95, 0.96 ]
Has 2008 7 81 2 1711 0.78 [ 0.40, 0.97 ] 0.95 [ 0.94, 0.96 ]
Kozlowski 2007 GC 8 331 11 6556 0.42 [ 0.20, 0.67 ] 0.95 [ 0.95, 0.96 ]
Kozlowski 2007 PC 19 311 7 3525 0.73 [ 0.52, 0.88 ] 0.92 [ 0.91, 0.93 ]
MacRae 2008 26 606 11 18322 0.70 [ 0.53, 0.84 ] 0.97 [ 0.97, 0.97 ]
O’Callaghan 2000 6 62 2 930 0.75 [ 0.35, 0.97 ] 0.94 [ 0.92, 0.95 ]
O’Leary 2006 44 1902 16 20378 0.73 [ 0.60, 0.84 ] 0.91 [ 0.91, 0.92 ]
Pajkrt 1998 9 283 0 1181 1.00 [ 0.66, 1.00 ] 0.81 [ 0.79, 0.83 ]
Prefumo 2005 41 250 6 247 0.87 [ 0.74, 0.95 ] 0.50 [ 0.45, 0.54 ]
Prefumo 2006 9 306 3 6792 0.75 [ 0.43, 0.95 ] 0.96 [ 0.95, 0.96 ]
Santiago 2007 9 424 4 3811 0.69 [ 0.39, 0.91 ] 0.90 [ 0.89, 0.91 ]
Schaelike 2009 33 552 26 10057 0.56 [ 0.42, 0.69 ] 0.95 [ 0.94, 0.95 ]
Scott 2004 5 112 0 1936 1.00 [ 0.48, 1.00 ] 0.95 [ 0.93, 0.95 ]
Sepulveda 2007 28 64 3 1157 0.90 [ 0.74, 0.98 ] 0.95 [ 0.93, 0.96 ]
Snijders 1998 268 7907 58 87569 0.82 [ 0.78, 0.86 ] 0.92 [ 0.92, 0.92 ]
Strah 2008 9 162 3 6922 0.75 [ 0.43, 0.95 ] 0.98 [ 0.97, 0.98 ]
Theodoropoulos 1998 10 162 1 3377 0.91 [ 0.59, 1.00 ] 0.95 [ 0.95, 0.96 ]
Thilaganathan 1999 17 787 4 8994 0.81 [ 0.58, 0.95 ] 0.92 [ 0.91, 0.92 ]
Zoppi 2001 58 926 6 9121 0.91 [ 0.81, 0.96 ] 0.91 [ 0.90, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
282First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 17. NT and age, 1FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 17 NT and age, 1FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Gasiorek-Wiens 2010 22 41 12 4022 0.65 [ 0.46, 0.80 ] 0.99 [ 0.99, 0.99 ]
Kagan 2010 241 564 154 55812 0.61 [ 0.56, 0.66 ] 0.99 [ 0.99, 0.99 ]
Maymon 2008 9 2 10 222 0.47 [ 0.24, 0.71 ] 0.99 [ 0.97, 1.00 ]
Wright 2008 153 371 111 36707 0.58 [ 0.52, 0.64 ] 0.99 [ 0.99, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 18. NT and age, 3FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 18 NT and age, 3FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Gasiorek-Wiens 2010 25 122 9 3941 0.74 [ 0.56, 0.87 ] 0.97 [ 0.96, 0.98 ]
Kagan 2010 296 1691 99 54685 0.75 [ 0.70, 0.79 ] 0.97 [ 0.97, 0.97 ]
Maymon 2008 11 7 8 217 0.58 [ 0.33, 0.80 ] 0.97 [ 0.94, 0.99 ]
Wright 2008 182 1112 82 35966 0.69 [ 0.63, 0.74 ] 0.97 [ 0.97, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 19. NT and age, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 19 NT and age, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Audibert 2001 9 201 3 3917 0.75 [ 0.43, 0.95 ] 0.95 [ 0.94, 0.96 ]
Bestwick 2010 66 1109 38 21071 0.63 [ 0.53, 0.73 ] 0.95 [ 0.95, 0.95 ]
Biagiotti 1998 22 10 10 190 0.69 [ 0.50, 0.84 ] 0.95 [ 0.91, 0.98 ]
Borrell 2005 19 185 6 3517 0.76 [ 0.55, 0.91 ] 0.95 [ 0.94, 0.96 ]
Brizot 2001 7 166 3 2820 0.70 [ 0.35, 0.93 ] 0.94 [ 0.94, 0.95 ]
De Graaf 1999 15 9 9 163 0.63 [ 0.41, 0.81 ] 0.95 [ 0.90, 0.98 ]
Gasiorek-Wiens 2001 174 1942 36 19807 0.83 [ 0.77, 0.88 ] 0.91 [ 0.91, 0.91 ]
Gasiorek-Wiens 2010 28 203 6 3860 0.82 [ 0.65, 0.93 ] 0.95 [ 0.94, 0.96 ]
Kagan 2010 320 2819 75 53557 0.81 [ 0.77, 0.85 ] 0.95 [ 0.95, 0.95 ]
Kozlowski 2007 GC 8 331 11 6556 0.42 [ 0.20, 0.67 ] 0.95 [ 0.95, 0.96 ]
Kozlowski 2007 PC 17 192 9 3644 0.65 [ 0.44, 0.83 ] 0.95 [ 0.94, 0.96 ]
Krantz 2000 24 289 9 5487 0.73 [ 0.54, 0.87 ] 0.95 [ 0.94, 0.96 ]
Lam 2002 24 810 11 15392 0.69 [ 0.51, 0.83 ] 0.95 [ 0.95, 0.95 ]
MacRae 2008 27 946 10 17982 0.73 [ 0.56, 0.86 ] 0.95 [ 0.95, 0.95 ]
Maymon 2008 12 11 7 213 0.63 [ 0.38, 0.84 ] 0.95 [ 0.91, 0.98 ]
Monni 2005 72 782 24 15776 0.75 [ 0.65, 0.83 ] 0.95 [ 0.95, 0.96 ]
Rozenberg 2002 11 311 10 5902 0.52 [ 0.30, 0.74 ] 0.95 [ 0.94, 0.96 ]
Sahota 2010 22 541 10 10281 0.69 [ 0.50, 0.84 ] 0.95 [ 0.95, 0.95 ]
Spencer 1999 153 47 57 899 0.73 [ 0.66, 0.79 ] 0.95 [ 0.93, 0.96 ]
Wald 2003 51 1994 34 37904 0.60 [ 0.49, 0.70 ] 0.95 [ 0.95, 0.95 ]
Wapner 2003 42 408 19 7747 0.69 [ 0.56, 0.80 ] 0.95 [ 0.95, 0.95 ]
Wright 2008 203 1854 61 35224 0.77 [ 0.71, 0.82 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 20. NT and age, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 20 NT and age, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Audibert 2001 8 178 4 3940 0.67 [ 0.35, 0.90 ] 0.96 [ 0.95, 0.96 ]
Benattar 1999 4 84 1 1567 0.80 [ 0.28, 0.99 ] 0.95 [ 0.94, 0.96 ]
Bestwick 2010 66 1109 38 21071 0.63 [ 0.53, 0.73 ] 0.95 [ 0.95, 0.95 ]
Biagiotti 1998 22 10 10 190 0.69 [ 0.50, 0.84 ] 0.95 [ 0.91, 0.98 ]
Borrell 2005 17 89 8 3613 0.68 [ 0.46, 0.85 ] 0.98 [ 0.97, 0.98 ]
Brizot 2001 9 213 1 2773 0.90 [ 0.55, 1.00 ] 0.93 [ 0.92, 0.94 ]
Chasen 2003 10 185 2 2142 0.83 [ 0.52, 0.98 ] 0.92 [ 0.91, 0.93 ]
Crossley 2002 20 628 17 11932 0.54 [ 0.37, 0.71 ] 0.95 [ 0.95, 0.95 ]
De Graaf 1999 15 9 9 163 0.63 [ 0.41, 0.81 ] 0.95 [ 0.90, 0.98 ]
Gasiorek-Wiens 2001 184 3039 26 18710 0.88 [ 0.82, 0.92 ] 0.86 [ 0.86, 0.86 ]
Gasiorek-Wiens 2010 28 203 6 3860 0.82 [ 0.65, 0.93 ] 0.95 [ 0.94, 0.96 ]
Gyselaers 2005 11 635 15 12546 0.42 [ 0.23, 0.63 ] 0.95 [ 0.95, 0.96 ]
Has 2008 7 81 2 1711 0.78 [ 0.40, 0.97 ] 0.95 [ 0.94, 0.96 ]
Kagan 2010 320 2819 75 53557 0.81 [ 0.77, 0.85 ] 0.95 [ 0.95, 0.95 ]
Kozlowski 2007 GC 8 331 11 6556 0.42 [ 0.20, 0.67 ] 0.95 [ 0.95, 0.96 ]
Kozlowski 2007 PC 19 311 7 3525 0.73 [ 0.52, 0.88 ] 0.92 [ 0.91, 0.93 ]
Krantz 2000 24 289 9 5487 0.73 [ 0.54, 0.87 ] 0.95 [ 0.94, 0.96 ]
Lam 2002 24 810 11 15392 0.69 [ 0.51, 0.83 ] 0.95 [ 0.95, 0.95 ]
MacRae 2008 26 606 11 18322 0.70 [ 0.53, 0.84 ] 0.97 [ 0.97, 0.97 ]
Marsk 2006 29 22 2 86 0.94 [ 0.79, 0.99 ] 0.80 [ 0.71, 0.87 ]
Mavrides 2002 24 48 6 156 0.80 [ 0.61, 0.92 ] 0.76 [ 0.70, 0.82 ]
Maymon 2008 12 11 7 213 0.63 [ 0.38, 0.84 ] 0.95 [ 0.91, 0.98 ]
Monni 2005 72 782 24 15776 0.75 [ 0.65, 0.83 ] 0.95 [ 0.95, 0.96 ]
Muller 2003 16 273 10 5184 0.62 [ 0.41, 0.80 ] 0.95 [ 0.94, 0.96 ]
Niemimaa 2001 3 186 2 1411 0.60 [ 0.15, 0.95 ] 0.88 [ 0.87, 0.90 ]
O’Callaghan 2000 6 62 2 930 0.75 [ 0.35, 0.97 ] 0.94 [ 0.92, 0.95 ]
O’Leary 2006 44 1902 16 20378 0.73 [ 0.60, 0.84 ] 0.91 [ 0.91, 0.92 ]
Orlandi 1997 6 104 1 633 0.86 [ 0.42, 1.00 ] 0.86 [ 0.83, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pajkrt 1998 8 249 1 1215 0.89 [ 0.52, 1.00 ] 0.83 [ 0.81, 0.85 ]
Prefumo 2005 41 250 6 247 0.87 [ 0.74, 0.95 ] 0.50 [ 0.45, 0.54 ]
Prefumo 2006 9 306 3 6792 0.75 [ 0.43, 0.95 ] 0.96 [ 0.95, 0.96 ]
Rozenberg 2002 11 311 10 5902 0.52 [ 0.30, 0.74 ] 0.95 [ 0.94, 0.96 ]
Sahota 2010 22 541 10 10281 0.69 [ 0.50, 0.84 ] 0.95 [ 0.95, 0.95 ]
Santiago 2007 9 424 4 3811 0.69 [ 0.39, 0.91 ] 0.90 [ 0.89, 0.91 ]
Sau 2001 8 51 0 2624 1.00 [ 0.63, 1.00 ] 0.98 [ 0.98, 0.99 ]
Schaelike 2009 33 552 26 10057 0.56 [ 0.42, 0.69 ] 0.95 [ 0.94, 0.95 ]
Schuchter 2001 11 211 8 9112 0.58 [ 0.33, 0.80 ] 0.98 [ 0.97, 0.98 ]
Schwarzler 1999 10 220 2 4291 0.83 [ 0.52, 0.98 ] 0.95 [ 0.94, 0.96 ]
Scott 2004 5 112 0 1936 1.00 [ 0.48, 1.00 ] 0.95 [ 0.93, 0.95 ]
Sepulveda 2007 28 64 3 1157 0.90 [ 0.74, 0.98 ] 0.95 [ 0.93, 0.96 ]
Snijders 1998 268 7907 58 87569 0.82 [ 0.78, 0.86 ] 0.92 [ 0.92, 0.92 ]
Spencer 1999 153 47 57 899 0.73 [ 0.66, 0.79 ] 0.95 [ 0.93, 0.96 ]
Strah 2008 9 162 3 6922 0.75 [ 0.43, 0.95 ] 0.98 [ 0.97, 0.98 ]
Theodoropoulos 1998 10 162 1 3377 0.91 [ 0.59, 1.00 ] 0.95 [ 0.95, 0.96 ]
Thilaganathan 1999 17 787 4 8994 0.81 [ 0.58, 0.95 ] 0.92 [ 0.91, 0.92 ]
Wald 2003 60 2394 25 37504 0.71 [ 0.60, 0.80 ] 0.94 [ 0.94, 0.94 ]
Wapner 2003 42 408 19 7747 0.69 [ 0.56, 0.80 ] 0.95 [ 0.95, 0.95 ]
Wojdemann 2005 9 154 3 8456 0.75 [ 0.43, 0.95 ] 0.98 [ 0.98, 0.98 ]
Wright 2008 203 1854 61 35224 0.77 [ 0.71, 0.82 ] 0.95 [ 0.95, 0.95 ]
Zoppi 2001 58 926 6 9121 0.91 [ 0.81, 0.96 ] 0.91 [ 0.90, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 21. NT and nasal bone, Absent NB + NT ≥ 95th centile.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 21 NT and nasal bone, Absent NB + NT ≥ 95th centile
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Matias 1998 34 30 4 418 0.89 [ 0.75, 0.97 ] 0.93 [ 0.91, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 22. Ductus and age, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 22 Ductus and age, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2005 15 70 10 3636 0.60 [ 0.39, 0.79 ] 0.98 [ 0.98, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 23. Ductus and age, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 23 Ductus and age, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2005 19 185 6 3521 0.76 [ 0.55, 0.91 ] 0.95 [ 0.94, 0.96 ]
Mavrides 2002 18 12 12 192 0.60 [ 0.41, 0.77 ] 0.94 [ 0.90, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 24. Ductus and age, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 24 Ductus and age, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2005 15 70 10 3636 0.60 [ 0.39, 0.79 ] 0.98 [ 0.98, 0.99 ]
Matias 2001 39 40 4 432 0.91 [ 0.78, 0.97 ] 0.92 [ 0.89, 0.94 ]
Mavrides 2002 18 12 12 192 0.60 [ 0.41, 0.77 ] 0.94 [ 0.90, 0.97 ]
Molina 2010 high risk 13 9 7 278 0.65 [ 0.41, 0.85 ] 0.97 [ 0.94, 0.99 ]
Prefumo 2005 18 26 29 471 0.38 [ 0.25, 0.54 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 25. Ductus, NT and age, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 25 Ductus, NT and age, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kagan 2010 104 530 18 19084 0.85 [ 0.78, 0.91 ] 0.97 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 26. Ductus, NT and age, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 26 Ductus, NT and age, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2005 19 44 6 3658 0.76 [ 0.55, 0.91 ] 0.99 [ 0.98, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 27. Ductus, NT and age, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 27 Ductus, NT and age, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2005 21 185 4 3517 0.84 [ 0.64, 0.95 ] 0.95 [ 0.94, 0.96 ]
Mavrides 2002 28 55 2 149 0.93 [ 0.78, 0.99 ] 0.73 [ 0.66, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 28. Ductus, NT and age, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 28 Ductus, NT and age, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2005 19 44 6 3658 0.76 [ 0.55, 0.91 ] 0.99 [ 0.98, 0.99 ]
Kagan 2010 104 530 18 19084 0.85 [ 0.78, 0.91 ] 0.97 [ 0.97, 0.98 ]
Mavrides 2002 28 55 2 149 0.93 [ 0.78, 0.99 ] 0.73 [ 0.66, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 29. Age and nasal bone, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 29 Age and nasal bone, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Monni 2005 56 99 40 16446 0.58 [ 0.48, 0.68 ] 0.99 [ 0.99, 1.00 ]
Prefumo 2005 19 33 28 464 0.40 [ 0.26, 0.56 ] 0.93 [ 0.91, 0.95 ]
Prefumo 2006 2 172 10 6182 0.17 [ 0.02, 0.48 ] 0.97 [ 0.97, 0.98 ]
Viora 2003 8 26 2 1716 0.80 [ 0.44, 0.97 ] 0.99 [ 0.98, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 30. Age, NT and tricuspid blood flow, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 30 Age, NT and tricuspid blood flow, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kagan 2010 104 530 18 19084 0.85 [ 0.78, 0.91 ] 0.97 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 31. Age, NT and nasal bone, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 31 Age, NT and nasal bone, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kagan 2010 101 569 21 19045 0.83 [ 0.75, 0.89 ] 0.97 [ 0.97, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 32. Age, NT and nasal bone, risk 1:300.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 32 Age, NT and nasal bone, risk 1:300
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Has 2008 7 61 2 1731 0.78 [ 0.40, 0.97 ] 0.97 [ 0.96, 0.97 ]
Prefumo 2005 17 25 30 472 0.36 [ 0.23, 0.51 ] 0.95 [ 0.93, 0.97 ]
Prefumo 2006 2 20 10 6334 0.17 [ 0.02, 0.48 ] 1.00 [ 1.00, 1.00 ]
Sepulveda 2007 29 127 2 1094 0.94 [ 0.79, 0.99 ] 0.90 [ 0.88, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 33. Age, NT and nasal bone, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 33 Age, NT and nasal bone, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Has 2008 7 61 2 1731 0.78 [ 0.40, 0.97 ] 0.97 [ 0.96, 0.97 ]
Kagan 2010 101 569 21 19045 0.83 [ 0.75, 0.89 ] 0.97 [ 0.97, 0.97 ]
Prefumo 2005 17 25 30 472 0.36 [ 0.23, 0.51 ] 0.95 [ 0.93, 0.97 ]
Prefumo 2006 2 20 10 6334 0.17 [ 0.02, 0.48 ] 1.00 [ 1.00, 1.00 ]
Sepulveda 2007 29 127 2 1094 0.94 [ 0.79, 0.99 ] 0.90 [ 0.88, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 34. Age, NT, nasal bone and ductus, risk NT>1:300 AND abnormal DV flow AND absent NB.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 34 Age, NT, nasal bone and ductus, risk NT>1:300 AND abnormal DV flow AND absent NB
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Prefumo 2005 10 2 37 495 0.21 [ 0.11, 0.36 ] 1.00 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 35. Age, NT, nasal bone, free ßhCG and PAPP-A, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 35 Age, NT, nasal bone, free hCG and PAPP-A, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cicero 2006 131 1008 9 19157 0.94 [ 0.88, 0.97 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 36. Age, NT, nasal bone, free ßhCG and PAPP-A, 1st trimester, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 36 Age, NT, nasal bone, free hCG and PAPP-A, 1st trimester, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cicero 2006 131 1008 9 19157 0.94 [ 0.88, 0.97 ] 0.95 [ 0.95, 0.95 ]
Has 2008 8 54 1 1738 0.89 [ 0.52, 1.00 ] 0.97 [ 0.96, 0.98 ]
Kagan 2010 111 490 11 19124 0.91 [ 0.84, 0.95 ] 0.98 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 37. Age, NT and free ßhCG, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 37 Age, NT and free hCG, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1998 23 10 9 190 0.72 [ 0.53, 0.86 ] 0.95 [ 0.91, 0.98 ]
Noble 1995 52 121 9 2306 0.85 [ 0.74, 0.93 ] 0.95 [ 0.94, 0.96 ]
Spencer 1999 170 47 40 899 0.81 [ 0.75, 0.86 ] 0.95 [ 0.93, 0.96 ]
Wald 2003 55 51 30 974 0.65 [ 0.54, 0.75 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 38. Age, NT and free ßhCG, 1st trimester, risk 1:240.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 38 Age, NT and free hCG, 1st trimester, risk 1:240
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Krantz 2000 26 289 7 5487 0.79 [ 0.61, 0.91 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 39. Age, NT and free ßhCG, 1st trimester, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 39 Age, NT and free hCG, 1st trimester, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1998 23 10 9 190 0.72 [ 0.53, 0.86 ] 0.95 [ 0.91, 0.98 ]
Krantz 2000 26 289 7 5487 0.79 [ 0.61, 0.91 ] 0.95 [ 0.94, 0.96 ]
Noble 1995 52 121 9 2306 0.85 [ 0.74, 0.93 ] 0.95 [ 0.94, 0.96 ]
Spencer 1999 170 47 40 899 0.81 [ 0.75, 0.86 ] 0.95 [ 0.93, 0.96 ]
Wald 2003 55 51 30 974 0.65 [ 0.54, 0.75 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 40. Age, NT and PAPP-A, 1st trimester, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 40 Age, NT and PAPP-A, 1st trimester, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Habayeb 2010 8 37 4 1458 0.67 [ 0.35, 0.90 ] 0.98 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 41. Age, NT and PAPP-A, 1st trimester, risk 1:185.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 41 Age, NT and PAPP-A, 1st trimester, risk 1:185
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Krantz 2000 27 289 6 5487 0.82 [ 0.65, 0.93 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 42. Age, NT and PAPP-A, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 42 Age, NT and PAPP-A, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1998 23 10 9 190 0.72 [ 0.53, 0.86 ] 0.95 [ 0.91, 0.98 ]
Spencer 1999 172 47 38 899 0.82 [ 0.76, 0.87 ] 0.95 [ 0.93, 0.96 ]
Wald 2003 67 51 18 974 0.79 [ 0.69, 0.87 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 43. Age, NT and PAPP-A, 1st trimester, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 43 Age, NT and PAPP-A, 1st trimester, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Biagiotti 1998 23 10 9 190 0.72 [ 0.53, 0.86 ] 0.95 [ 0.91, 0.98 ]
Habayeb 2010 8 37 4 1458 0.67 [ 0.35, 0.90 ] 0.98 [ 0.97, 0.98 ]
Krantz 2000 27 289 6 5487 0.82 [ 0.65, 0.93 ] 0.95 [ 0.94, 0.96 ]
Spencer 1999 172 47 38 899 0.82 [ 0.76, 0.87 ] 0.95 [ 0.93, 0.96 ]
Wald 2003 67 51 18 974 0.79 [ 0.69, 0.87 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 44. Age, NT and total hCG, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 44 Age, NT and total hCG, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 52 51 33 974 0.61 [ 0.50, 0.72 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 45. Age, NT and AFP, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 45 Age, NT and AFP, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 52 51 33 974 0.61 [ 0.50, 0.72 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 46. Age, NT and ITA, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 46 Age, NT and ITA, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Spencer 2002 43 11 11 213 0.80 [ 0.66, 0.89 ] 0.95 [ 0.91, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 47. Age, NT and inhibin, 1st trimester, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 47 Age, NT and inhibin, 1st trimester, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 8 0 4 28 0.67 [ 0.35, 0.90 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 48. Age, NT and inhibin, 1st trimester, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 48 Age, NT and inhibin, 1st trimester, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 9 1 3 27 0.75 [ 0.43, 0.95 ] 0.96 [ 0.82, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 49. Age, NT and inhibin, 1st trimester, risk 1:400.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 49 Age, NT and inhibin, 1st trimester, risk 1:400
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 9 2 3 26 0.75 [ 0.43, 0.95 ] 0.93 [ 0.76, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 50. Age, NT and inhibin, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 50 Age, NT and inhibin, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 52 51 33 974 0.61 [ 0.50, 0.72 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 51. Age, NT and inhibin, 1st trimester, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 51 Age, NT and inhibin, 1st trimester, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 9 1 3 27 0.75 [ 0.43, 0.95 ] 0.96 [ 0.82, 1.00 ]
Wald 2003 52 51 33 974 0.61 [ 0.50, 0.72 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 52. Age, NT, PAPP-A and free ßhCG, 1st trimester, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 52 Age, NT, PAPP-A and free hCG, 1st trimester, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bestwick 2010 82 362 24 22280 0.77 [ 0.68, 0.85 ] 0.98 [ 0.98, 0.99 ]
Borrell 2009 50 136 16 7048 0.76 [ 0.64, 0.85 ] 0.98 [ 0.98, 0.98 ]
Christiansen 2005 9 0 3 28 0.75 [ 0.43, 0.95 ] 1.00 [ 0.88, 1.00 ]
Christiansen 2009 48 6 26 255 0.65 [ 0.53, 0.76 ] 0.98 [ 0.95, 0.99 ]
Christiansen 2010 21 6 7 479 0.75 [ 0.55, 0.89 ] 0.99 [ 0.97, 1.00 ]
Cocciolone 2008 FTS 55 344 11 18491 0.83 [ 0.72, 0.91 ] 0.98 [ 0.98, 0.98 ]
Salomon 2010 55 293 25 21119 0.69 [ 0.57, 0.79 ] 0.99 [ 0.98, 0.99 ]
Schaelike 2009 46 202 13 10407 0.78 [ 0.65, 0.88 ] 0.98 [ 0.98, 0.98 ]
Sorensen 2011 79 364 21 19230 0.79 [ 0.70, 0.87 ] 0.98 [ 0.98, 0.98 ]
Torring 2010 33 4 13 641 0.72 [ 0.57, 0.84 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 53. Age, NT, PAPP-A and free ßhCG, 1st trimester, risk 1:150.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 53 Age, NT, PAPP-A and free hCG, 1st trimester, risk 1:150
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bestwick 2010 85 543 21 22097 0.80 [ 0.71, 0.87 ] 0.98 [ 0.97, 0.98 ]
Borrell 2009 52 201 14 6983 0.79 [ 0.67, 0.88 ] 0.97 [ 0.97, 0.98 ]
Kublickas 2009 26 136 3 3742 0.90 [ 0.73, 0.98 ] 0.96 [ 0.96, 0.97 ]
Merz 2011 431 4336 69 119210 0.86 [ 0.83, 0.89 ] 0.96 [ 0.96, 0.97 ]
Sorensen 2011 83 500 17 19094 0.83 [ 0.74, 0.90 ] 0.97 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 54. Age, NT, PAPP-A and free ßhCG, 1st trimester, risk 1:200.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 54 Age, NT, PAPP-A and free hCG, 1st trimester, risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bestwick 2010 87 724 19 21916 0.82 [ 0.73, 0.89 ] 0.97 [ 0.97, 0.97 ]
Borrell 2009 53 266 13 6918 0.80 [ 0.69, 0.89 ] 0.96 [ 0.96, 0.97 ]
Cocciolone 2008 FTS 58 609 8 18226 0.88 [ 0.78, 0.95 ] 0.97 [ 0.97, 0.97 ]
Kublickas 2009 26 182 3 3696 0.90 [ 0.73, 0.98 ] 0.95 [ 0.95, 0.96 ]
Kuc 2010 171 1191 52 25877 0.77 [ 0.71, 0.82 ] 0.96 [ 0.95, 0.96 ]
Okun 2008 FTS 52 521 10 13904 0.84 [ 0.72, 0.92 ] 0.96 [ 0.96, 0.97 ]
Salomon 2010 62 499 18 20913 0.78 [ 0.67, 0.86 ] 0.98 [ 0.97, 0.98 ]
Sorensen 2011 85 656 15 18938 0.85 [ 0.76, 0.91 ] 0.97 [ 0.96, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 55. Age, NT, PAPP-A and free ßhCG, 1st trimester, risk 1:220.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 55 Age, NT, PAPP-A and free hCG, 1st trimester, risk 1:220
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wax 2009 7 207 1 2016 0.88 [ 0.47, 1.00 ] 0.91 [ 0.89, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 56. Age, NT, PAPP-A and free ßhCG, 1st trimester, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 56 Age, NT, PAPP-A and free hCG, 1st trimester, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bestwick 2010 89 883 17 21757 0.84 [ 0.76, 0.90 ] 0.96 [ 0.96, 0.96 ]
Borrell 2005 20 64 4 2987 0.83 [ 0.63, 0.95 ] 0.98 [ 0.97, 0.98 ]
Borrell 2009 55 330 11 6854 0.83 [ 0.72, 0.91 ] 0.95 [ 0.95, 0.96 ]
Centini 2005 6 60 0 342 1.00 [ 0.54, 1.00 ] 0.85 [ 0.81, 0.88 ]
Christiansen 2005 10 1 2 27 0.83 [ 0.52, 0.98 ] 0.96 [ 0.82, 1.00 ]
Christiansen 2009 61 14 13 247 0.82 [ 0.72, 0.90 ] 0.95 [ 0.91, 0.97 ]
Christiansen 2010 23 15 5 488 0.82 [ 0.63, 0.94 ] 0.97 [ 0.95, 0.98 ]
Crossley 2002 28 628 6 11932 0.82 [ 0.65, 0.93 ] 0.95 [ 0.95, 0.95 ]
Kublickas 2009 27 225 2 3653 0.93 [ 0.77, 0.99 ] 0.94 [ 0.93, 0.95 ]
Marsk 2006 29 8 2 100 0.94 [ 0.79, 0.99 ] 0.93 [ 0.86, 0.97 ]
Muller 2003 19 256 7 5201 0.73 [ 0.52, 0.88 ] 0.95 [ 0.95, 0.96 ]
Niemimaa 2001 4 132 1 1465 0.80 [ 0.28, 0.99 ] 0.92 [ 0.90, 0.93 ]
Rissanen 2007 12 394 1 4301 0.92 [ 0.64, 1.00 ] 0.92 [ 0.91, 0.92 ]
Rozenberg 2007 41 370 10 12963 0.80 [ 0.67, 0.90 ] 0.97 [ 0.97, 0.97 ]
Salomon 2010 64 612 16 20800 0.80 [ 0.70, 0.88 ] 0.97 [ 0.97, 0.97 ]
Schielen 2006 15 190 6 3822 0.71 [ 0.48, 0.89 ] 0.95 [ 0.95, 0.96 ]
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Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Schuchter 2002 12 245 2 4543 0.86 [ 0.57, 0.98 ] 0.95 [ 0.94, 0.95 ]
Sorensen 2011 86 784 14 18810 0.86 [ 0.78, 0.92 ] 0.96 [ 0.96, 0.96 ]
Stenhouse 2004 14 283 1 4702 0.93 [ 0.68, 1.00 ] 0.94 [ 0.94, 0.95 ]
Torring 2010 39 18 7 627 0.85 [ 0.71, 0.94 ] 0.97 [ 0.96, 0.98 ]
Vadiveloo 2009 40 649 4 9496 0.91 [ 0.78, 0.97 ] 0.94 [ 0.93, 0.94 ]
Valinen 2007 21 232 3 4509 0.88 [ 0.68, 0.97 ] 0.95 [ 0.94, 0.96 ]
Wald 2003 71 48 14 977 0.84 [ 0.74, 0.91 ] 0.95 [ 0.94, 0.97 ]
Wojdemann 2005 10 138 1 6292 0.91 [ 0.59, 1.00 ] 0.98 [ 0.97, 0.98 ]
Wortelboer 2009 66 677 21 19529 0.76 [ 0.65, 0.84 ] 0.97 [ 0.96, 0.97 ]
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Test 57. Age, NT, PAPP-A and free ßhCG, 1st trimester, risk 1:300.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 57 Age, NT, PAPP-A and free hCG, 1st trimester, risk 1:300
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barrett 2008 29 374 3 9867 0.91 [ 0.75, 0.98 ] 0.96 [ 0.96, 0.97 ]
Bestwick 2010 90 1041 16 21599 0.85 [ 0.77, 0.91 ] 0.95 [ 0.95, 0.96 ]
Borrell 2005 20 76 4 2975 0.83 [ 0.63, 0.95 ] 0.98 [ 0.97, 0.98 ]
Borrell 2009 55 388 11 6796 0.83 [ 0.72, 0.91 ] 0.95 [ 0.94, 0.95 ]
Brameld 2008 50 695 10 21525 0.83 [ 0.71, 0.92 ] 0.97 [ 0.97, 0.97 ]
Cocciolone 2008 FTS 60 866 6 17969 0.91 [ 0.81, 0.97 ] 0.95 [ 0.95, 0.96 ]
Cowans 2009 650 1124 76 55210 0.90 [ 0.87, 0.92 ] 0.98 [ 0.98, 0.98 ]
Ekelund 2008 201 3404 24 92016 0.89 [ 0.85, 0.93 ] 0.96 [ 0.96, 0.97 ]
Gyselaers 2005 21 1130 5 12051 0.81 [ 0.61, 0.93 ] 0.91 [ 0.91, 0.92 ]
Hadlow 2005 29 374 3 10030 0.91 [ 0.75, 0.98 ] 0.96 [ 0.96, 0.97 ]
Has 2008 8 65 1 1727 0.89 [ 0.52, 1.00 ] 0.96 [ 0.95, 0.97 ]
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Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hormansdorfer 2011 37 512 3 5956 0.93 [ 0.80, 0.98 ] 0.92 [ 0.91, 0.93 ]
Huang 2010 23 199 2 6894 0.92 [ 0.74, 0.99 ] 0.97 [ 0.97, 0.98 ]
Jaques 2007 55 659 8 15281 0.87 [ 0.77, 0.94 ] 0.96 [ 0.96, 0.96 ]
Kozlowski 2007 GC 15 347 4 6540 0.79 [ 0.54, 0.94 ] 0.95 [ 0.94, 0.95 ]
Kozlowski 2007 PC 23 306 3 3530 0.88 [ 0.70, 0.98 ] 0.92 [ 0.91, 0.93 ]
Kublickas 2009 27 268 2 3610 0.93 [ 0.77, 0.99 ] 0.93 [ 0.92, 0.94 ]
Leung 2009 31 544 3 9474 0.91 [ 0.76, 0.98 ] 0.95 [ 0.94, 0.95 ]
Malone 2005 75 2023 17 34095 0.82 [ 0.72, 0.89 ] 0.94 [ 0.94, 0.95 ]
Marchini 2010 6 66 2 1463 0.75 [ 0.35, 0.97 ] 0.96 [ 0.95, 0.97 ]
Maxwell 2011 FTS 76 1101 18 31283 0.81 [ 0.71, 0.88 ] 0.97 [ 0.96, 0.97 ]
Nicolaides 2005 301 4100 24 71396 0.93 [ 0.89, 0.95 ] 0.95 [ 0.94, 0.95 ]
O’Leary 2006 50 827 10 21453 0.83 [ 0.71, 0.92 ] 0.96 [ 0.96, 0.97 ]
Salomon 2010 64 709 16 20703 0.80 [ 0.70, 0.88 ] 0.97 [ 0.96, 0.97 ]
Santiago 2007 12 212 1 4023 0.92 [ 0.64, 1.00 ] 0.95 [ 0.94, 0.96 ]
Schaelike 2009 52 517 7 10092 0.88 [ 0.77, 0.95 ] 0.95 [ 0.95, 0.96 ]
Scott 2004 5 143 0 1905 1.00 [ 0.48, 1.00 ] 0.93 [ 0.92, 0.94 ]
Sorensen 2011 88 921 12 18673 0.88 [ 0.80, 0.94 ] 0.95 [ 0.95, 0.96 ]
Wald 2003 71 56 14 969 0.84 [ 0.74, 0.91 ] 0.95 [ 0.93, 0.96 ]
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Test 58. Age, NT, PAPP-A and free ßhCG, 1st trimester, 1FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 58 Age, NT, PAPP-A and free hCG, 1st trimester, 1FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bestwick 2010 78 226 28 22414 0.74 [ 0.64, 0.82 ] 0.99 [ 0.99, 0.99 ]
Borrell 2009 46 72 20 7112 0.70 [ 0.57, 0.80 ] 0.99 [ 0.99, 0.99 ]
Christiansen 2009 37 3 37 258 0.50 [ 0.38, 0.62 ] 0.99 [ 0.97, 1.00 ]
Christiansen 2010 21 5 7 498 0.75 [ 0.55, 0.89 ] 0.99 [ 0.98, 1.00 ]
Kagan 2010 308 564 87 55812 0.78 [ 0.74, 0.82 ] 0.99 [ 0.99, 0.99 ]
Koster 2011 89 8 62 839 0.59 [ 0.51, 0.67 ] 0.99 [ 0.98, 1.00 ]
Maymon 2008 14 2 5 222 0.74 [ 0.49, 0.91 ] 0.99 [ 0.97, 1.00 ]
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Test 59. Age, NT, PAPP-A and free ßhCG, 1st trimester, 3FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 59 Age, NT, PAPP-A and free hCG, 1st trimester, 3FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bestwick 2010 87 679 19 21961 0.82 [ 0.73, 0.89 ] 0.97 [ 0.97, 0.97 ]
Borrell 2009 52 216 14 6968 0.79 [ 0.67, 0.88 ] 0.97 [ 0.97, 0.97 ]
Christiansen 2009 53 8 21 253 0.72 [ 0.60, 0.81 ] 0.97 [ 0.94, 0.99 ]
Christiansen 2010 23 15 5 488 0.82 [ 0.63, 0.94 ] 0.97 [ 0.95, 0.98 ]
Cowans 2010 64 11 6 364 0.91 [ 0.82, 0.97 ] 0.97 [ 0.95, 0.99 ]
Kagan 2010 352 1691 43 54685 0.89 [ 0.86, 0.92 ] 0.97 [ 0.97, 0.97 ]
Koster 2011 107 25 44 822 0.71 [ 0.63, 0.78 ] 0.97 [ 0.96, 0.98 ]
Maymon 2008 16 7 3 217 0.84 [ 0.60, 0.97 ] 0.97 [ 0.94, 0.99 ]
Wright 2010 762 6674 124 215801 0.86 [ 0.84, 0.88 ] 0.97 [ 0.97, 0.97 ]
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Test 60. Age, NT, PAPP-A and free ßhCG, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 60 Age, NT, PAPP-A and free hCG, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bestwick 2010 91 1132 15 21508 0.86 [ 0.78, 0.92 ] 0.95 [ 0.95, 0.95 ]
Biagiotti 1998 24 10 8 190 0.75 [ 0.57, 0.89 ] 0.95 [ 0.91, 0.98 ]
Borrell 2005 21 153 3 2898 0.88 [ 0.68, 0.97 ] 0.95 [ 0.94, 0.96 ]
Borrell 2009 55 359 11 6825 0.83 [ 0.72, 0.91 ] 0.95 [ 0.94, 0.95 ]
Christiansen 2009 59 13 15 248 0.80 [ 0.69, 0.88 ] 0.95 [ 0.92, 0.97 ]
Christiansen 2010 24 25 4 478 0.86 [ 0.67, 0.96 ] 0.95 [ 0.93, 0.97 ]
Cowans 2010 65 19 5 356 0.93 [ 0.84, 0.98 ] 0.95 [ 0.92, 0.97 ]
De Graaf 1999 20 9 4 163 0.83 [ 0.63, 0.95 ] 0.95 [ 0.90, 0.98 ]
Kagan 2010 359 2819 36 53557 0.91 [ 0.88, 0.94 ] 0.95 [ 0.95, 0.95 ]
Koster 2011 116 42 35 805 0.77 [ 0.69, 0.83 ] 0.95 [ 0.93, 0.96 ]
Kozlowski 2007 GC 15 347 4 6540 0.79 [ 0.54, 0.94 ] 0.95 [ 0.94, 0.95 ]
Kozlowski 2007 PC 23 191 3 3645 0.88 [ 0.70, 0.98 ] 0.95 [ 0.94, 0.96 ]
Maxwell 2011 FTS 81 1619 13 30765 0.86 [ 0.78, 0.92 ] 0.95 [ 0.95, 0.95 ]
Maymon 2008 17 11 2 213 0.89 [ 0.67, 0.99 ] 0.95 [ 0.91, 0.98 ]
Orlandi 1997 6 35 1 702 0.86 [ 0.42, 1.00 ] 0.95 [ 0.93, 0.97 ]
Perni 2006 20 230 2 4363 0.91 [ 0.71, 0.99 ] 0.95 [ 0.94, 0.96 ]
Rissanen 2007 12 235 1 4460 0.92 [ 0.64, 1.00 ] 0.95 [ 0.94, 0.96 ]
Sahota 2010 28 541 4 10281 0.88 [ 0.71, 0.96 ] 0.95 [ 0.95, 0.95 ]
Spencer 1999 187 47 23 899 0.89 [ 0.84, 0.93 ] 0.95 [ 0.93, 0.96 ]
Spencer 2008 27 16 4 304 0.87 [ 0.70, 0.96 ] 0.95 [ 0.92, 0.97 ]
Torring 2010 44 32 2 613 0.96 [ 0.85, 0.99 ] 0.95 [ 0.93, 0.97 ]
Wald 2003 71 51 14 974 0.84 [ 0.74, 0.91 ] 0.95 [ 0.94, 0.96 ]
Wapner 2003 48 408 13 7747 0.79 [ 0.66, 0.88 ] 0.95 [ 0.95, 0.95 ]
Wright 2010 797 11124 89 211351 0.90 [ 0.88, 0.92 ] 0.95 [ 0.95, 0.95 ]
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Test 61. Age, NT, PAPP-A and free ßhCG, 1st trimester, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 61 Age, NT, PAPP-A and free hCG, 1st trimester, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barrett 2008 29 374 3 9867 0.91 [ 0.75, 0.98 ] 0.96 [ 0.96, 0.97 ]
Bestwick 2010 89 883 17 21757 0.84 [ 0.76, 0.90 ] 0.96 [ 0.96, 0.96 ]
Biagiotti 1998 24 10 8 190 0.75 [ 0.57, 0.89 ] 0.95 [ 0.91, 0.98 ]
Borrell 2005 20 64 4 2987 0.83 [ 0.63, 0.95 ] 0.98 [ 0.97, 0.98 ]
Borrell 2009 55 330 11 6854 0.83 [ 0.72, 0.91 ] 0.95 [ 0.95, 0.96 ]
Brameld 2008 50 695 10 21525 0.83 [ 0.71, 0.92 ] 0.97 [ 0.97, 0.97 ]
Centini 2005 6 60 0 342 1.00 [ 0.54, 1.00 ] 0.85 [ 0.81, 0.88 ]
Christiansen 2005 10 1 2 27 0.83 [ 0.52, 0.98 ] 0.96 [ 0.82, 1.00 ]
Christiansen 2009 61 14 13 247 0.82 [ 0.72, 0.90 ] 0.95 [ 0.91, 0.97 ]
Christiansen 2010 23 15 5 488 0.82 [ 0.63, 0.94 ] 0.97 [ 0.95, 0.98 ]
Cocciolone 2008 FTS 60 866 6 17969 0.91 [ 0.81, 0.97 ] 0.95 [ 0.95, 0.96 ]
Cowans 2009 650 1124 76 55210 0.90 [ 0.87, 0.92 ] 0.98 [ 0.98, 0.98 ]
Cowans 2010 65 19 5 356 0.93 [ 0.84, 0.98 ] 0.95 [ 0.92, 0.97 ]
Crossley 2002 28 628 6 11932 0.82 [ 0.65, 0.93 ] 0.95 [ 0.95, 0.95 ]
De Graaf 1999 20 9 4 163 0.83 [ 0.63, 0.95 ] 0.95 [ 0.90, 0.98 ]
Ekelund 2008 201 3404 24 92016 0.89 [ 0.85, 0.93 ] 0.96 [ 0.96, 0.97 ]
Go 2005 18 188 3 1550 0.86 [ 0.64, 0.97 ] 0.89 [ 0.88, 0.91 ]
Gyselaers 2005 21 1130 5 12051 0.81 [ 0.61, 0.93 ] 0.91 [ 0.91, 0.92 ]
Hadlow 2005 29 374 3 10030 0.91 [ 0.75, 0.98 ] 0.96 [ 0.96, 0.97 ]
Has 2008 8 65 1 1727 0.89 [ 0.52, 1.00 ] 0.96 [ 0.95, 0.97 ]
Hormansdorfer 2011 37 512 3 5956 0.93 [ 0.80, 0.98 ] 0.92 [ 0.91, 0.93 ]
Huang 2010 23 199 2 6894 0.92 [ 0.74, 0.99 ] 0.97 [ 0.97, 0.98 ]
Jaques 2007 55 659 8 15281 0.87 [ 0.77, 0.94 ] 0.96 [ 0.96, 0.96 ]
Jaques 2010 FTS 101 1732 9 36742 0.92 [ 0.85, 0.96 ] 0.95 [ 0.95, 0.96 ]
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Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kagan 2010 359 2819 36 53557 0.91 [ 0.88, 0.94 ] 0.95 [ 0.95, 0.95 ]
Koster 2011 116 42 35 805 0.77 [ 0.69, 0.83 ] 0.95 [ 0.93, 0.96 ]
Kozlowski 2007 GC 15 347 4 6540 0.79 [ 0.54, 0.94 ] 0.95 [ 0.94, 0.95 ]
Kozlowski 2007 PC 23 306 3 3530 0.88 [ 0.70, 0.98 ] 0.92 [ 0.91, 0.93 ]
Krantz 2000 30 289 3 5487 0.91 [ 0.76, 0.98 ] 0.95 [ 0.94, 0.96 ]
Kublickas 2009 27 225 2 3653 0.93 [ 0.77, 0.99 ] 0.94 [ 0.93, 0.95 ]
Kuc 2010 171 1191 52 25877 0.77 [ 0.71, 0.82 ] 0.96 [ 0.95, 0.96 ]
Leung 2009 31 544 3 9474 0.91 [ 0.76, 0.98 ] 0.95 [ 0.94, 0.95 ]
Malone 2005 75 2023 17 34095 0.82 [ 0.72, 0.89 ] 0.94 [ 0.94, 0.95 ]
Marchini 2010 6 66 2 1463 0.75 [ 0.35, 0.97 ] 0.96 [ 0.95, 0.97 ]
Marsk 2006 29 8 2 100 0.94 [ 0.79, 0.99 ] 0.93 [ 0.86, 0.97 ]
Maxwell 2011 FTS 76 1101 18 31283 0.81 [ 0.71, 0.88 ] 0.97 [ 0.96, 0.97 ]
Maymon 2008 17 11 2 213 0.89 [ 0.67, 0.99 ] 0.95 [ 0.91, 0.98 ]
Merz 2011 431 4336 69 119210 0.86 [ 0.83, 0.89 ] 0.96 [ 0.96, 0.97 ]
Molina 2010 screening 20 205 3 6603 0.87 [ 0.66, 0.97 ] 0.97 [ 0.97, 0.97 ]
Montalvo 2005 14 163 5 4332 0.74 [ 0.49, 0.91 ] 0.96 [ 0.96, 0.97 ]
Muller 2003 19 256 7 5201 0.73 [ 0.52, 0.88 ] 0.95 [ 0.95, 0.96 ]
Nicolaides 2005 301 4100 24 71396 0.93 [ 0.89, 0.95 ] 0.95 [ 0.94, 0.95 ]
Niemimaa 2001 4 132 1 1465 0.80 [ 0.28, 0.99 ] 0.92 [ 0.90, 0.93 ]
O’Leary 2006 50 827 10 21453 0.83 [ 0.71, 0.92 ] 0.96 [ 0.96, 0.97 ]
Okun 2008 FTS 52 521 10 13904 0.84 [ 0.72, 0.92 ] 0.96 [ 0.96, 0.97 ]
Orlandi 1997 6 35 1 702 0.86 [ 0.42, 1.00 ] 0.95 [ 0.93, 0.97 ]
Perni 2006 20 230 2 4363 0.91 [ 0.71, 0.99 ] 0.95 [ 0.94, 0.96 ]
Rissanen 2007 12 394 1 4301 0.92 [ 0.64, 1.00 ] 0.92 [ 0.91, 0.92 ]
Rozenberg 2007 41 370 10 12963 0.80 [ 0.67, 0.90 ] 0.97 [ 0.97, 0.97 ]
Sahota 2010 28 541 4 10281 0.88 [ 0.71, 0.96 ] 0.95 [ 0.95, 0.95 ]
Salomon 2010 64 612 16 20800 0.80 [ 0.70, 0.88 ] 0.97 [ 0.97, 0.97 ]
Santiago 2007 12 212 1 4023 0.92 [ 0.64, 1.00 ] 0.95 [ 0.94, 0.96 ]
Schaelike 2009 52 517 7 10092 0.88 [ 0.77, 0.95 ] 0.95 [ 0.95, 0.96 ]
Schielen 2006 15 190 6 3822 0.71 [ 0.48, 0.89 ] 0.95 [ 0.95, 0.96 ]
Schuchter 2002 12 245 2 4543 0.86 [ 0.57, 0.98 ] 0.95 [ 0.94, 0.95 ]
Scott 2004 5 143 0 1905 1.00 [ 0.48, 1.00 ] 0.93 [ 0.92, 0.94 ]
Sorensen 2011 88 921 12 18673 0.88 [ 0.80, 0.94 ] 0.95 [ 0.95, 0.96 ]
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Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Spencer 1999 187 47 23 899 0.89 [ 0.84, 0.93 ] 0.95 [ 0.93, 0.96 ]
Spencer 2008 27 16 4 304 0.87 [ 0.70, 0.96 ] 0.95 [ 0.92, 0.97 ]
Stenhouse 2004 14 283 1 4702 0.93 [ 0.68, 1.00 ] 0.94 [ 0.94, 0.95 ]
Torring 2010 39 18 7 627 0.85 [ 0.71, 0.94 ] 0.97 [ 0.96, 0.98 ]
Vadiveloo 2009 40 649 4 9496 0.91 [ 0.78, 0.97 ] 0.94 [ 0.93, 0.94 ]
Valinen 2007 21 232 3 4509 0.88 [ 0.68, 0.97 ] 0.95 [ 0.94, 0.96 ]
Wald 2003 71 48 14 977 0.84 [ 0.74, 0.91 ] 0.95 [ 0.94, 0.97 ]
Wapner 2003 52 767 9 7388 0.85 [ 0.74, 0.93 ] 0.91 [ 0.90, 0.91 ]
Wax 2009 7 207 1 2016 0.88 [ 0.47, 1.00 ] 0.91 [ 0.89, 0.92 ]
Wojdemann 2005 10 138 1 6292 0.91 [ 0.59, 1.00 ] 0.98 [ 0.97, 0.98 ]
Wortelboer 2009 66 677 21 19529 0.76 [ 0.65, 0.84 ] 0.97 [ 0.96, 0.97 ]
Wright 2010 797 11124 89 211351 0.90 [ 0.88, 0.92 ] 0.95 [ 0.95, 0.95 ]
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Test 62. Age, NT, PAPP-A and uE3, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 62 Age, NT, PAPP-A and uE3, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Maymon 2005 19 28 5 524 0.79 [ 0.58, 0.93 ] 0.95 [ 0.93, 0.97 ]
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Test 63. Age, NT, PAPP-A and ITA, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 63 Age, NT, PAPP-A and ITA, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2007 FTS 19 538 4 10214 0.83 [ 0.61, 0.95 ] 0.95 [ 0.95, 0.95 ]
Spencer 2002 45 11 9 213 0.83 [ 0.71, 0.92 ] 0.95 [ 0.91, 0.98 ]
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Test 64. Age, NT, PAPP-A and inhibin, 1st trimester, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 64 Age, NT, PAPP-A and inhibin, 1st trimester, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 9 0 3 28 0.75 [ 0.43, 0.95 ] 1.00 [ 0.88, 1.00 ]
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Test 65. Age, NT, PAPP-A and inhibin, 1st trimester, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 65 Age, NT, PAPP-A and inhibin, 1st trimester, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 10 1 2 27 0.83 [ 0.52, 0.98 ] 0.96 [ 0.82, 1.00 ]
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Test 66. Age, NT, PAPP-A and inhibin, 1st trimester, risk 1:400.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 66 Age, NT, PAPP-A and inhibin, 1st trimester, risk 1:400
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 10 1 2 27 0.83 [ 0.52, 0.98 ] 0.96 [ 0.82, 1.00 ]
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Test 67. Age, NT, PAPP-A and inhibin, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 67 Age, NT, PAPP-A and inhibin, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 68 51 17 974 0.80 [ 0.70, 0.88 ] 0.95 [ 0.94, 0.96 ]
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Test 68. Age, NT, PAPP-A and inhibin, 1st trimester, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 68 Age, NT, PAPP-A and inhibin, 1st trimester, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 10 1 2 27 0.83 [ 0.52, 0.98 ] 0.96 [ 0.82, 1.00 ]
Wald 2003 68 51 17 974 0.80 [ 0.70, 0.88 ] 0.95 [ 0.94, 0.96 ]
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Test 69. Age, NT, PAPP-A and ADAM12, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 69 Age, NT, PAPP-A and ADAM12, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Spencer 2008 26 16 5 304 0.84 [ 0.66, 0.95 ] 0.95 [ 0.92, 0.97 ]
Torring 2010 38 32 8 613 0.83 [ 0.69, 0.92 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 70. Age, NT, PAPP-A and ADAM12, 1st trimester, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 70 Age, NT, PAPP-A and ADAM12, 1st trimester, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Torring 2010 37 23 9 622 0.80 [ 0.66, 0.91 ] 0.96 [ 0.95, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 71. Age, NT, free ßhCG and ADAM12, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 71 Age, NT, free hCG and ADAM12, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Spencer 2008 21 16 10 304 0.68 [ 0.49, 0.83 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 72. Age, NT, AFP and free ßhCG, 1st trimester, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 72 Age, NT, AFP and free hCG, 1st trimester, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benattar 1999 5 120 0 1531 1.00 [ 0.48, 1.00 ] 0.93 [ 0.91, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 73. Age, NT, AFP and free ßhCG, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 73 Age, NT, AFP and free hCG, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 56 51 29 974 0.66 [ 0.55, 0.76 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 74. Age, NT, AFP and free ßhCG, 1st trimester, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 74 Age, NT, AFP and free hCG, 1st trimester, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benattar 1999 5 120 0 1531 1.00 [ 0.48, 1.00 ] 0.93 [ 0.91, 0.94 ]
Wald 2003 56 51 29 974 0.66 [ 0.55, 0.76 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 75. Age, NT, AFP and PAPP-A, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 75 Age, NT, AFP and PAPP-A, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 68 51 17 974 0.80 [ 0.70, 0.88 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 76. Age, NT, total hCG and PAPP-A, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 76 Age, NT, total hCG and PAPP-A, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 68 51 17 974 0.80 [ 0.70, 0.88 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 77. Age, NT, total hCG and inhibin, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 77 Age, NT, total hCG and inhibin, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 53 51 32 974 0.62 [ 0.51, 0.73 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 78. Age, NT, free ßhCG and inhibin, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 78 Age, NT, free hCG and inhibin, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 56 51 29 974 0.66 [ 0.55, 0.76 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 79. Age, NT, PAPP-A, free ßhCG, 1st trimester serum, ductus venosus pulsivity index, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 79 Age, NT, PAPP-A, free hCG, 1st trimester serum, ductus venosus pulsivity index, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2009 59 359 7 6825 0.89 [ 0.79, 0.96 ] 0.95 [ 0.94, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 80. Age, free ßhCG and PAPP-A, if risk 1:42-1:1000, NT, final 1:250 risk.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 80 Age, free hCG and PAPP-A, if risk 1:42-1:1000, NT, final 1:250 risk
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vadiveloo 2009 39 588 5 9557 0.89 [ 0.75, 0.96 ] 0.94 [ 0.94, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 81. Age, NT, ductus, free ßhCG and PAPP-A, 1st trimester, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 81 Age, NT, ductus, free hCG and PAPP-A, 1st trimester, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2009 51 72 15 7112 0.77 [ 0.65, 0.87 ] 0.99 [ 0.99, 0.99 ]
Kagan 2010 117 490 5 19124 0.96 [ 0.91, 0.99 ] 0.98 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 82. Age, NT, ductus, free ßhCG and PAPP-A, 1st trimester, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 82 Age, NT, ductus, free hCG and PAPP-A, 1st trimester, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2005 20 37 4 3014 0.83 [ 0.63, 0.95 ] 0.99 [ 0.98, 0.99 ]
Borrell 2009 55 180 11 7004 0.83 [ 0.72, 0.91 ] 0.97 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 83. Age, NT, ductus, free ßhCG and PAPP-A, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 83 Age, NT, ductus, free hCG and PAPP-A, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2005 22 153 2 2898 0.92 [ 0.73, 0.99 ] 0.95 [ 0.94, 0.96 ]
Borrell 2009 59 359 7 6825 0.89 [ 0.79, 0.96 ] 0.95 [ 0.94, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 84. Age, NT, ductus, free ßhCG and PAPP-A, 1st trimester, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 84 Age, NT, ductus, free hCG and PAPP-A, 1st trimester, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Borrell 2005 20 37 4 3014 0.83 [ 0.63, 0.95 ] 0.99 [ 0.98, 0.99 ]
Borrell 2009 55 180 11 7004 0.83 [ 0.72, 0.91 ] 0.97 [ 0.97, 0.98 ]
Kagan 2010 117 490 5 19124 0.96 [ 0.91, 0.99 ] 0.98 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 85. Age, NT, nasal bone, free ßhCG and PAPP-A, 1st trimester, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 85 Age, NT, nasal bone, free hCG and PAPP-A, 1st trimester, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kagan 2010 111 490 11 19124 0.91 [ 0.84, 0.95 ] 0.98 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 86. Age, NT, nasal bone, free ßhCG and PAPP-A, 1st trimester, risk 1:300.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 86 Age, NT, nasal bone, free hCG and PAPP-A, 1st trimester, risk 1:300
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Has 2008 8 54 1 1738 0.89 [ 0.52, 1.00 ] 0.97 [ 0.96, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 87. Age, NT, tricuspid blood flow, free ßhCG and PAPP-A, 1st trimester, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 87 Age, NT, tricuspid blood flow, free hCG and PAPP-A, 1st trimester, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kagan 2010 111 510 11 19104 0.91 [ 0.84, 0.95 ] 0.97 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 88. Age, NT, fetal heart rate, free ßhCG and PAPP-A, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 88 Age, NT, fetal heart rate, free hCG and PAPP-A, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kagan 2010 359 2819 36 53557 0.91 [ 0.88, 0.94 ] 0.95 [ 0.95, 0.95 ]
Maiz 2009 115 975 7 18517 0.94 [ 0.89, 0.98 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 89. Age, NT, fetal heart rate, nasal bone, free ßhCG and PAPP-A, 1st trimester, risk 1:200.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 89 Age, NT, fetal heart rate, nasal bone, free hCG and PAPP-A, 1st trimester, risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kagan 2010 116 843 6 18771 0.95 [ 0.90, 0.98 ] 0.96 [ 0.95, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 90. age, NT, fetal heart rate, ductus, free ßhCG and PAPP-A, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 90 age, NT, fetal heart rate, ductus, free hCG and PAPP-A, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Maiz 2009 118 975 4 18517 0.97 [ 0.92, 0.99 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 91. Age, NT, fetal heart rate, tricuspid blood flow, free ßhCG and PAPP-A,1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 91 Age, NT, fetal heart rate, tricuspid blood flow, free hCG and PAPP-A,1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kagan 2010 117 981 5 18633 0.96 [ 0.91, 0.99 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 92. Age, NT, AFP, free ßhCG and PAPP-A, 1st trimester, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 92 Age, NT, AFP, free hCG and PAPP-A, 1st trimester, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Muller 2003 19 256 7 5201 0.73 [ 0.52, 0.88 ] 0.95 [ 0.95, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 93. Age, NT, AFP, free ßhCG and PAPP-A, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 93 Age, NT, AFP, free hCG and PAPP-A, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
De Graaf 1999 20 9 4 163 0.83 [ 0.63, 0.95 ] 0.95 [ 0.90, 0.98 ]
Wald 2003 71 51 14 974 0.84 [ 0.74, 0.91 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 94. Age, NT, AFP, free ßhCG and PAPP-A, 1st trimester, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 94 Age, NT, AFP, free hCG and PAPP-A, 1st trimester, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
De Graaf 1999 20 9 4 163 0.83 [ 0.63, 0.95 ] 0.95 [ 0.90, 0.98 ]
Muller 2003 19 256 7 5201 0.73 [ 0.52, 0.88 ] 0.95 [ 0.95, 0.96 ]
Wald 2003 71 51 14 974 0.84 [ 0.74, 0.91 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 95. Age, NT, total hCG, inhibin and PAPP-A, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 95 Age, NT, total hCG, inhibin and PAPP-A, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 69 51 16 974 0.81 [ 0.71, 0.89 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 96. Age, NT, PAPP-A, free ßhCG and PGH, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 96 Age, NT, PAPP-A, free hCG and PGH, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 64 13 10 248 0.86 [ 0.77, 0.93 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 97. Age, NT, PAPP-A, free ßhCG and GHBP, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 97 Age, NT, PAPP-A, free hCG and GHBP, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2009 67 13 7 248 0.91 [ 0.81, 0.96 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 98. Age, NT, PAPP-A, free ßhCG and PIGF, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 98 Age, NT, PAPP-A, free hCG and PIGF, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cowans 2010 66 19 4 356 0.94 [ 0.86, 0.98 ] 0.95 [ 0.92, 0.97 ]
Koster 2011 118 42 33 805 0.78 [ 0.71, 0.84 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 99. Age, NT, PAPP-A, free ßhCG and total hCG, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 99 Age, NT, PAPP-A, free hCG and total hCG, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Koster 2011 116 42 35 805 0.77 [ 0.69, 0.83 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 100. Age, NT, PAPP-A, free ßhCG and PP13, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 100 Age, NT, PAPP-A, free hCG and PP13, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Koster 2011 116 42 35 805 0.77 [ 0.69, 0.83 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 101. Age, NT, PAPP-A, free ßhCG and ADAM12, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 101 Age, NT, PAPP-A, free hCG and ADAM12, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2010 25 25 3 478 0.89 [ 0.72, 0.98 ] 0.95 [ 0.93, 0.97 ]
Koster 2011 116 42 35 805 0.77 [ 0.69, 0.83 ] 0.95 [ 0.93, 0.96 ]
Spencer 2008 25 16 6 304 0.81 [ 0.63, 0.93 ] 0.95 [ 0.92, 0.97 ]
Torring 2010 43 32 3 613 0.93 [ 0.82, 0.99 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 102. Age, NT, PAPP-A, free ßhCG and ADAM12, 1st trimester, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 102 Age, NT, PAPP-A, free hCG and ADAM12, 1st trimester, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2010 24 14 4 489 0.86 [ 0.67, 0.96 ] 0.97 [ 0.95, 0.98 ]
Torring 2010 40 17 6 628 0.87 [ 0.74, 0.95 ] 0.97 [ 0.96, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 103. Age, NT, PAPP-A, free ßhCG and ADAM12, 1st trimester, mixed cut-points.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 103 Age, NT, PAPP-A, free hCG and ADAM12, 1st trimester, mixed cut-points
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2010 24 14 4 489 0.86 [ 0.67, 0.96 ] 0.97 [ 0.95, 0.98 ]
Koster 2011 116 42 35 805 0.77 [ 0.69, 0.83 ] 0.95 [ 0.93, 0.96 ]
Spencer 2008 25 16 6 304 0.81 [ 0.63, 0.93 ] 0.95 [ 0.92, 0.97 ]
Torring 2010 40 17 6 628 0.87 [ 0.74, 0.95 ] 0.97 [ 0.96, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 104. Age, NT, free ßhCG, PAPP-A and inhibin, 1st trimester, risk 1:100.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 104 Age, NT, free hCG, PAPP-A and inhibin, 1st trimester, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 10 0 2 28 0.83 [ 0.52, 0.98 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 105. Age, NT, free ßhCG, PAPP-A and inhibin, 1st trimester, risk 1:250.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 105 Age, NT, free hCG, PAPP-A and inhibin, 1st trimester, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 11 1 1 27 0.92 [ 0.62, 1.00 ] 0.96 [ 0.82, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 106. Age, NT, free ßhCG, PAPP-A and inhibin, 1st trimester, risk 1:400.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 106 Age, NT, free hCG, PAPP-A and inhibin, 1st trimester, risk 1:400
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christiansen 2005 11 1 1 27 0.92 [ 0.62, 1.00 ] 0.96 [ 0.82, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 107. Age, NT, free ßhCG, PAPP-A and inhibin, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 107 Age, NT, free hCG, PAPP-A and inhibin, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 71 51 14 974 0.84 [ 0.74, 0.91 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 108. Age, NT, PAPP-A, free ßhCG, ADAM12 and PlGH, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 108 Age, NT, PAPP-A, free hCG, ADAM12 and PlGH, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Koster 2011 120 42 31 805 0.79 [ 0.72, 0.86 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 109. Age, NT, total hCG, inhibin, PAPP-A, AFP and uE3, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 109 Age, NT, total hCG, inhibin, PAPP-A, AFP and uE3, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 71 51 14 974 0.84 [ 0.74, 0.91 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 110. Age, NT, free ßhCG, inhibin, PAPP-A, AFP and uE3,1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 110 Age, NT, free hCG, inhibin, PAPP-A, AFP and uE3,1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 73 51 12 974 0.86 [ 0.77, 0.92 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 111. Age, NT, PAPP-A, free ßhCG, ADAM12, total hCG and PlGF, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 111 Age, NT, PAPP-A, free hCG, ADAM12, total hCG and PlGF, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Koster 2011 120 42 31 805 0.79 [ 0.72, 0.86 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 112. Age, NT, PAPP-A, free ßhCG, ADAM12, total hCG, PlGF and PP13, 1st trimester, 5FPR.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 112 Age, NT, PAPP-A, free hCG, ADAM12, total hCG, PlGF and PP13, 1st trimester, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Koster 2011 121 42 30 805 0.80 [ 0.73, 0.86 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 113. NT, free ßhCG and PAPP-A, 1st trimester incidence rate 63.3%.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 113 NT, free hCG and PAPP-A, 1st trimester incidence rate 63.3%
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hormansdorfer 2011 36 307 4 6161 0.90 [ 0.76, 0.97 ] 0.95 [ 0.95, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 114. NT, PAPP-A, free ßhCG and maternal age - maternal age < 35 years.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 114 NT, PAPP-A, free hCG and maternal age - maternal age < 35 years
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hadlow 2005 14 165 3 8042 0.82 [ 0.57, 0.96 ] 0.98 [ 0.98, 0.98 ]
Krantz 2000 7 169 1 3589 0.88 [ 0.47, 1.00 ] 0.96 [ 0.95, 0.96 ]
Marchini 2010 2 35 1 1200 0.67 [ 0.09, 0.99 ] 0.97 [ 0.96, 0.98 ]
Schielen 2006 1 27 1 1704 0.50 [ 0.01, 0.99 ] 0.98 [ 0.98, 0.99 ]
Wapner 2003 8 151 4 3933 0.67 [ 0.35, 0.90 ] 0.96 [ 0.96, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 115. NT, PAPP-A, free ßhCG and maternal age - maternal age ≥ 35 years.
Review: First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening
Test: 115 NT, PAPP-A, free hCG and maternal age - maternal age ≥ 35 years
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hadlow 2005 15 209 0 1988 1.00 [ 0.78, 1.00 ] 0.90 [ 0.89, 0.92 ]
Krantz 2000 23 289 2 1729 0.92 [ 0.74, 0.99 ] 0.86 [ 0.84, 0.87 ]
Marchini 2010 4 39 1 261 0.80 [ 0.28, 0.99 ] 0.87 [ 0.83, 0.91 ]
Schielen 2006 14 163 5 2118 0.74 [ 0.49, 0.91 ] 0.93 [ 0.92, 0.94 ]
Wapner 2003 44 619 5 3452 0.90 [ 0.78, 0.97 ] 0.85 [ 0.84, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Direct (head-to-head) comparisons of the diagnostic accuracy of the 10 most evaluated first trimester ultrasound
markers alone or in combination with first trimester serum tests
Ratio of
DORs
(95% CI);
P value
(Studies)
Nasal
bone
NT Nasal
bone and
age
Ductus
and age
NT and
age
NT, nasal
bone and
age
NT,
free ßhCG
and age
NT,
PAPP-A
and age
NT,
PAPP-A,
free ßhCG
and age
NT -
Nasal
bone and
age
- -
Ductus
and age
1.19 (0.12,
11.4); P =
0.84
(K = 1)
- 0.85 (0.21,
3.41); P =
0.76
(K = 1)
NT and
age
0.62 (0.13,
2.93); P =
0.50
(K = 2)
1.25 (0.90,
1.74); P =
0.17
(K = 3)
0.84 (0.48,
1.49); P =
0.52
(K = 3)
1.07 (0.51,
2.23); P =
0.85
(K = 3)
NT, nasal
bone and
0.61 (0.12,
3.10); P =
- 4.01 (1.51,
10.6); P =
0.95 (0.23,
3.97); P =
1.05 (0.70,
1.56); P =
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Table 1. Direct (head-to-head) comparisons of the diagnostic accuracy of the 10 most evaluated first trimester ultrasound
markers alone or in combination with first trimester serum tests (Continued)
age 0.50
(K = 2)
0.01
(K = 2)
0.93
(K = 1)
0.82
(K = 5)
NT,
free ßhCG
and age
- 2.15 (1.33,
3.50); P =
0.007
(K = 2)
- - 1.47 (1.00,
2.15); P =
0.05
(K = 4)
-
NT,
PAPP-A
and age
- 2.86 (1.73,
4.73); P =
0.001
(K = 2)
- - 1.88 (1.27,
2.78); P =
0.004
(K = 4)
- 1.28 (0.84,
1.93); P =
0.23
(K = 4)
NT,
PAPP-A,
free ßhCG
and age
3.83 (0.89,
16.4); P =
0.07
(K = 2)
4.35 (2.00,
9.46); P =
0.015
(K = 4)
- 3.00 (0.42,
21.2); P =
0.19
(K = 1)
3.19 (2.19,
4.66); P <
0.0001
(K = 25)
1.23 (0.63,
2.40); P =
0.50
(K = 2)
2.06 (1.31,
3.22); P =
0.004
(K = 4)
1.61 (1.02,
2.55); P =
0.043
(K = 4)
NT,
PAPP-A,
free
ßhCG,
ADAM 12
and age
- - - - - - - - 0.87 (0.49,
1.52); P =
0.60
(K = 4)
- Indicates pairs of tests where there were no head-to head comparisons of the two tests in a study. Direct comparisons were made
using only data from studies that compared each pair of tests in the same population. Ratio of diagnostic odds ratios (DORs) were
computed by division of the DOR for the test in the row by the DOR for the test in the column. If the ratio of DORs is greater
than one, then the diagnostic accuracy of the test in the row is higher than that of the test in the column; if the ratio is less than one,
the diagnostic accuracy of the test in the column is higher than that of the test in the row.
Table 2. Indirect comparisons of the diagnostic accuracy of the 10 most evaluated first trimester ultrasound markers alone or
in combination with first trimester serum tests
Ratio of
DORs
(95%CI)
; P value
Nasal
bone
NT Nasal
bone and
age
Ductus
and age
NT and
age
NT, nasal
bone and
age
NT, free
ßhCG
and age
NT,
PAPP-A
and age
NT,
PAPP-A,
free
ßhCG
and age
DOR
(95%CI)
Studies
132 (71,
245) K =
11
45
(31, 67)K
= 13
40
(7, 224)K
= 4
41 (18,
92) K = 5
46
(37, 57)K
= 50
66
(24, 180)
K = 5
65 (51,
84)
K = 5
80 (59,
109)
K = 5
133 (114,
155)
K = 69
NT 45
(31, 67)K
= 13
0.34 (0.
16, 0.71);
P = 0.006
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Table 2. Indirect comparisons of the diagnostic accuracy of the 10 most evaluated first trimester ultrasound markers alone or
in combination with first trimester serum tests (Continued)
Nasal
bone and
age
40
(7, 224)K
= 4
0.31 (0.
05, 1.90);
P = 0.18
0.90 (0.
16, 5.05);
P = 0.89
Ductus
and age
41 (18,
92) K = 5
0.31 (0.
11, 0.87);
P = 0.03
0.90 (0.
37, 2.20);
P = 0.80
1.00 (0.
11, 9.34);
P = 1.00
NT and
age
46
(37, 57)K
= 50
0.35 (0.
19, 0.66);
P = 0.002
1.02 (0.
66, 1.58);
P = 0.92
1.14 (0.
23, 5.61);
P = 0.87
1.14 (0.
52, 2.49);
P = 0.74
NT, nasal
bone and
age
66
(24, 180)
K = 5
0.50 (0.
14, 1.81);
P = 0.26
1.47 (0.
47, 4.58);
P = 0.48
1.64 (0.
12, 21.5);
P = 0.62
1.64 (0.
33, 8.08);
P = 0.46
1.43 (0.
52, 3.98);
P = 0.48
NT, free
ßhCG
and age
65 (51,
84)
K = 5
0.49 (0.
25, 0.98);
P = 0.04
1.44 (0.
89, 2.34);
P = 0.12
1.61 (0.
26, 10.1);
P = 0.56
1.61 (0.
65, 3.99);
P = 0.26
1.41 (1.
02, 1.96);
P = 0.04
0.98 (0.
30, 3.19);
P = 0.98
NT,
PAPP-A
and age
80
(59, 109)
K = 5
0.61 (0.
29, 1.25);
P = 0.16
1.77 (1.
05, 3.00);
P = 0.04
1.98 (0.
30, 13.1);
P = 0.42
1.98 (0.
76, 5.15);
P = 0.14
1.73 (1.
19, 2.53);
P = 0.005
1.21 (0.
35, 4.13);
P = 0.73
1.23 (0.
74, 2.05);
P = 0.35
NT,
PAPP-A,
free
ßhCG
and age
133 (114,
155)
K = 69
1.00 (0.
55, 1.84);
P = 1.00
2.
93 (1.96,
4.40); P <
0.0001
3.27 (0.
68, 15.8);
P = 0.14
3.27 (1.
53, 7.00);
P = 0.003
2.
87 (2.21,
3.72); P <
0.0001
2.00 (0.
73, 5.45);
P = 0.17
2.03 (1.
52, 2.72)
P < 0.
0001
1.65 (1.
17, 2.34)
P = 0.005
NT,
PAPP-A,
free
ßhCG,
ADAM
12 and
age
85
(58, 124)
K = 4
0.64 (0.
30, 1.37);
P = 0.23
1.88 (1.
07, 3.32);
P = 0.03
2.10 (0.
31, 14.1);
P = 0.39
2.10 (0.
78, 5.63);
P = 0.12
1.84 (1.
19, 2.84);
P = 0.007
1.28 (0.
37, 4.47);
P = 0.65
1.30 (0.
81, 2.09)
P = 0.26
1.06 (0.
61, 1.86)
P = 0.81
0.64 (0.
43, 0.96)
P = 0.03
Indirect comparisons were made using all available data for each pair of tests. Ratios of diagnostic odds ratios (DORs) were computed
by division of the DOR for the test in the row by the DOR for the test in the column. If the ratio of DORs is greater than one, then
the diagnostic accuracy of the test in the row is higher than that of the test in the column; if the ratio is less than one, the diagnostic
accuracy of the test in the column is higher than that of the test in the row.
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Table 3. Summary of study characteristics
Study NT,
PAPP-A,
free ßhCG
and age
Nasal
bone
NT and
age
NT Maternal
age (range)
in years
Reference
standard
Population Study
design
Study loca-
tion
Acacio
2001
X Mean 35.8
(21-45)
CVS biopsy,
amniocen-
te-
sis or blood
or placenta
used for fetal
karyotyping
High-
risk referral
for invasive
testing
Retrospec-
tive study of
patient
notes
South
America
Audibert
2001
X Mean 30.1,
all
< 38, 86% <
35, 14% ≥
35
Prenatal
karyotype
conducted
(in 7.6% of
patients) de-
pending on
presence of
risk > 125,
high mater-
nal
age, parental
anxiety, his-
tory of chro-
moso-
mal defects
or parental
translo-
cation or ab-
normal sec-
ond
trimester
scan age
Routine
screening
Prospec-
tive consec-
utive series
France
Babbur
2005
X Median 37
(19-46)
Inva-
sive testing
offered to
women with
NT > 3 mm
or risk > 1:
250 as de-
fined by
combined
NT and
serum
Women re-
questing
screening
(self-pay-
ing service)
and women
attending
on account
of previous
pregnancy
history of fe-
Prospective
cohort
UK
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Table 3. Summary of study characteristics (Continued)
results (CVS
from 11
weeks, am-
niocen-
tesis from15
weeks)
. Rapid in
situ hybridi-
sation test in
patients
with risk >
1:30.Node-
tails given of
any follow-
up to birth
tal
abnormality
Barrett
2008
X Mean 34.9
for
screen posi-
tives, 30.
5 for screen
negatives
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort Australia
Belics
2011
Mean 36.4
(15-46) for
Down’s
cases, 29.8
(15-
49) for unaf-
fected preg-
nancies
Amniocen-
tesis or CVS
(85% of
women) or
follow-up to
birth
High-
risk referral
for invasive
testing
Cohort Budapest
Benattar
1999
X Mean
32 (16-46),
8.3% > 35
Amnio-
centesis due
to mater-
nal age > 38
years (6.1%
or women).
Kary-
otyping en-
couraged for
women with
positive re-
sult on one
or more in-
dex test. No
de-
tails of ref-
Routine
screening
Prospective
cohort
France
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Table 3. Summary of study characteristics (Continued)
erence stan-
dard for in-
dex test neg-
ativewomen
Bestwick
2010
X X X Median 39
for Down’s
cases, 34 for
unaffected
pregnancies
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
UK
Biagiotti
1998
X X Un-
clear (maybe
all ≥ 38)
Amniocen-
tesis or CVS
High-
risk referral
for invasive
testing
Case control Italy
Borenstein
2008
Median 35
(17-49)
CVS High-
risk referral
for invasive
testing
Prospective
cohort
UK
Borrell
2005
X X Not
reported
CVS (high-
risk women)
or follow-up
to birth
Routine
screening
Retrospec-
tive cohort
Spain
Borrell
2009
X Mean 32 Karyotyp-
ing or
follow-up to
birth
Rou-
tine screen-
ing and
high-risk re-
ferral
Prospective
cohort
Spain
Brameld
2008
X Me-
dian 31 (14-
47), 20% ≥
35
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
Australia
Brizot
2001
X Median 28
(13-46), 19.
4% ≥ 35
An-
tenatal kary-
otyping (5.
9% of preg-
nan-
cies: 62% of
high-
risk, 29% of
medium-
risk and 3%
of the low-
Routine
screening
Prospective
cohort
Brazil
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Table 3. Summary of study characteristics (Continued)
risk women)
. Follow-up
to birth (85.
3% of
women)
Centini
2005
X ≥ 35 (35-
44)
Amniocen-
tesis in
women high
risk
on screening
(16.2%)
. Follow-up
at birth in
women who
were
low risk on
screening
High-
risk patients
undergo-
ing routine
screening
Retrospec-
tive cohort
Italy
Chasen
2003
X Median
33 (IQR 31-
36), 36.2%
≥ 35
Karyotyp-
ing or fol-
low-
up to birth
in 96.1% of
patients
Routine
screening
Prospec-
tive consec-
utive cohort
USA
Chen
2009
Median 30
(20-44) for
Down’s
cases, 32
(19-40) for
controls
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Case control China
Chris-
tiansen
2005
X Not
reported
Karyotyp-
ing
Screening
pro-
grammes for
syphilis and
Down’s syn-
drome
Case control Denmark
Chris-
tiansen
2009
X Median 37.
5 for Down’s
cases, 36.4
for controls
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Case control Denmark
Chris-
tiansen
2010
X Median 36
(25-44) for
Down’s
cases, 29
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Case control Denmark
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Table 3. Summary of study characteristics (Continued)
(17-45) for
controls
Cicero
2004a
Median 37
(16-48)
CVS High-
risk referral
for invasive
testing
Prospective
cohort
USA
Cicero
2006
X Median 35
(18-50)
CVS or am-
niocen-
tesis (in high
risk women)
or follow-up
to birth
Routine
screening
Prospective
cohort
UK
Cocci-
olone
2008 (first
trimester
screening
cohort)
X Median 31.
3
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort Australia
Cowans
2009
X Mean
38 (16-49)
for Down’s
cases, 29
(13-
56) for unaf-
fected preg-
nancies
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort UK
Cowans
2010
X Mean 37.0
(IQR 32.9-
40.5)
for Down’s
cases, 32.
4 (IQR 29.
0-35.9) for
controls
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Case control UK
Crossley
2002
X X Median 29.
9, 15.4% ≥
35
CVS (of-
fered where
women had
high NT
measure-
ments), am-
niocentesis
or follow-up
to birth
Routine
screening
Prospective
cohort
UK
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Table 3. Summary of study characteristics (Continued)
De Graaf
1999
X X Not
reported
CVS
and amnio-
centesis
High-
risk referral
for invasive
testing
Case control Netherlands
Ekelund
2008
X Not
reported
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort Denmark
Gasiorek-
Wiens
2001
X Median 33
(15-49), 36.
1% > 35
CVS, am-
niocentesis
or follow-up
to birth
Routine
screening
Prospective
cohort
Germany,
Switzerland
and Austria
Gasiorek-
Wiens
2010
X Median 35.
1 (13.2-46.
7)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort Germany
Go 2005 X 49% ≤ 35,
51% ≥ 36
Inva-
sive testing
or follow-up
to birth
Routine
screening
Retrospec-
tive cohort
Netherlands
Gyselaers
2005
X X Not
reported
CVS, am-
niocentesis
or follow-up
to birth
Routine
screening
Prospective
cohort
Belgium
Habayeb
2010
Median 35.
4 (18-49)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort UK
Hadlow
2005*
X Mean 30.7,
21.2% ≥ 35
CVS, am-
niocentesis
or follow-up
to birth
Routine
screening
Prospective
cohort
Australia
Hafner
1998*
X Me-
dian 28 (15-
49) 6.9% ≥
35
Amniocen-
tesis or CVS
in patients
with previ-
ous Down’s
pregnancy, >
35 years or
with a
positive bio-
Routine
screening
Prospective
cohort
Austria
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Table 3. Summary of study characteristics (Continued)
chem-
ical test re-
sult. Other
women un-
derwent
scan at 22
weeks and,
if NT >2.5
mm special
examination
directed
to examina-
tion of fetal
heart.
Follow-up
to birth
Has 2008 X X X Median 28.
3 (17-45)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort Turkey
Hewitt
1996
X Median 37
(21-48)
CVS High-
risk referral
for invasive
testing
Prospective
cohort
Australia
Hormans-
dorfer
2011
X Mean 31.1
(16-46),
22% ≥ 35
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
Germany
Huang
2010
X Median 30
(15-47)
, mean 29.8
(SD 3.3)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort Taiwan
Jaques
2007
X Mean 33
(16-51), 18.
5% ≥ 37
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
Australia
Jaques
2010 FTS
(first
trimester
screening)
X Mean 16.
3% ≥ 37
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
Australia
342First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Summary of study characteristics (Continued)
Kagan
2010
X X Mean 35.4
(14.1-52.2)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
UK
Kim 2006 X Mean 29.9
(SD 3.3)
Amniocen-
tesis or CVS
in patients
con-
sidered high
risk (NT >
2.5, aged >
35 years,
positive bio-
chem-
ical test re-
sult, history
or chromo-
so-
mal abnor-
mality, fetal
struc-
tural abnor-
mality at ul-
trasound or
other
reason). Fol-
low-up to
birth
Routine
screening
Retrospec-
tive cohort
South Korea
Koster
2011
X Median
37 (IQR 36-
39)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Case control Netherlands
Kozlowski
2007 GC
(Gynae-
cologists’
practices)
X X Median 32
(15-48), 26.
4% ≥ 35
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort Germany
Kozlowski
2007
PC (Prena-
tal centre)
X X Median 34
(14-46), 43.
2% ≥ 35
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort Germany
Krantz
2000*
X X 34.7% ≥ 35 Not
reported
Routine
screening
Prospective
cohort
USA
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Table 3. Summary of study characteristics (Continued)
Kublickas
2009
X 51% ≥ 35 Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
Sweden
Kuc 2010 X Not
reported
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Case control Netherlands
Lam 2002 X Mean 30.
5 (19% ≥
35) for unaf-
fected preg-
nancies
Women
con-
sidered high
risk offered
CVS (0.7%)
or amnio-
centesis (11.
8%).
Follow-up
to birth
Routine
screening
Prospective
cohort
Hong Kong
Leung
2009
X X Median
32 (IQR 30-
35), 27.4%
≥ 35
Amniocen-
tesis or
follow-up to
birth
Routine
screening
Prospective
cohort
China
MacRae
2008
X Not
reported
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
UK
Maiz 2007 Median 35
(17-49)
CVS High-
risk referral
for invasive
testing
Prospective
cohort
UK
Maiz 2009 Median 34.
5 (14.1-50.
1)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
UK
Malone
2004
X Mean 30.1
(16-47), 22.
1% ≥ 35
Amnio-
centesis (in
women con-
sidered high
risk,
n = 510) or
follow-up to
Routine
screening
Prospective
cohort
USA
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Table 3. Summary of study characteristics (Continued)
birth
Malone
2005
X 21.6% ≥ 35 Amniocen-
te-
sis offered to
women with
positive
results from
any screen-
ing
test. Follow-
up to birth
Routine
screening
Prospective
cohort
USA
Marchini
2010*
X Median 31.
3 (18-45),
19.7% ≥ 35
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
Italy
Marsis
2004
X Mean 37.8
(35-43)
Amnio-
centesis (un-
clear in
which
patients this
was
conducted)
or follow-up
to birth
Screening of
pa-
tients ≥ 35
years of age
Prospective
cohort
Indonesia
Marsk
2006
X X Mean 38.5
(SD 4.0) for
Down’s
cases, 35.5
(SD 4.0) for
controls
Not
reported
Routine
screening
Case control Sweden
Matias
1998
Median 35
(17-46)
Fetal kary-
otyping. In
cases where
NT
above 95th
percentile or
ab-
normal duc-
tus venousus
flow, follow-
up scan con-
ducted at
14-16 weeks
High-
risk referral
for invasive
testing
Prospective
cohort
UKandPor-
tugal
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Table 3. Summary of study characteristics (Continued)
Matias
2001
Median 35
(17-46)
Fetal kary-
otyping. In
cases where
NT
above 95th
percentile or
ab-
normal duc-
tus venousus
flow, follow-
up scan con-
ducted at
14-16 weeks
High-
risk referral
for invasive
testing
Prospective
cohort
Portugal
Mavrides
2002
X Median 35
(15-42)
CVS or fol-
low-up
High-
risk referral
for invasive
testing
Prospective
cohort
UK
Maxwell
2011 FTS
(first
trimester
screening
cohort)
X Median 31
(14-48), 24.
3% ≥ 35
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
Australia
Maymon
2005
Mean 33.7
(SD 4.9) for
Down’s
cases, 30.3
(SD 4.5) for
controls
Amniocen-
tesis (recom-
mended for
women with
higher risk
on first or
second
trimester
testing) or
follow-up to
birth
Routine
screening
Case control Israel
Maymon
2008
X X Not
reported
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Case control USA
Merz 2011 X Not
reported
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
Germany
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Table 3. Summary of study characteristics (Continued)
Michai-
lidis
2001
X Mean 30.1
(13-50), 21.
1% ≥ 35,
11.9% ≥ 37
Karyotyp-
ing in
women con-
sidered
at risk due to
index test re-
sults, age or
family his-
tory or those
with consid-
erable
anxiety (632
women, 8.
5%) or
follow-up to
birth
Routine
screening
Prospective
cohort
UK
Molina
2010 high
risk (High-
risk
cohort)
X Mean 32.7
(16.7-47.5)
CVS High-
risk referral
for invasive
testing
Cohort Spain
Molina
2010
screening
(Screening
cohort)
X Not
reported
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort Spain
Monni
2005
X Median 32
(14-49)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
Italy
Montalvo
2005
X Mean 31.1
(14-49), 25.
9% ≥35
Inva-
sive testing
offered to
women con-
sidered high
risk
from screen-
ing results or
follow-up to
birth
Routine
screening
Prospective
cohort
Spain
Moon
2007
X Mean 35.5
(SD 4.8) for
Down’s
cases,
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
Korea
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Table 3. Summary of study characteristics (Continued)
31.7 (SD 3.
4) for unaf-
fected preg-
nancies
Muller
2003
X X Not
reported
Invasive
testing (of-
fered to
women with
high NT
measure-
ment) or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
France
Nicolaides
1992
X Median 38
(22-47)
Fetal kary-
otyp-
ing by am-
niocente-
sis (52%) or
CVS (48%)
High-
risk referral
for invasive
testing
Prospective
cohort
UK
Nicolaides
2005
X Median 31
(13-49)
Amniocen-
tesis or CVS
(patients
considered
high risk
based on
screening)
. First
trimester
presence/
absence of
nasal bone,
presence/
absence of
tricuspid re-
gurgitation
or normal/
abnormal
Doppler
studies
(patients
of inter-
mediate
risk on first
trimester
Routine
screening
Prospective
cohort
UK
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Table 3. Summary of study characteristics (Continued)
screening
and did not
undergo
CVS or am-
niocentesis.
With the
addition of
information
from these
tests, if
adjusted risk
was high,
CVS was
performed)
. Follow-up
to birth
Niemimaa
2001
X X 17.5% ≥ 35 Invasive
testing (pa-
tients con-
sidered high
risk based
on NT
screening)
or follow-up
to birth
Routine
screening
Prospective
cohort
Finland
Noble
1995
Me-
dian 34 (15-
47), 47% ≥
35
Kary-
otyping per-
formed
(27% of
women) due
to increased
NT (14%),
advanced
maternal age
(10%), pre-
vi-
ous chromo-
somally ab-
nor-
mal child (0.
5%)
or parental
anxiety
(2%).
Ultrasound
exami-
Rou-
tine screen-
ing in a high
risk popula-
tion
Prospective
cohort
UK
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Table 3. Summary of study characteristics (Continued)
nation at 20
weeks (65%
of patients)
. Follow-up
to birth (9%
of women)
O’Callaghan
2000
X Median 32 CVS, am-
niocentesis
or neonatal
karyotyping
or follow-up
to birth
Routine
screening
Prospective
cohort
Australia
O’Leary
2006
X X Me-
dian 31 (14-
47), 20% ≥
35
CVS or am-
niocentesis
(women as-
sessed to be
high risk on
screening)
or follow-up
to birth
Routine
screening
Prospective
cohort
Australia
Okun
2008 FTS
(first
trimester
screening
cohort)
X Mean 34 Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
Canada
Orlandi
1997
X X Range 15 to
46, 35% ≥
35
Not
reported
Routine
screening
Prospective
cohort
Italy
Orlandi
2003
X Median 31.
7 (SD 4.0)
for Down’s
cases,
36.5 (SD 4.
1) for unaf-
fected preg-
nancies
CVS or am-
niocente-
sis (women
considered
high risk on
screening on
the basis of
NT and bio-
chemical re-
sults, but
not on nasal
bone screen-
ing, or if re-
quested
Rou-
tine screen-
ing (2 cen-
tres) or in
referred pa-
tients (1
centre)
Prospective
cohort
Italy and
Netherlands
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Table 3. Summary of study characteristics (Continued)
due to age or
anxiety) or
follow-up to
birth
Orlandi
2005
X Median 30.
5 (SD 8.2)
Not
reported
Routine
screening
Retrospec-
tive cohort
Italy
Otaño
2002
X Median 36
(19-44)
CVS High-
risk referral
for invasive
testing
Prospective
cohort
Argentina
Pajkrt
1998
X Mean 31.
4 (SD 5.7),
24% ≥ 35
Pre-
natal kary-
otyping of-
fered to pa-
tients con-
sidered high
risk or ma-
ternal anxi-
ety
(conducted
in 24%) or
follow-up to
birth
Routine
screening
Prospective
cohort
Netherlands
Pajkrt
1998a
X Mean 37.6
(22-46)
Prenatal
karyotyping
High-
risk referral
for invasive
testing
Consecutive
cohort
Netherlands
Palomaki
2007 FTS
(first
trimester
screening
cohort)
Mean 32.3
(SD 4.6)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
Canada
Perni 2006 X Median 33.
0 (IQR 31.
0-36.0)
CVS or am-
niocente-
sis. Cytoge-
netic testing
in cases of
miscarriage.
Follow-up
to birth
Routine
screening
Retrospec-
tive cohort
USA
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Table 3. Summary of study characteristics (Continued)
Prefumo
2005
X Median 37
(19-46)
CVS High-
risk referral
for invasive
testing
Prospective
cohort
UK
Prefumo
2006
X Mean 31.4
(14.5-50.2)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
UK
Ramos-
Corpas
2006
X Mean 30.1
(15-46) (SD
5.37), 18%
≥ 35
Invasive
testing of-
fered to pa-
tients con-
sidered high
risk
at screening
(> 1:300) or
follow-up to
birth
Routine
screening
Prospective
cohort
Spain
Rissanen
2007
X 29.5, 17.7%
≥35
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
Finland
Rozenberg
2002
X Median 30.
5 (18-37)
Amnio-
centesis of-
fered to pa-
tients with
NT >3mm
or serum
marker risk
was > 1:250,
or follow-up
to birth
Routine
screening
Prospective
cohort
France
Rozenberg
2007
X Mean 30.9
(SD 4.5)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
Canada
Sahota
2010
X X Median 33.
1, 30.1% ≥
35
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
China
Salomon
2010
X Median 30.
7 (18.0-46.
Karyotyp-
ing or
Routine
screening
Prospective
cohort
France
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Table 3. Summary of study characteristics (Continued)
3) follow-up to
birth
Santiago
2007
X X Mean 30.6
(14-46)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
Spain
Sau 2001 X Mean 28
(SD 5)
In-
vasive test-
ing (women
with
high risk on
screening)
or follow-up
to birth
Routine
screening
Prospective
cohort
UK
Schaelike
2009
X X 31.0% ≥35 Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
Germany
Schielen
2006*
X Median 36.
5 (18-47)
Inva-
sive testing
or follow-up
to birth
Routine
screening
Retrospec-
tive cohort
Netherlands
Schuchter
2001
X Mean 28
(15-46), 10.
7% ≥ 35
CVS (of-
fered to
patients
with first
trimester
NT > 3.5
mm), am-
niocentesis
(offered
to patients
with first
trimester
NT 2.5-
3.4 mm,
high risk
on second
trimester
serum
testing (>
1:250) and
those > 35
Routine
screening
Retrospec-
tive cohort
Austria
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Table 3. Summary of study characteristics (Continued)
years) or
follow-up to
birth
Schuchter
2002
X X 13% > 35 CVS
and amnio-
centesis (of-
fered to pa-
tients with
increased
risk (> 1:
400) at first
trimester
screening.
CVS recom-
mended
when NT >
3.5 or when
women did
not
want to wait
until the 15
th week for
amnio-
centesis), or
follow-up to
birth
Routine
screening
Prospective
cohort
Austria
Schwarzler
1999
X Mean 29.4
(16-47)
In-
vasive test-
ing (women
considered
high risk on
screening)
or follow-up
to birth
Routine
screening
Prospec-
tive consec-
utive cohort
UK
Scott 2004 X X Me-
dian 32 (15-
44), 29% ≥
35
Inva-
sive testing
or follow-up
to birth
Routine
screening
Prospective
cohort
Australia
Sepulveda
2007
X X Median 33
(14-47), 35.
4% ≥ 35
CVS, am-
niocentesis,
cordocente-
sis or follow-
up to birth
Routine
screening
Prospective
cohort
Chile
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Table 3. Summary of study characteristics (Continued)
Snijders
1998
X Median 31
(14-49)
CVS
and amnio-
cente-
sis (9.6% of
women) or
follow-up to
birth
Routine
screening
Prospective
cohort
UK
Sorensen
2011
X Median 34
(23-44) for
Down’s
cases; mean
30.4
(16-45), 16.
5% ≥ 35 for
unaffected
pregnancies
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
Denmark
Spencer
1999
X X X Median 38
(19-46) for
Down’s
cases, 36
(15-47) for
controls
Inva-
sive testing
(high-
risk women)
or follow-up
to birth
Routine
screening
Case control UK
Spencer
2002
Median 36
(20-44) for
Down’s
cases, 30
(16-41) for
controls
Not
reported
Routine
screening
Case control UK
Spencer
2008
X Median 35.
8 for Down’s
cases, 29.3
for controls
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Case control Denmark
Stenhouse
2004
X Me-
dian 32 (14-
45), 27% ≥
35
In-
vasive test-
ing offered
to women
with screen-
ing risk of
> 1:250 or
follow-up to
birth
Routine
screening
Prospective
cohort
UK
Strah 2008 X Median 28.
6 (15-42)
Karyotyp-
ing or
Routine
screening
Cohort Slovenia
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Table 3. Summary of study characteristics (Continued)
follow-up to
birth
Theodor-
opoulos
1998
X Median 29
(16-48), 7.
8% ≥ 37
CVS or am-
niocente-
sis or follow-
up to birth.
Unclear ref-
erence stan-
dard in cases
of intrauter-
ine death,
miscarriages
and termi-
nations
Routine
screening
Prospective
cohort
Greece
Thila-
ganathan
1999
X Mean 29
(15-45)
CVS (of-
fered to pa-
tients
considered
high risk on
screening)
or follow-up
to birth
Routine
screening
Prospective
cohort
UK
Timmer-
man
2010
Mean 34.5
(19-45)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Prospective
cohort
Netherlands
Torring
2010
X Mean 35 for
Down’s
cases, 31 for
controls
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Case control Denmark
Vadiveloo
2009
X Median 33.
1, 36.9% ≥
35
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
UK
Valinen
2007
X Mean 29.6,
18.6% ≥ 35
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
Finland
Viora
2003
Median 32
(18-47)
CVS or
follow-up to
birth
Routine
screening
Prospective
cohort
Italy
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Table 3. Summary of study characteristics (Continued)
Wald 2003 X X X Not
reported
In-
vasive test-
ing (follow-
ing second
trimester
screening)
or follow-up
to birth
Routine
screening
Case control UK and
Austria
Wapner
2003*
X X Mean
35 (SD 4.6)
, 50% ≥ 35
Invasive
testing. Mis-
carriage
with cytoge-
netic test-
ing. Follow-
up to birth
Routine
screening
Prospective
cohort
USA
Wax 2009 X Mean 36.7
(SD 3.2)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Retrospec-
tive cohort
USA
Wojde-
mann
2005
X X Mean 29,
10.8% ≥ 35
Invasive
testing (in
cases of in-
creased risk)
or follow-up
to birth
Referrals for
screening
Prospective
cohort
Denmark
Wortel-
boer
2009
X Median 34.
9 (15-48)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort Netherlands
Wright
2008
X Median 35.
2 (16-52)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort UK
Wright
2010
X Median 31.
9 (IQR 27.
7-35.8)
Karyotyp-
ing or
follow-up to
birth
Routine
screening
Cohort UK,
Denmark
and Cyprus
Zoppi
2001
X Median 33
(14-48)
Amniocen-
tesis, CVS
or follow-up
to birth
Routine
screening
Prospective
cohort
Italy
*The study provided data for the subset of women with maternal age of 35 or more.
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X indicates that the test was evaluated in the study.
CVS = chorionic villus sampling; IQR = interquartile range; SD = standard deviation.
Table 4. Investigation of the effect of type of population
Correc-
tion made
for miss-
ing false
negatives
in studies
with de-
layed veri-
fication of
test nega-
tives
NT NT and maternal age NT, PAPP-A, free ßhCG and mater-
nal age
Ratio
of DORs
(95% CI);
P value
Sensitivity at 5% FPR
(95% CI) (studies)
Ratio
of DORs
(95% CI);
P value
Sensitivity at 5% FPR
(95% CI) (studies)
Ratio
of DORs
(95% CI);
P value
Sensitivity at 5% FPR
(95% CI) (studies)
Screening
(n = 9)
High risk
(n = 4)
Screening
(n = 46)
High risk
(n = 4)
Screening
(n = 66)
High risk
(n =3)
No FN
correction
0.68 (0.26,
1.77);
P = 0.40
73 (62, 81) 64 (45, 80) 0.34 (0.17,
0.69);
P = 0.003
72 (68, 76) 47 (31, 63) 0.41 (0.16,
1.00); P =
0.05
88 (86, 89) 74 (54, 88)
FN
increased
+10%
0.69 (0.27,
1.78);
P = 0.40
70 (59, 79) 62 (42, 78) 0.40 (0.20,
0.82);
P = 0.01
69 (64, 73) 47 (31, 64) 0.48 (0.19,
1.20); P =
0.11
86 (84, 87) 74 (53, 88)
FN
increased
+20%
0.74 (0.29,
1.92);
P = 0.50
69 (57, 78) 62 (42, 78) 0.43 (0.21,
0.89);
P = 0.02
67 (63, 71) 47 (31, 64) 0.51 (0.20,
1.28); P =
0.15
85 (83, 87) 74 (54, 88)
FN
increased
+30%
0.81 (0.31,
2.09);
P = 0.63
67 (55, 76) 62 (42, 78) 0.46 (0.22,
0.97);
P = 0.04
66 (61, 70) 47 (30, 64) 0.55 (0.22,
1.38); P =
0.20
84 (82, 86) 74 (54, 88)
FN
increased
+40%
0.76 (0.29,
2.02);
P = 0.55
66 (53, 76) 59 (39, 77) 0.50 (0.24,
1.02);
P = 0.06
64 (60, 68) 47 (31, 64) 0.59 (0.24,
1.48); P =
0.26
83 (81, 85) 74 (54, 88)
FN
increased
+50%
0.81 (0.30,
2.15): P =
0.65
64 (52, 75) 59 (39, 77) 0.52 (0.25,
1.08);
P = 0.08
63 (58, 67) 47 (30, 64) 0.62 (0.25,
1.56); P =
0.31
82 (80, 84) 74 (54, 88)
DOR = diagnostic odds ratio
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A P P E N D I C E S
Appendix 1. Search strategy
Database: Ovid MEDLINE
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 exp Pregnancy-Associated Plasma Protein-A/
4 pregnancy associated plasma protein a.mp.
5 papp-a.mp.
6 exp Chorionic Gonadotropin, beta Subunit, Human/
7 (b-hcg or bhcg).mp.
8 human chorionic gonadotropin.mp.
9 exp alpha-Fetoproteins/
10 alphafetoprotein$.mp.
11 alpha-fetoprotein$.mp.
12 afp.mp.
13 (unconjugated estriol or unconjugated oestriol).mp.
14 ue3.mp.
15 exp INHIBINS/
16 inhibin a.mp.
17 ultrasound.mp.
18 amniocentesis/
19 chorion$ vill$ sampling.mp.
20 Chorionic Villi-Sampling/
21 nasal bone.mp.
22 tricuspid regurgitation.mp.
23 ductus venosus.mp
24 marker$.mp.
25 screen$.mp.
26 detect$.mp.
27 accura$.mp.
28 predict$.mp.
29 ROC.mp.
30 ROC curve/
31 AUC.mp.
32 Area under curve/
33 exp false negative reactions/ or exp false positive reactions/
34 (false positive$ or false negative$).mp.
35 likelihood ratio$.mp.
36 sensitiv$.mp.
37 specific$.mp.
38 diagnos$.ti,ab.
39 “reproducibility of results”.mp.
40 reference value$.mp.
41 reference standard$.mp.
42 exp Down Syndrome/
43 downs syndrome.mp.
44 down syndrome.mp.
45 trisomy 21.mp.
46 Aneuploidy/
47 aneuploidy.mp.
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48 Mosaicism/
49 mosaicism.mp.
50 or/1-41
51 or/42-49
52 50 and 51
53 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
54 52 and 53
55 animal/ not (humans/ and animal/)
56 54 not 55
*******************************************************
Embase via Dialog Datastar
1. PRENATAL-DIAGNOSIS#.DE.
2. FETUS-ECHOGRAPHY#.DE.
3. PREGNANCY-ASSOCIATED-PLASMA-PROTEIN-A#.DE.
4. CHORIONIC-GONADOTROPIN-BETA-SUBUNIT#.DE.
5. HCG.AB.
6. PAPP.AB.
7. ALPHA-FETOPROTEIN#.DE.
8. AFP.AB.
9. ALPHA ADJ FETOPROTEIN$
10. ALPHAFETOPROTEIN$
11. BETA ADJ HUMAN ADJ CHORIONIC ADJ GONADOTROPIN
12. PREGNANCY ADJ ASSOCIATED ADJ PLASMA ADJ PROTEIN
13. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).TI.
14. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).AB.
15. UE3
16. INHIBIN-A#.DE.
17. INHIBIN ADJ A
18. ULTRASOUND
19. AMNIOCENTESIS
20. CHORION-VILLUS-SAMPLING.DE.
21. NASAL ADJ BONE
22. TRICUSPID ADJ REGURGITATION
23. DUCTUS ADJ VENOSUS
24. MARKER ORMARKERS
25. SCREEN OR SCREENING
26. DETECT OR DETECTING OR DETECTION
27. FALSE ADJ POSITIVE$
28. FALSE ADJ NEGATIVE$
29. SENSITIVITY OR SENSITIVE OR SENSITIVITIES
30. SPECIFICITY OR SPECIFICITIES
31. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).TI.
32. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).AB.
33. ROC.AB.
34. AUC.AB.
35. AREA-UNDER-THE-CURVE.DE.
36. ROC-CURVE.DE.
37. ACCURA$
38. PREDICT$
39. REPRODUCIBILITY.DE.
40. REFERENCE ADJ VALUE$
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41. REFERENCE-VALUE.DE.
42. REFERENCE ADJ STANDARD$
43. DOWN-SYNDROME#.DE.
44. DOWN ADJ SYNDROME OR DOWNS ADJ SYNDROME
45. TRISOMY ADJ ’21’
46. MOSAICISM
47. ANEUPLOIDY
48. ANTENATAL$ OR PRENATAL$ OR PREGNANCY OR PREGNANT OR TRIMESTER$ OR MATERNAL OR FETUS
OR FOETUS OR FOETAL OR FETAL
49. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19
OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR
37 OR 38 OR 39 OR 40 OR 41 OR 42
50. 43 OR 44 OR 45 OR 46 OR 47
51. 48 AND 49 AND 50
52. HUMAN=YES
53. 51 AND 52
ADJ = adjacent AB = abstract
TI = title $ = truncation symbol DE = descriptor (similar to MeSH)
*******************************************************
CINAHL via OVID
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 pregnancy associated plasma protein.mp.
4 papp$.ti,ab.
5 exp Gonadotropins, chorionic/
6 (b-hcg or bhcg).mp.
7 human chorionic gonadotropin.mp.
8 exp alpha-Fetoproteins/
9 alphafetoprotein$.mp.
10 alpha-fetoprotein$.mp.
11 afp.mp.
12 (unconjugated estriol or unconjugated oestriol).mp.
13 ue3.mp.
14 inhibin$.mp.
15 ultrasound.mp.
16 amniocentesis/
17 chorion$ vill$ sampling.mp.
18 Chorionic Villi-Sampling/
19 nasal bone.mp.
20 tricuspid regurgitation.mp.
21 ductus venosus.mp.
22 marker$.mp.
23 screen$.mp.
24 detect$.mp.
25 accura$.mp.
26 predict$.mp.
27 ROC.mp.
28 ROC curve/
29 AUC.mp.
30 “area under curve”.mp.
31 exp false negative reactions/ or exp false positive reactions/
32 (false positive$ or false negative$).mp.
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33 likelihood ratio$.mp.
34 sensitiv$.mp.
35 specific$.mp.
36 diagnos$.ti,ab.
37 “reproducibility of results”.mp.
38 reference value$.mp.
39 reference standard$.mp.
40 exp Down Syndrome/
41 downs syndrome.mp.
42 down syndrome.mp.
43 trisomy 21.mp.
44 aneuploidy.mp.
45 mosaicism.mp.
46 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
47 or/1-39
48 or/40-45
49 47 and 48 and 46
*******************************************************
Search terms and instructions for Biosis
The following search terms were entered separately in standard search box (select ‘Titles/subject/abstract’ from the drop-down box on
the right of the search box).
1. “reference standard*”
2. “reference value*”
3. “reproducibility of results”
4. diagnos*
5. sensitiv*
6. specific*
7. “likelihood ratio*”
8. “false negative*“
9. “false positive*”
10. “area under curve”
11. ROC
12. AUC
13. predict*
14. detect*
15. marker*
16. screen*
17. accura*
18. “ductus venosus”
19. “nasal bone”
20. “tricuspid regurgitation”
21. “chorion* vill* sampling”
22. amniocentesis
23. ultrasound
24. inhibin*
25. “unconjugated oestriol”
26. “unconjugated estriol”
27. afp
28. “alpha fetoprotein*”
29. alphafetoprotein*
30. “ b hcg”
31. “human chorionic gonadotrophin”
32. “papp a”
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33. “pregnancy associated plasma protein”
34. “nuchal translucency”
35. foetal
36. fetal
37. foetus
38. fetus
39. prenatal*
40. antenatal*
41. pregnan*
42. trimester*
43. “trisomy 21”
44. mosaicism
45. “down* syndrome”
The search then used the history function to combine terms:
1-34 - combine using OR
35 - 42 - combine using OR
43 - 45 - combine using OR
The three sets were combined using AND
The combined search strategy had the form
(((((((al: ”trisomy 21“) or (al: (mosaicism))) or (al: ”down* syndrome“))) and (((((((((((((((((((((((((((((((((((al: ”reference stan-
dard*“) or (al: ”reference value*“)) or (al: ”reproducibility of results“)) or (al: (diagnos*))) or (al: (specific*))) or (al: (sensitiv*)))
or (al: ”likelihood ratio*“)) or (al: ”false negative*“)) or (al: ”false positive*“)) or (al: ”area under curve“)) or (al: (auc))) or (al:
(roc))) or (al: (predict*))) or (al: (accura*))) or (al: (detect*))) or (al: (screen*))) or (al: (marker*))) or (al: ”ductus venosus“))
or (al: ”tricuspid regurgitation“)) or (al: ”nasal bone“)) or (al: ”chorion* vill* sampling“)) or (al: (amniocentesis))) or (al:
(ultrasound))) or (al: (inhibin*))) or (al: ”unconjugated oestriol“)) or (al: ”unconjugated estriol“)) or (al: (afp))) or (al: ”alpha
feto protein*“)) or (al: ”alpha fetoprotein*“)) or (al: ”b hcg“)) or (al: ”human chorionic gonadotropin“)) or (al: ”papp a“))
or (al: ”pregnancy associated plasma protein“)) or (al: ”nuchal translucency“)))) and (((((((((al: (foetal)) or (al: (fetal))) or (al:
(foetus))) or (al: (fetus))) or (al: (pregnan*))) or (al: (trimester*))) or (al: (prenatal*))) or (al: (antenatal*))))))
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol intended to investigate several additional outcomes downstream from test accuracy, should they be reported in the test
accuracy studies. When we attempted to extract this information however, it was found to be available in very few studies, and where
such information was found, it was difficult to extract meaningful data to allow for comparison between studies, as data were not
reported in a universal manner. In several studies such outcomes were estimated rather than measured. Often they were not reported
at all. The outcomes stated in the protocol which have not been included are: harms of testing; need for further testing; side effects
of test; interventions and side effects; other abnormalities detected by testing; spontaneous miscarriage; miscarriage subsequent to
invasive procedure, with or without normal karyotype; fetal karyotype; termination of pregnancy (prior to definitive testing or in
a karyotypically normal pregnancy and following confirmation of Down’s syndrome or following detection of other chromosomal
abnormalities); stillbirth; livebirth of affected and unaffected fetus; uptake of definitive testing by women.
The following refinements to the eligibility criteria were imposed to ensure that the quality of the included literature remained high.
We excluded studies that identified fewer than five Down’s syndrome pregnancies in their study population. We excluded studies that
had less than 80% follow-up of participants.
In addition, the analytical strategy was informed by the volume of tests and studies included, and developed so that we focused on key
tests and test combinations by a) only meta-analysed tests that were included in four or more studies or b) showed more than 70%
sensitivity for more than 90% specificity. In addition, a requirement that a minimum of 10 studies for a single test was required before
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subgroup analysis was undertaken. Consequently, several potential sources of heterogeneity were not investigated due to lack of data.
To investigate the impact of multifetal pregnancies, we excluded studies in a sensitivity analysis to determine the effect on our estimates
of test accuracy. This was done because data were limited for meta-regression analyses.
We intended to conduct sensitivity analyses on the analysis investigating the effect of maternal age on test sensitivity. This was not
possible due to limited data. Instead we performed the sensitivity analyses when comparing high-risk populations with routine screening
populations. This comparison was considered a proxy for the effect of maternal age because the main indication for referral for invasive
testing was often increased risk due to advanced maternal age. Due to lack of information, we were unable to consider the impact of
age standardisation and improvements in technology on the estimates of test performance.
N O T E S
This review belongs to a suite of reviews examining antenatal screening for Down’s syndrome which includes:
• First trimester serum tests for Down’s syndrome screening (Alldred 2015);
• Urine tests for Down’s syndrome screening (Alldred 2015a)
• Second trimester serum tests for Down’s syndrome screening (Alldred 2012);
• First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (this
review)
• First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening (in press).
The plans for these reviews were described in a generic protocol (Alldred 2010) published in the Cochrane Library in 2010. The
project as a whole has been much larger than initially anticipated, both in terms of size and statistical complexity. The initial search was
completed in 2007 and an updated search in August 2011. After identifying studies appropriate for inclusion, a significant amount of
time has been devoted to data management and analysis.
The authors are conscious of the time lag from the latest literature search to publication, and the potential for the introduction of new
urine tests in this time frame. The authors are also conscious of the potential for publication of new data pertaining to tests included in
this review. Whilst not fulfilling the usual Cochrane up-to-date criteria, this review is published because it provides historical context
in what is a rapidly-changing field, and because it is unlikely to ever be repeated.
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